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In Australasia, Head and Neck Cancer (HNC) is more common and survivable than ever 
before. As a result, the population prevalence of HNC patients (including HNC survivors) in 
our communities is ever-increasing. Most of these patients are, at least, partially dentate, and 
are at high risk of dental disease. Most will seek dental care in the private sector with general 
dentists. Problematically, little is known about the capacity of general dentists to provide 
treatment for these complex patients.  
  
This study, which is believed to be the first of its kind in this space, will seek to describe the 




A cross-sectional survey of a random and representative sample of 800 New Zealand general 
dentists was undertaken. The survey was self-administered, from a digital platform. 
Participants were invited into the study by email, and this email contained an embedded 
hyperlink to the survey. Data were collected on sample demographics and various aspects of 
the knowledge, attitude and behaviour of general dentists treating patients with a history of 
HNC. A total of 156 surveys were completed (20.4% response rate). 
 
Data was analysed using SPSS software (version 25), by the investigator. Qualitative 





The majority (73.4%) of registered general dentists who responded to the survey invitation 
felt that providing dental treatment for HNC patients fell within their scope of practice, 
however one quarter of dentists had not seen any HNC patients during the previous year in 
practice, and only 1 in 20 had seen significant numbers (20 or more HNC patients). HNC 
patient flow was positively associated with the dentist being female, in a metropolitan-based 
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practice, having had work experience in the public sector and currently working in both 
public and private practices. 
 
General dentists were found to have sufficient knowledge to treat HNC patients, in practise if 
not in theory. On average, dentists answered 9.6 questions correctly out of total of 15 
questions (64% of questions answered correctly, on average). HNC patient flow over the 
preceding year, being aged 50 to 59 years, and having 30 to 39 years of clinical experience, 
were associated with superior knowledge.  
 
The study found that dentists lacked confidence in providing dental treatment for HNC 
patients. Only one quarter of New Zealand graduates and about 10% of overseas graduates 
reported that they were confident treating HNC patients. Willingness to provide basic dental 
treatment for a HNC patient was related to the invasiveness of the treatment itself; typically, 
the more invasive a procedure, the fewer dentists who would consider undertaking it. 
Similarly, a clinician’s experience providing basic dental care to HNC patients during the 
previous year in practice was also dependent on procedural invasiveness. 
 
Almost all dentists would give oral hygiene instruction to HNC patients, but only one third 
would drill down into dietary strategies for oral health. Of greatest concern was the low rate 
of smoking cessation intervention provided, although this was consistent with rates reported 
in the evidence base. 
 
New Zealand graduates tended to score better than their overseas-trained counterparts in 




In general, dentists have a good level of knowledge about HNC, but they are not able to 
confidently translate this into practise to provide basic dental treatment for this complex 
group of patients who are at high risk of dental disease. 
 
This study has not been able to clearly identify and describe the barriers to this conversion.  
Some evidence exists that the majority of dentists do not feel that their undergraduate 
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qualification had adequately prepared them to see HNC patients. Further study in this area is 
needed, and greater use of qualitative techniques is recommended.   
 
Contextual frameworks in this space must be reviewed in order to support access to dental 
care for HNC patients.  Dental education requires revision across the scholastic spectrum- 
including undergraduate learning, seasoning of new-graduates and strategies to update 
experienced clinicians with current evidence-based knowledge. Funding of public dental 
services should be reviewed so that it is viable for public dental clinics to integrate their 
dentists into established cancer care teams. Patient care pathways by which HNC patients can 
access dental services should be clarified and made transparent to both primary healthcare 
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Cancer of the mouth and middle throat (Head and Neck Cancer/HNC) is prevalent, and more 
patients than ever before are being diagnosed with it. There were 1179 cases of HNC diagnosed 
in New South Wales (NSW) in 2014, and this figure is estimated to increase to 1433 cases by 
2021 (Cancer Institute NSW, 2017). This is a forecast increase of 21.5% over 7 years. Between 
2000 and 2010 there were 1916 cases recorded in New Zealand (Gavidi et al., 2014). It should 
be noted that the age-standardised incidence of HNC in Australia fell between 1982 and 2009 
from 19.3 to 16.8 per 100,000 despite increased overall diagnoses. This was due to Australia’s 
population growth and aging demographic (Australian Institute of Health and Welfare 
(AIHW), 2014, 11 June). No such statistics are available for New Zealand. 
HNC has also become more survivable. Five-year survivability (the chance of living for at least 
5 years after initial cancer diagnosis) has improved from 52.9% for those diagnosed between 
1995 and 1999, to 59.6% for patients first treated between 2005 to 2009 (Cancer Institute NSW, 
2017).  
The Australian Institute of Health and Welfare (AIHW) and the New Zealand Ministry of 
Health have reported that most adults living in New Zealand and Australia today will have 
some natural teeth (Chrisopoulos et al., 2016; New Zealand Ministry of Health, 2010). It  
follows that most HNC survivors will be at least partially dentate and will require access to 
routine general dental care for stabilisation, maintenance and rehabilitation of their dentition 
into the future. Problematically, the literature also describes the substantial oral health burden 
that HNC patients face as a direct result of cancer treatment (Andrews and Griffiths, 2001a; 
Barry, 2005; Beech et al., 2014; Epstein et al., 2014; Fattore et al., 1988; Hancock et al., 2003; 
Huber and Terezhalmy, 2003; McCaul, 2012; Murdoch-Kinch and Zwetchkenbaum, 2011; 
Noone and Barclay, 2017; Ray-Chaudhuri et al., 2013; Specht, 2002; Sroussi et al., 2017), 
which would translate to HNC patients having greater-than-average need for dental care. 
Because most dentists in New Zealand and Australia work in general practice in the private 
sector (Chrisopoulos et al., 2016; Dental Council of New Zealand (DCNZ), 2017) and most 
patients are not eligible for free treatment through the public sector, the majority of HNC 
survivors will seek care in the private sector from general dental practitioners. Indeed, the 
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literature acknowledges this and supports HNC patients being treated by general dentists with 
sufficient HNC knowledge and experience in treating patients with a history of HNC (Burke 




As discussed above, more Australasians are being diagnosed with HNC at the same time as 
HNC is becoming more survivable (Cancer Institute NSW, 2017; Gavidi et al., 2014). This 
means an increasing prevalence of HNC survivors within the population, most of which are 
partially dentate, at least. Access to dental care for these people is primarily self-funded through 
the private dental sector. 
After three years practising as a dentist with Capital and Coast District Health Board in New 
Zealand, followed by 17 years as a Sydney West Cancer Network (SWCN) Head and Neck 
Cancer Service dentist in NSW (Australia), I have gained the impression that general dentists 
are typically uncomfortable treating patients with a history of HNC. Medicolegal risk 
mitigation, complexity of care, the volume of treatment required and deficient knowledge are 
some of the reasons anecdotally cited. In addition, HNC patients report that they find it difficult 
to access dental care, which may be related to why they tend to delay presentation until dental 
disease is widespread and severe (Bertl et al., 2016). 
There have been some studies of the level of knowledge, attitudes and practise among general 
dental practitioners with regard to providing dental treatment for patients with a history of 
HNC; however, none of this has been undertaken in the Antipodes, or in the last few years.  
Indeed, the evidence-base on this topic has almost completely concentrated on assessing 
knowledge and behaviours of dentists with regard to screening and diagnosis of HNC, rather 
than evaluating how well the profession is able to support survivors of HNC (Borhan-Mojabi 
et al., 2012; Hertrampf et al., 2011; Horowitz et al., 2000). These studies have generally 
reported an inadequate level of knowledge and practise among general dentists with regard to 
screening and identification of HNC (Borhan-Mojabi et al., 2012; Hertrampf et al., 2011; 
Horowitz et al., 2000).  
Accordingly, the primary aim of this study is to investigate and evaluate the knowledge, 




The study will be a cross-sectional survey of practising general dentists in New Zealand. This 
survey will be piloted for validation and then administered in a web-based format to a random 
sample of New Zealand general dentists, using Dental Council New Zealand (DCNZ) 
registrants in the general practice scope of dental practice as a sampling frame. Data will be 
analysed using SPSS software.  Face-to-face interview with key informants (general dentists 
identified as having a lot of experience working with HNC patients) will yield qualitative data 
which will be analysed thematically and used to help interpret the survey findings and describe 
the preparedness and competence of dentists treating HNC patients. Recommendations to 
address any gaps in performance and knowledge of general dentists will be made.   
 
1.3. Aims/Objectives  
The aims and objectives of the study will be:  
1. To summarise what is currently known in the literature with regard to general 
dentists treating patients with a history of HNC treatment; 
2. To describe who, where and how general dental practitioners are treating HNC 
patients in New Zealand currently; and 
3. To identify gaps in practise or barriers to providing dental care, and make 
recommendations about how these may be addressed by the profession. 
 
1.4. Research Questions   
The research questions that this study will aim to address are divided into 3 domains. 
1.4.1. Knowledge Domain 
 
i. Do general dentists in New Zealand have sufficient knowledge to treat HNC patients? 
 
1.4.2. Attitude Domain 
 
i. Are general dentists in New Zealand sufficiently confident in their ability to treat 
HNC patients? 
ii. Are general dentists in New Zealand willing to see HNC patients in their practices?  
4 
 
iii. What treatments would general dentists be happy to deliver for HNC patients? 
iv.  Are general dentists interested in continuing professional development (CPD) on this 
topic? 
 
1.4.3. Practise (Behaviour) Domain 
 
i. Are general dentists in New Zealand seeing HNC in their practices?  
ii. What are the characteristics of general dentists that treat HNC patients? 
iii. What treatments have general dentists performed for HNC patients?  
iv. What are the barriers to general dentists treating HNC patients?  
 
 
1.5. Thesis Structure 
 
This thesis is divided into seven chapters. Chapter One is the introduction. This is followed 
by Chapter Two, which is a literature review outlining what is currently known about general 
dentists treating HNC patients in practice. Methods are provided in Chapter Three, and this 
chapter describes how the study was shaped, including design, execution and data analysis. 
Chapter Four outlines study results. Chapter Five discusses these findings, and Chapter Six 





Chapter Two: Literature Review 
 
 
2.1. Definition of Head and Neck Cancer 
 
Head and Neck Cancer (HNC) is a broad term used to define the cancers of the oral cavity 
[tongue, floor of the mouth, gums, palate (Horowitz et al., 2000)], the pharynx (oro-, naso- and 
hypopharynx) and larynx (including hypopharynx) (US National Cancer Institute, 2018a; b).  
This anatomical area is depicted in Figure 1 below.  
 
Figure 1: Anatomical sites and subsites in the Head and Neck 
 
Pazdur, R., Coia, L., & Hoskins, W. (2005). Cancer Management: A Multidisciplinary 





This term encompasses both malignant HNC variants and locally destructive benign epithelial 
proliferations such as Wharton’s Tumour and Basal Cell Carcinoma (BCC).  
 
It is important to note that cancers which arise from anatomical structures outside of the head 
and neck are excluded from this definition, regardless of where they clinically present. For 
example, lymphomas such as Hodgkin’s disease may present with cervical lymphadenopathy; 
however, they are of haematological origin and are not therefore classified as HNC. This 
distinction is important as non-HNC has different epidemiology and management and is 
associated with less dental co-morbidities than HNC. 
 
2.2. Head and Neck Cancer Pathogenesis 
 
HNC is a term that refers to a heterogeneous range of cancers which are broadly grouped 
together, despite being distinctly different lesions. Oral squamous cell carcinoma (OSCC, 
Oral Cancer) affects the mucosa of the oral cavity and vermillion border of the lips. The 
major risk factors associated with OSCC are tobacco and alcohol use (Hashibe et al., 2007; 
Hashibe et al., 2009; Zhang et al., 2015).  
 
In a systematic review of 13830 HNC patients participating in 28 (largely hospital-based) 
case-control studies undertaken worldwide and published between 1957 and 2013, Zhang et 
al (Zhang et al., 2015) reported that heavy smokers have nearly 7 times the odds of 
developing HNC relative to never-smokers (95% CI 4.8-9.5).  
 
In fact, carcinogenesis is directly related to the ‘pack years’ of smoking (number of packs of 
cigarettes smoked each day multiplied by the number of years that the patient has smoked 
for) and the amount of alcohol consumed per day (Zhang et al., 2015). Zhang et al (Zhang et 
al., 2015) concludes that tobacco is a stronger risk factor for HNC than alcohol intake across 
light, moderate and heavy levels of consumption.   
 
People who consume both alcohol and tobacco are at greater risk than those who use either 
product alone, and the associated combined synergistic risk is greater than the summative 
value associated with each individual behaviour (Hashibe et al., 2009). Thirty-five percent of 
all HNC in a population is due to this combination of smoking and drinking (population 
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attributable risk; PAR) (Hashibe et al., 2009).  
 
Oropharyngeal carcinoma (OPC) is variant of HNC which presents posterior to the oral 
cavity. Infection with human papillomavirus (HPV), especially HPV subtype 16, is a risk 
factor for some types and others are associated with tobacco and alcohol use (Gillison et al., 
2015; Hobbs et al., 2006; Rettig and D'Souza, 2015). This association is particularly strong 
for tonsillar cancer; in a meta-analysis of 17 matched case-control studies (2612 cases total) 
Hobbs et al has reported an odds ratio of 15.1 (95% CI 6.8-33.7) for this site (Hobbs et al., 
2006). The fraction of HNC attributable to HPV infection in the population (population 
attributable fraction; PAF) is estimated to be 45.8% for oropharyngeal cancer and 24.2% for 
oral cancer, with HPV subtype 16 implicated in 82.2% of all HPV-associated cancers and 
90% of oropharyngeal cancers (Gillison et al., 2015).  
 
Transmission of HPV is largely through oral sexual contact (Daley et al., 2011; Rettig and 
D'Souza, 2015). At least 50% of all sexually active males and females will acquire HPV 
during their lifetime, although most will clear the disease (their immune system will self-
eradicate HPV from the body) within 2 years of infection (Ho et al., 1998). Two-thirds of 
infected people will be unaware of their HPV status, and the risk profile of these people 
differs from those with traditional smoking-associated and alcohol-associated HNC, in that 
those with HPV-positive tumours are likely to be younger and to have had more sexual 
partners (Ho et al., 1998; Sivasithamparam et al., 2013). 
 
As a significant proportion of HNC is driven by HPV infection, it follows that HPV 
vaccination may prevent HNC. In fact, several prophylactic HPV vaccines have been 
available since 2006 through primary preventative programs targeting cervical cancer, 
including Cervarix, Gardasil, and more recently Gardasil 9. These vaccines are 90-100% 
effective against anogenital precancer (Lehtinen and Dillner, 2013) and are projected to 
dramatically reduce the incidence of cervical cancer after 2050 (Jit et al., 2014).   
 
The prophylactic benefit of an HPV vaccine in preventing HNC can only be assumed at this 
time (Gillison et al., 2015; Wang et al., 2018). There is no evidentiary proof in the literature 
partly because the association between HNC and HPV is relatively new knowledge; the 
elucidation of an association between HPV and HNC came about some 25 years after that of 
HPV and cervical cancer, and epidemiological evidence proving the efficacy of the latter is 
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only just starting to be published. For example, a Cochrane review published in 2018 
concluded only that HPV vaccination is effective in preventing precancer in adolescents 
(Arbyn et al., 2018). In addition, there is a latency period of 10 to 30 years between infection 
with HPV and development of HNC (Gillison et al., 2015) and, prior to 2014, a clinical 
disease endpoint (precancer) was required as evidence in clinical trials, which was not 
possible to detect in OPC (Gillison et al., 2015). Subsequently, the World Health 
Organization (WHO) recognized vaccination efficacy against HPV as a proxy for endpoint 
disease so research in this space has really only just begun (International Agency for 
Research on Cancer (ed) IARC Working Group Reports, 2014).  
 
It should be noted that HPV is considered to be a positive prognostic factor for HNC, in that 
treatment of HPV-positive HNC is associated with more favourable outcomes, such as better 
survivability and  less treatment morbidity (Klein and Grandis, 2010). In contrast, alcohol-
associated and tobacco-associated HNC has a poorer prognosis (Klein and Grandis, 2010). 
 
Salivary gland tumours are also categorised as HNC, but they are different from OSCC and 
OPC again.  The aetiology of salivary tumours is largely unknown; however, some variants 
are associated with specific genetic mutations (Lin et al., 2018). 
 
Other risk factors for HNC include chewing of betel quid (OSCC), occupational exposure to 
wood dust (nasopharyngeal cancer; NPC), asbestos (laryngeal cancer) and formaldehyde 
(paranasal sinus and nasal cavity tumours) (Nee, 2013). Asian ancestry- especially Chinese 
heritage- is a known risk marker for NPC (Nee, 2013).  
At a molecular level, the pathogenesis of HNC is considered to be a multistep process, with 
an accrual of genetic mutations and over-expression or under-expression of cell proteins 
leading to development of dysplasia, carcinoma-in-situ (precancer) and finally invasive 
carcinoma (Klein and Grandis, 2010). Critically altered cellular pathways in HNC include 
p53, epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor 
(VEGFR) and signal transducer and activator of transcription 3 (STAT3) (Klein and Grandis, 
2010). In addition, changes to the tumour microenvironment arising from exposure also 
enable tumour progression (Klein and Grandis, 2010). 
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2.3. Classification of Head and Neck Cancer 
 
HNC is staged according to the American Joint Committee on Cancer (AJCC) TNM 
Classification System for Malignant Tumors, which encompasses the size of the primary tumor 
(T), extent of lymph node involvement (N) and the presence of distant metastasis (M) as a 
means of identifying how much cancer is in the body and where it is located (Edge et al., 2010).  
Stage I and II tumors correspond to early disease, and Stages III and IV represent locally 
advanced and metastatic cancer, respectively (Edge et al., 2010). Stage at presentation is 
directly related to prognosis of disease; tumors that are detected earlier have better 
survivability and less morbidity than late stage disease (Baatenburg de Jong et al., 2001; 
Edge et al., 2010).  
HNC may also be described according to the primary site of cancer origin (such as, 
nasopharynx, lateral tongue, and tonsil) and histological subtype (for example, squamous cell 
carcinoma (SCC), adenoid cystic carcinoma, mucoepidermoid carcinoma) (American Joint 
Committee on Cancer (AJCC), 2018; Edge et al., 2010). 
 
Used together, these complementary systems of categorisation directly inform treatment 
planning, prognostication, and the comparison of treatment outcomes (American Joint 
Committee on Cancer (AJCC), 2018; Edge et al., 2010; Huber and Terezhalmy, 2003).  
 
 
2.4. Clinical presentation of Head and Neck Cancer  
The presentation of HNC is clinically insidious, in that the signs and symptoms are often 
innocuous and nonspecific in nature. For example, a persistent sore throat, a lump in the 
neck, a non-healing sore in the mouth and voice changes, are common presentations of HNC, 
but are more frequently associated with less serious conditions (National Cancer Institute, 
2017). For this reason, HNC is rarely diagnosed at an early stage, with more than half of all 
tumours declaring themselves only once they are of significant size, and after treatment for 
more common ailments has failed (Chaturvedi et al., 2013; Silverman, 2001; 




2.5. Head and Neck Cancer Epidemiology 
 
Over 90% of HNC is squamous in origin (squamous cell carcinoma; SCC), arising from the 
squamous epithelium mucosal lining of the oral cavity and oropharynx (Marur and Forastiere, 
2008). In Australia, most HNC patients are between 40 and 70 years of age at initial 
presentation. HNC has a 3:1 predilection for men (Huber and Terezhalmy, 2003; Marur and 
Forastiere, 2008), and Australians have between a 1 in 49 (Goodyer, 2016) and 1 in 60 (Cancer 
Institute NSW, 2017) risk of developing HNC by 85 years of age. In both Australia and New 
Zealand, HNC has a significantly higher incidence in the Indigenous population (Australian 
Institute of Health and Welfare (AIHW), 2018; Moore et al., 2015).  
 
The Australian Institute of Health and Welfare (AIHW) has reported that HNC was the seventh 
most diagnosed cancer in Australia in 2013 (Cancer Australia, 2018). By 2021, it is projected 
that the incidence of HNC will increase to account for 2.9% of all new cancer diagnoses in 
NSW (Australia) (Cancer Institute NSW, 2017). Between 2000 and 2010, 42 people in every 
one million were diagnosed with a new OSCC in New Zealand (Yakin et al., 2017). 
Despite those with HNC being at high risk of developing a secondary tumour (Garavello et 
al., 2006) or a second primary tumour (León et al., 1999; Sturgis and Miller, 1995), HNC 
survivorship has improved over time (Cancer Australia, 2018). NSW (Australia) patients 
diagnosed between 1995 and 1999 had a 52.9% chance of surviving five years or more after 
diagnosis, while it was 59.6% for patients diagnosed between 2005 and 2009 (Cancer 
Institute NSW, 2017). This is on-par with five year survival rates for HNC in New Zealand 
which fluctuated between 1998 and 2011, but were highest 2010 through 2011 (New Zealand 
Ministry of Health, 2015). This statistic may be a product of the changing epidemiology of 
HNC. The incidence of tobacco-related HNC (typically presenting visibly in the oral cavity) 
has decreased in most developed countries following a decline in the prevalence of smoking 
(Chaturvedi et al., 2013). At the same time, the incidence of HPV-driven HNC has risen 
significantly (Hong et al., 2016; Rettig and D'Souza, 2015). As previously discussed, HPV-
positive oropharyngeal HNC is associated with significantly better treatment outcomes than 
traditional tobacco-associated and alcohol-associated tumours (despite presenting in the 
oropharynx and therefore being less detectable to visual examination, and tending to be 
associated with more advanced nodal disease when first diagnosed) (Chaturvedi et al., 2008; 
Hong et al., 2013). AIHW data collected from a case series of more than 500 patients treated 
at 10 teaching hospitals in Australia over the last 2 decades shows a steady increase in the 
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proportion of HPV-driven oropharyngeal SCC cases, from 20.2% of all HNC diagnosed 
between 1987 and 1995 to 63.5% diagnosed between 2006 and 2010 (Hong et al., 2016).  
These data are consistent with those from smaller Australian studies (Hong et al., 2010), New 
Zealand studies (Chelimo and Elwood, 2015; Elwood et al., 2014), and studies undertaken in 
other developed countries (Chaturvedi et al., 2008; Evans et al., 2013). They are also 
consistent with studies that show an increase in HNC among never-smokers, over time (Hong 
et al., 2016).  
 
 
2.6. Head and Neck Cancer Treatment 
 
HNC is typically treated with complex and costly multi-modality regimens combining 





Most HNC patients will receive high-dose radiotherapy (RTx) either as primary treatment or 
adjuvant to (following) surgery to the oral cavity and orofacial structures. RTx is typically 
delivered by a linear accelerator (Figure 2) that generates and delivers ionising radiation with 
curative or palliative intent, depending on tumour classification and patient acceptance. The 
aim of RTx is to deliver optimum RTx dose to the tumour (usually to the limit of tissue 














Figure 2: Sydney West Cancer Network (SWCN) Linear Accelerator, Crown Princess 
Mary Cancer Care Centre, Westmead Hospital, NSW, Australia. 
 
 
Photo: H Dixon 12 October 2018. 
 
 
RTx damages cellular DNA and therefore affects the ability of the cell to function. As shown 
in Figure 3, the mechanism of action is through both direct damage to the DNA and 
concurrent indirect damage via formation of free radicals that themselves can be injurious 
(Alford, July 12, 2017). The RTx has to pass through healthy tissue to reach its target and 
these cells are also damaged by the treatment (Alford, July 12, 2017). Unlike normal healthy 
cells which can usually repair themselves, cancer cells lack the ability to repair damage to 
their DNA, and so the cancer cell ultimately dies (Alford, July 12, 2017). This is the rationale 
for delivering RTx across numerous sessions over time, to allow the healthy cells in the field 





Figure 3: Mechanism of action of RTx. 
 
 
Adapted from: Huber, M., & Terezhalmy, G. (2003). The head and neck radiation oncology 
patient. Quintessence International, 34(9):693-717.  
 
 
The RTx dose is expressed as the dose absorbed by the tissues, and it is measured in standard 
units of Gray (Gy) (Andrews and Griffiths, 2001a). One Gy is the equivalent of 1Joule/Kg of 
energy (Andrews and Griffiths, 2001a). Typical cumulative dose (the total radiation dose 
delivered to the tissues during all RTx sessions) for HNC ranges between 60 and 70Gy. A 
typical curative course of RTx will last for six weeks, with fractions of about 2Gy being 
delivered on a daily basis over a course of 30 treatments.  
 
Head and neck epithelial tissues (such as saliva glands and mucous membranes) are 
especially sensitive to RTx because they are composed of rapidly dividing cells (that is, they 
are very ‘dose-effect’ sensitive; this is a term that reflects tissue response to RTx dose) 
(Huber and Terezhalmy, 2003). To ensure accurate placement of RTx, the treatment is 
14 
 
simulated during a pre-treatment ‘planning phase’ based on computerised tomography (CT) 
imaging of the head and neck structures, and of the tumour itself. 
 
Over the last ten years, conventional external beam HNC RTx has largely been superseded by 
conformal dosimetry techniques (Intensity Modulated Radiotherapy; IMRT) that are able to 
spare normal tissue through shaping of radiation to the dimensions of the tumour (Taylor and 
Powell, 2004). This will be discussed further when considering the dental side-effects of RTx 




Chemotherapy (CTx) is rarely used alone to treat HNC; rather, it is used concurrently with RTx 
or neo-adjuvant to (before) RTx for synergistic effect, making the cancer more susceptible to 
RTx (Jawad et al., 2015). If RTx is the equivalent of ‘burning’ the tumour and surgery (S/R; 
surgical resection) is to ‘cut it out’, then CTx works by ‘poisoning’ cancer through cytotoxic 
effect. Chemotherapeutic agents generally cause cell death or prevent cell growth by inhibiting 
the function of cellular processes, such as microtubule or protein function and DNA synthesis. 
CTx is distinct from S/R and RTx in that it is able to work systemically rather than affecting 
only the cells in a certain area. Chemotherapeutic drugs such as 5-Flurouracil (5-FU) and 
Cisplatin typically deliver better survival outcomes when combined with RTx than adjuvant 
RTx alone (Nguyen et al., 2002); however, for some patients comorbidities may preclude use 




Surgery (S/R; surgical resection) is often the first-line treatment option for HNC; indeed for 
early tumours, it is often single-modality treatment. Used by Head and Neck, Ear Nose and 
Throat (ENT), Plastic, and Maxillofacial surgeons, the aim of S/R with curative intent in 
HNC is complete macroscopic surgical excision with an appropriate safety margin, according 
to the type, site and stage of the tumour. Excision margins are a consistent prognostic 
indicator and major consideration for use of adjuvant therapies such as RTx (Hinni et al., 
2013). Local tumour control is best achieved by complete surgical excision of tumour with 
‘adequate’ margins, however this judgement is surgeon and pathologist dependent, with 
margins typically being described as  ‘involved’, ‘clear’, ‘close’ or ‘negative’ (Hinni et al., 
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2013). In addition, an ‘adequate’ margin may not be surgically achievable if the tumour 
involves, or lies in close proximity to, a vital anatomical structure. An accurate and 
standardised approach to defining surgical margins is lacking, and there is no universal 
definition of what constitutes an adequate margin, which makes the decision to proceed to 
adjuvant therapy based on reasonableness of surgical margins somewhat ambiguous (Hinni et 
al., 2013).  
 
There is no oncological role for debulking surgery to improve the chances of success with 
adjuvant chemoradiation (treatment that combines RTx and CTx); however, it may be used 
for symptom palliation (such as airway maintenance) (Homer, 2016). 
 
Among high-risk patients with resected HNC (and those with unresectable disease), 
concurrent postoperative CTx and RTx significantly improves the rates of local and regional 
disease control and disease-free survival (Adelstein et al., 1997; Wanebo et al., 1997). 
However, the trade-off is that combined treatment is associated with a substantial increase in 
adverse side-effects. 
 
Lymphatic drainage for HNC is via the neck, therefore neck dissection is often undertaken in 
addition to treating the primary site of the tumour (Subramanian et al., 2006; Thurnher et al., 
2016). This may be total (all neck nodes removed), selective (just the cancerous nodes 
removed) or, in cases where it is unclear whether the cancer has metastasized to the 
lymphatics, a sentinel node biopsy, where the first lymph node or nodes to which a particular 
anatomical site drain are removed and examined histologically before a surgical decision is 
made about the need for wider excision (Subramanian et al., 2006; Thurnher et al., 2016). 
 
Less invasive techniques- such as transoral laser microsurgery (TLM) and transoral robotic 
surgery (TORS)- have been developed as viable alternatives to traditional open surgical 
approaches for some tumours, especially tongue base and supraglottic resections (Homer, 









The literature now demonstrates that the immune system plays a pivotal role in oncogenesis 
and cancer progression. Novel immune-based therapies have been developed to exploit this 
by recruiting the patient’s own immune system to directly target the cancer (Ling et al., 2018; 
Zolkind and Uppaluri, 2017). These immunotherapeutic drugs differ from traditional 
chemotherapeutic agents in that they are directed against specific cellular proteins rather than 
all dividing cells in general. In this way, treatment is targeted to only the tumour and the 
surrounding microenvironment, which limits treatment-associated toxicity. 
 
Epidermal growth factor receptor (EGFR) overexpression can be identified in 80-90% of 
squamous cell HNC (Rubin-Grandis et al., 1998). It is associated with poor treatment 
outcomes (Rubin-Grandis et al., 1998). It can be targeted with tumour antigen-specific-
monoclonal antibodies such as Cetuximab (Erbitux®), which stimulates an immune response 
through cell lysis and opsonisation of tumour cells for phagocytosis (Lopez-Albaitero et al., 
2009) and, in turn, elicits a T-cell response (Lopez-Albaitero et al., 2009; Rubin-Grandis et 
al., 1998). RTx with concurrent Cetuximab may be prescribed for patients who are medically 
unfit to receive Cisplatin CTx, and ongoing clinical trials continue to investigate the role of 
Cetuximab-RTx in treatment de-intensification of HPV-positive loco-regionally advanced 
oropharyngeal HNC (Ling et al., 2018).  
Other immunotherapy trials are evaluating the use of drugs which target PD-1 (programmed 
cell death protein-1) on the cellular surface (Dogan et al., 2018). Prembrolizumab 
(Keytruda®) is one such drug which counters the cell protein responsible for preventing 
autoimmunity and has the potential to allow cancer cells to evade the immune response 
(Merck Sharp & Dohme Corp, 2018). Anti-PD-1 trials are especially efficacious in the setting 
of newly diagnosed high risk and locally advanced HNC, and anti PD-1 is also being used in 
conjunction with RTx for delaying progression in recurrent or metastatic disease (European 
Society of Medical Oncology, 2017) .  
 
It is worth noting that Cetuximab only recently became publically funded for use in HNC in 
Australia and New Zealand. Cetuximab funding was approved in Australia in 2010  
(Australian Government Department of Health, 2010) and in New Zealand in early 2018 (The 
PharmaLetter, 2017, 15 November). Prembrolizumab remains unfunded for use in HNC in 
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Australia and New Zealand at present, and patients currently pay about $200,000 for private 
access to a single course of treatment. 
 
2.7. Multidisciplinary Management of Head and Neck Cancer 
 
Individualised patient-centric treatment plans are facilitated through multidisciplinary teams 
(MDTs) which have become the standard of care for HNC (Licitra et al., 2016). Such teams 
comprise healthcare professionals with specific areas of expertise, who exercise shared 
decision-making responsibility in accordance with evidence-based practice, clinical 
experience and availability of resources (Friedland et al., 2011; Licitra et al., 2016). Both 
Australia and New Zealand HNC centres use the MDT treatment paradigm. Figure 4 depicts 
the Sydney West Cancer Network (SWCN) Head and Neck Cancer MDT. In the US context 
and in some Australian treatment facilities, the dentist on this team is known as the ‘Dental 
Oncologist’ and is considered to be a core member of the MDT (Furlow, 2017; Peter 
McCallum Cancer Centre, 2018). Other MDT members include radiation and medical 
oncologists, speech pathologists, dieticians, nurses, social workers and various surgical 
specialists.  
 
HNC might be considered to be one of the best oncological areas for a multidisciplinary 
approach to care due to the economic burden and complexity of management; a broad range 
of histological subtypes and anatomical subsites is involved and multi-modality treatment is 
typically associated with significant treatment-induced toxicity, some of which is permanent 
and requires concurrent management by several healthcare practitioners. Greater use of 
guideline-directed approaches, better communication, enhanced cost-effectiveness of care, 
less time to treatment and improved outcomes are some of the benefits attributed to a MDT 
approach to care (Bossi and Alfieri, 2016; Licitra et al., 2016; Westin and Stalfors, 2008). 
 
Despite these benefits, MDTs are costly to the health system, and their patient outcomes have 







Figure 4: Sydney West Cancer Network (SWCN) Head and Neck MDT. 
 
 
SWCN Head and Neck MDT reviewing Computerized Tomography (CT), histopathology and 
Positron Emission Tomography (PET) scan results to inform a patient treatment plan. Photo: 








It is universally recognised that HNC patients experience significantly greater orofacial and 
dental morbidity than their counterparts in the community (Andrews and Griffiths, 2001a; b). 
This is because the majority of HNC patients to date have been treated with a multimodality 
combination of surgery, RTx and chemotherapy, which are nonselective in their mode of 
action, affecting healthy and cancerous tissues alike.  
 
Dental caries, periodontal disease, mucositis, osteoradionecrosis, lymphedema, jaw stiffness, 
chronic ulceration and oral mucosal infection are some of the broad range of acute and chronic 
side-effects noted in the literature (Andrews and Griffiths, 2001a). Trismus may be a concern 
if the temporomandibular joint apparatus and/or muscles of mastication (particularly the lateral 
pterygoid muscles) are in the RTx field (McCaul, 2012; Murdoch-Kinch and Zwetchkenbaum, 
2011; Sroussi et al., 2017). These complications will be expanded on in sections 2.8.2 and 
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2.8.3, although discussing specific management options is beyond the scope of this thesis and 
will not be elaborated on further.  
 
The extent of these complications is RTx dose-related, location-dependent and often severe, 
particularly when RTx doses of 45Gy or more are delivered bilaterally to the orofacial tissues, 
which is typical for HNC (Andrews and Griffiths, 2001b; Jawad et al., 2015; Rothwell, 1987). 
The side-effects are such that treatment may sometimes be abandoned before completion, and 
this impacts directly on the odds of long-term patient survival.   
 
 
2.8.2. Acute Side-effects  
 
Acute side-effects of HNC treatment are those which persist while the patient is undergoing 
treatment and resolve once treatment is ceased. Most CTx and immunotherapy side-effects are 
acute in nature. These are summarised by the author in Table 1, and include mucositis 
(breakdown of the lining of the mouth and throat), epidermitis (breakdown of the integrity of 
the overlying skin) and alteration of taste (Andrews and Griffiths, 2001b). 
 
 
Table 1: Acute Side-effects associated with HNC treatment. 
 
Mucositis     Acute viral infection (i.e. Herpes Simplex Virus) 
Oral infections (i.e. candidiasis)  Pain 
Soft tissue necrosis    Epidermitis 
Alteration of taste (dysgeusia)  Nutritional compromise 
Loss of taste (ageusia)   Reduction in taste (hypogeusia) 
 
 
Patients who undertake chemoradiation will typically experience greater short-term morbidity 
than those being treated with RTx alone. Nausea, mucositis and alteration/loss of taste are all 
anticipated to be worse for the former group. 
 
Mucositis (Figure 5) is the most prevalent acute side-effect associated with treatment of HNC 
RTx (Carl, 1995). The pathogenesis of mucositis is poorly understood, but is not just the 
result of the toxic effects on dividing epithelial cells (Barker et al., 2005). Data suggest that 
most of the oral mucosal cells and tissues play a role in the loss of mucosal integrity (Sonis, 
1998). It has been proposed that oral microorganisms, particularly gram-negative bacteria 
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(which have lipopolysaccharide in their cell walls) induce upregulation of proinflammatory 
cytokines which lead to prolonged mucositis of greater severity (Sonis et al., 2004). 
 
 
Figure 5: Mucositis. 
 
 
Clinical photo of widespread oral mucositis in patient who was five weeks into a six week 
course of high dose chemoradiotherapy for NPC.  Photo: A/Prof C Griffiths 2010. 
 
 
Mucositis begins as erythema and rapidly progresses to widespread ulceration of the 
oesophagus and gastrointestinal mucosa (including the mouth) once a 30Gy cumulative 
radiation dose has been received (Murdoch-Kinch and Zwetchkenbaum, 2011). Figure 5 
shows the typical clinical appearance of mucositis. Mucosa in the oral cavity, pharynx and 
larynx responds early to fractionated RTx as these cells have a high turnover rate and low 
resistance to radiation. Fractionated doses of 2Gy/day will result in mucositis within one 
week (Million, 1984). This often necessitates a feeding tube being surgically inserted through 
the abdominal wall (a procedure known as percutaneous enteric gastrostomy; PEG) or 
through the nose (nasogastric; NG tube) for nutritional purposes. Mucositis peaks two weeks 
into treatment and may persist for up to 5-7 weeks after radiotherapy ceases (Murdoch-Kinch 
and Zwetchkenbaum, 2011). It is particularly severe in patients with heavily restored 
dentitions, due to radiation scatter (Chin et al., 2009; Hoffman et al., 2016). In addition, the 
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ulceration may become a portal for infection, particularly in those patients undertaking CTx, 
due to compromised immunity. 
 
Other common acute side-effects include acute viral infection and alteration of taste. Viral 
infection usually results from reactivation of latent Herpes Simplex Virus (HSV) rather than 
new infection (Andrews and Griffiths, 2001a). Taste reduction (hypoguesia) occurs rapidly to 
a cumulative dose of 30Gy and then slows down as the acuity of all tastes approaches nil 
(ageusia) (Andrews and Griffiths, 2001a). Taste is usually fully restored between 2 and 4 
months post-treatment, although some hypogeusia or dyguesia (altered taste perception) may 
persist (Andrews and Griffiths, 2001a).  
 
 
2.8.3. Chronic Side-effects 
 
Many radiotherapy side-effects are chronic and are associated with lifelong compromised 
quality of life (QoL) scores (reflecting compromised QoL) for both HNC patients and those 
caring for them (Nightingale et al., 2016; Rathod et al., 2015). QoL is a complex concept that 
represents a multidimensional, subjective assessment of the impact of a condition or 
treatment, on life (Rathod et al., 2015). Table 2 shows some of the chronic side-effects 




Table 2:  Chronic Side Effects of Head and Neck Cancer Treatment. 
 
Hyposalivation, xerostomia    Dysphagia 
Chronic mouth ulceration    Osteoradionecrosis 
Dental caries      Trismus 
Periodontal disease      Alopecia  
Fibrosis       Muscle atrophy 




These sequelae are particularly relevant to this study because they represent the challenges 
which the general dentist will face when providing dental treatment to HNC patients. For 
example, rapid development and progression of dental caries arising from hyposalivation 
(salivary gland hypofunction), limited access to perform dental treatment due to trismus, loss 
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of elasticity or atrophy in the facial musculature, difficulty placing the patient in an ergonomic 
position for treatment due to neck fibrosis and swallowing problems. 
 
Dry mouth (Figure 6) is the most frequently reported late (permanent) side-effect of RTx 
because saliva glands are particularly radiosensitive (Barker et al., 2005). In addition, salivary 
glands may have been wholly or partially surgically resected. This can lead to a subjective 
feeling of dry mouth (xerostomia) which is usually but not always, accompanied by an 
objective clinical reduction in saliva flow (hyposalivation; salivary gland hypofunction). The 
literature has reported that 64% of patients treated with conventional RTx will continue to 
report moderate-to-severe permanent xerostomia when assessed up to 22 years after treatment 
(Wijers et al., 2002). Modern 3D techniques such as IMRT have improved the potential for 
‘gland sparing’ (shaping of the RTx beams as to avoid normal salivary tissue, where possible) 
and lessened the resultant hyposalivation and xerostomia to some extent. 
 
Onset is usually within the first week of radiation treatment with conventional fractionation of 
2Gy/day (Murdoch-Kinch et al., 2008). Dysfunction is due to cell death and fibrosis, with the 
glandular architecture (parenchymal tissue) replaced with loose fibrous connective tissue and 
ductal remains infiltrated by lymphocytes and plasma cells (Andrews and Griffiths, 2001a).  
The volume of parotid gland irradiated seems to be a major factor in the development of a 
subjective feeling of xerostomia (Andrews and Griffiths, 2001a), because the serous acini it 
contains are particularly sensitive. RTx therefore usually results in a mucinous saliva which is 
less lubricating. 
 
The incidence of xerostomia is dose-related. At doses used for HNC, patients are 10 times more 
likely to experience xerostomia than those who have not been irradiated (Beech et al., 2014). 
 
Dry mouth is both qualitative and quantitative. Saliva is less able to perform its usual protective 
functions of lubrication, buffering, tooth remineralisation, taste and digestion (Andrews and 
Griffiths, 2001a; Fox, 1989). The volume of saliva is reduced and saliva becomes thick, 
viscous, ropey and frothy with poorer buffering and clearance capacity (McCaul, 2012). Figure 
6 is a clinical photo that shows typical post-RTx saliva- thick and sticky. The pH and the levels 
of calcium, inorganic phosphorus, zinc, lysozyme and amylase in the saliva are reduced 
(Fattore et al., 1988). The oral microbiome undertakes a dysbiotic shift to become more 
cariogenic (Andrews and Griffiths, 2001a).  
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Figure 6: ‘Dry Mouth’. 
 
 
Thick, ropey, sticky and frothy saliva as a side-effect of HNC RTx.  This patient is 10 years 
post-RTx for left alveolar HNC. Photo: H Dixon 14 August 2018. 
 
 
Another related late complication of HNC treatment is the development of ‘radiation caries’. 
This can occur as early as 3 months after RTx and can affect any tooth surface, including those 
which are usually resistant to dental caries, such as the incisal surface of mandibular incisors 
(Dreizen et al., 1977; Murdoch-Kinch and Zwetchkenbaum, 2011). Dry mouth and frequent 
intake of high calorie/high-carbohydrate nutritional products (usually as a result of persistent 
dysphagia and taste aberrations) can lead to this distinct and aggressive pattern of rapid dental 
decay which ‘ringbarks’ exposed smooth tooth surfaces circumferentially at the 
cementoenamel junction  (Andrews and Griffiths, 2001a; b; Sroussi et al., 2017).  
 
Figure 7 depicts two serial dental orthopantomogram (OPG) radiographs recorded for a patient 
that was treated by SWCN Head and Neck Cancer MDT in 2009. The first image was recorded 
at time of pre-treatment dental assessment. The second image was recorded only 18 months 
later and shows the distinct pattern of ‘radiation caries’ described above. Figure 8 shows a 
clinical photograph of another HNC patient that was treated in 2015 with SWCN. It is 
important to note that this effect arises from changes to the oral environment attributable to 
24 
 
RTx rather than as a direct effect of radiotherapy on teeth. It has been suggested that a direct 
histological effect on the crystalline structure on tooth enamel may occur, making the tooth 
more susceptible to caries, but the effect has been determined to be minor and unlikely to be 
of clinical significance (Burke et al., 2012).  
 




Serial OPGs recorded pre-chemo radiotherapy and 18 months post-chemo radiotherapy for a 
HNC patient with a base of tongue primary tumour.  Note the degree, pattern and rate of dental 
caries development and non-union of the surgical cut at the left angle of mandible (made during 







Figure 8: ‘Radiation caries’- clinical presentation. 
 
 
Clinical photo of ‘radiation caries’.  Patient received high-dose RTx with comprehensive fields 
and curative intent in 2015 for a base of tongue HNC.  Right-sided lesions have been treated 
with glass ionomer restorations (GC-Fuji BULK and GC Fuji IX EXTRA) for caries control.  
The left-sided dentition remains unrestored. Photo: H Dixon 14 August 2018. 
 
 
Poor healing/non-healing of bone irradiated to 40Gy and over is also a permanent side-effect 
of HNC RTx  (Fattore et al., 1988). This osteoradionecrosis (ORN) (depicted in Figure 9) is 
not a primary infection of irradiated bone; it is a metabolic deficiency created by radiation-
induced cellular injury in which the bone essentially becomes non-vital with limited healing 
and remodelling potential (Andrews and Griffiths, 2001a; b). Two-thirds of all cases are 
initiated by trauma such as dental extractions, ill-fitting dentures or biopsy, with the remaining 
one-third occurring spontaneously (Myers and Marx, 1990). This has important implications 
for the provision of surgical dental care and other dental procedures post-RTx, such as dental 










Figure 9: Osteoradionecrosis. 
 
 
OPG radiograph magnifying left body of mandible to demonstrate ORN in a patient who 




The exact pathophysiology is not clear and a number of proposed mechanisms have been 
postulated (Nadella et al., 2015). Until recently, Marx’s theory of hypoxia, hypovascularity 
and hypocellularity (Triple-H Theory) was the model widely accepted (Andrews and Griffiths, 
2001a; b; Marx, 1983). Based on histological examination of 26 consecutive ORN cases from 
which 12 en-bloc specimens were harvested, Marx suggested that radiation led to the formation 
of boney tissue which is devoid of cells and vasculature, and is therefore predisposed to 
breakdown and development of a chronic wound that is unable to heal (Marx, 1983). This is 
distinct from the Radiation-Induced Fibroatrophic Theory that is popular today and proposes 
that the release of bioactive fibrogenic cytokines that activate and dysregulate fibroblastic 
activity is the driving force behind ORN (Nadella et al., 2015). 
 
ORN is notoriously difficult to treat and can lead to pain, functional issues and pathological 
fracture of the mandible. Hyperbaric Oxygen Therapy (HBO) delivers oxygen tensions of 
1,500-2,200mmHg at the arteriole level to provide deep perfusion of the tissues and purports 
to accelerate healing and stimulate neovascularisation and osteoclastic activity within the 
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wound (Latham, 2017). The evidence-base confirming HBO efficacy is problematic; the only 
randomised control trial in this area to date was prematurely ceased due to worse outcomes in 
the HBO arm of the study (Annane et al., 2004). Overall, other studies purporting to 
demonstrate effect suffer from design flaws such as small sample size. A 2012 Cochrane 
review has only been able to conclude that HBO has ‘some’ benefit in providing mucosal 
coverage and preventing wound dehiscence, and it recommends that further studies are carried 
out to prove effect (Bennett et al., 2016). 
 
Pharmacological management with the PENTOCLO drug regimen comprised of 
Pentoxyphylline (a phosphodiesterase inhibitor used in peripheral vasculature disease to 
dilate blood vessels), Tocopherol (vitamin E, which is a free-radical scavenger) and 
Clodronate (a bisphosphonate drug that regulates bone metabolism) has been used since 2005 
to treat ORN (Delanian et al., 2005; Delanian et al., 2011). Studies have demonstrated the 
effectiveness of PENTOCLO versus placebo and therapy with single agents in radiation-
induced trauma to non-oral body sites (Delanian et al., 2005; Delanian et al., 2011). There are 
some promising PENTOCLO studies in the evidence-base, however most have come from a 
single French research group to date (Delanian et al., 2005; Delanian et al., 2011) and 
replication in other centres is needed.  
In the small group of patients who are treated with S/R alone, and those who proceed to S/R 
with adjuvant RTx, sequelae such as trismus, microstomia, impinging flap position and soft 
tissue tethering can hinder good oral hygiene and therefore increase the lifelong risk of 
developing dental disease. 
It is worth noting that the delivery of RTx has become considerably more sophisticated over 
time and this has modified the orodental side-effect profile traditionally associated with HNC 
RTx. Modern conformal RTx techniques, such as Intensity Modulated Radiation Therapy 
(IMRT) have become the standard of care over the last ten years (Taylor and Powell, 2004), 
and studies have concluded that IMRT provides tumor control rates equal to or better than 
conventional external beam techniques (Lee et al., 2002; Puri et al., 2005). 
 
Conformal techniques differ from conventional methods in that a radical dose can be delivered 
to the tumor while sparing as much normal tissue as practicable. This  results in less radiation-
induced complications than conventional external beam radiation treatment (Bhide and 
Nutting, 2010; Taylor and Powell, 2004). For example, organ preservation can be achieved 
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through partial sparing of major salivary glands using advanced computerised technology to 
custom-collimate radiation to tumour shape and size. This can be visualised by viewing the 
Dose Volume Histogram (DVH) or (coloured) computerised treatment plan (see Figure 10) 
which illustrate the dosimetry (total cumulative dose and dose fractions) delivered to specific 
anatomical structures. As such, IMRT minimises the dose delivered to adjacent normal tissues 
and so typically induces less severe hyposalivation (Sim et al., 2018) which can be expected to 
gradually and partially improve over time (Henson et al., 2001; Jabbari et al., 2005; Murdoch-
Kinch et al., 2008). As such, it follows that there should be less dry-mouth-associated late 
toxicity, such as caries, than with older external beam approaches. The cumulative radiation 
dose delivered by these conformal techniques still far exceeds the biological tolerance of most 
anatomical tissues which are irradiated however, and a cumulative dose of more than 23Gy to 
the parotid salivary gland can be expected to cause permanent damage to salivary tissue (Lee 
et al., 2016). In fact, a 2018 study examining the effect of IMRT on 24 patients with NPC in 
Singapore has suggested that both resting and stimulated saliva flow is still permanently and 
substantially reduced two years after RTx (Sim et al., 2018). Problematically, IMRT also 
delivers radiation as a broad ‘dose wash’ to the oral cavity, including areas that were 
traditionally shielded from damage with conventional external beam techniques. This poses 
additional dental management problems because most of the oral cavity now exposed, albeit to 


















Figure 10: RTx dose treatment plan. 
 
 
 RTx plan demonstrating dose wash for laryngeal cancer; posterior mandible bilaterally will 
have received a cumulative dose of about 50-55Gy at this level (CT slice) in the transverse 




2.9. Dental Profile of Head and Neck Cancer patients 
 
Adult Antipodeans are less likely than ever before to be edentulous (Australian Research 
Centre for Population Oral Health (ARCPOH), 2007; Chrisopoulos et al., 2016; New Zealand 
Ministry of Health, 2010). The prevalence of edentulism reduced between 1979 and 2002 
among all ages and both genders, and in all Australian States and Territories (Sanders et al 
2004). Indeed, adult edentulism in Australia is projected to decrease by 2.7 to 3.1 percent by 
2021 and 0.4 to 1.0 percent by 2041 (Australian Research Centre for Population Oral Health 
(ARCPOH), 2007). Similarly, national oral health surveys conducted in New Zealand in 1976 
(Cutress et al., 1979) and 1988 (Hunter et al., 1992) reported the prevalence of edentulism in 
people 65 to 74 years of age to be 72.3% and 58.6%, respectively. 
 
At the same time, the incidence of HPV- positive HNC, which typically presents in a younger 
population, has overtaken that of traditional HNC (Hong et al., 2016; Rettig and D'Souza, 
2015). This has meant that, for the first time, dentists who are treating HNC patients are 
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managing fully dentate patients with little dental experience, good oral hygiene and in-situ 
wisdom teeth, in the context of highly morbid medical treatment.  
 
Furthermore, the use of conformal RTx techniques has redefined which teeth are in the high-
dose field, along with the degree of oral side-effects (such as hyposalivation) that may be 
anticipated as a direct result of life-saving medical management. This has led to a shift in 
treatment paradigm among dentists working with HNC patients, from one in which teeth in the 
high-dose field are prophylactically extracted prior to RTx in an attempt to mitigate the future 
risk of ORN, to a more conservative and preventive approach which acknowledges that the 
evidence-base has failed to produce high-level proof that pre-RTx extractions reduce future 
dental problems for HNC patients and, accordingly, aims to preserve functional teeth wherever 
possible.  
 
Evidence exists that HNC patients typically have high levels of untreated dental disease at 
initial cancer diagnosis.  For example, a 2017 American study dentally assessed 356 HNC 
patients prior to treatment and reported that 37% of these patients already had dental caries and 
47% had periodontal disease (Brennan et al., 2017).   
 
Furthermore, high levels of dental disease are also apparent in patients who have completed 
HNC RTx. A 2014 study that assessed 314 patients treated for NPC has reported an increased 
incidence of dental complications at one year (16%), 3 years (36%), 5 years (55%) and 7 years 
(74%) after treatment, with 35% of all patients developing caries and 5% developing ORN 
over 111 months (Siala et al., 2014). A later study of 48 HNC patients treated 6 months 
previously for HNC reported that 90% presented with considerable treatment needs about 20 
months post-treatment, with one-third of teeth having caries and two-thirds with 30% or more 
average periodontal bone loss (Bertl et al., 2016). Other studies have reported worsening of 
periodontal disease after radiotherapy (Ammajan et al., 2013; Epstein et al., 1998). These 
studies should be interpreted with care; much of the data were collected prior to the widespread 
adoption of modern conformal radiotherapy techniques which are known to induce less-severe 
chronic dental side-effects. There is currently a large prospective multicentre cohort study 
underway in the US to investigate the oral health of patients up to 2 years after HNC treatment, 
with the goal being update of this knowledge in the modern context (the Clinical Registry of 
Dental Outcomes (OraRad) Study) (Lalla et al., 2017). In addition, none of these studies make 
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reference to the frequency of specific dental treatments that were required after treatment for 
HNC (such as dental crowns, dentures or fillings). 
 
It is therefore likely that the average HNC patient will have a number of natural teeth at higher-
than-average risk of dental disease for the remainder of his/her life. It follows that such teeth 
will need to be professionally assessed and maintained into the future.  
 
2.10. The Dentist 
 
The following section will address the role of the dentist in managing HNC patients and the 
access that HNC patients currently have to dental care as part of their HNC treatment plan. It 
will also examine which dentists have the required knowledge and technical competencies to 
treat HNC patients, and assess the actual level of knowledge, attitude and behaviour of 




Because the orodental side-effects of treatment are many, varied and often permanent, key 
authors in the evidence-base recommend that a dentist assesses HNC patients before, during 
and after treatment (Barry, 2005; Fattore et al., 1988; Hoffman et al., 2016; McCaul, 2012) to 
minimise the impact of side-effects on overall QoL. The UK National Institute for Clinical 
Evidence (NICE) has also recommended that every HNC patient should have a pre-treatment 
dental assessment (National Institute for Clinical Excellence (NICE), 2004).   
The efficacy of pre-treatment dental review is well documented (Keys and McCosland, 1976). 
It involves identification and elimination of dental disease prior to cancer treatment (including 
extraction of teeth with poor long term prognosis), improving patient awareness of the expected 
acute and chronic side-effects of treatment (including information on how they can access 
appropriate dental care), and implementation of strategies to manage anticipated side-effects 
such as diet modification and appropriate oral hygiene regimens (Andrews and Griffiths, 
2001b; Jawad et al., 2015). As discussed previously, the demand for pre-treatment dental 
stabilisation is high among HNC patients entering treatment; Lockhart and Clark have reported 
that 97% of dentate HNC patients examined prior to RTx needed immediate dental care in their 
1994 study (Lockhart and Clark, 1994).  
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No universally accepted evidence-based standard criteria/models of care exist to guide decision 
making, and intervention is subject to clinical judgement (Barker et al., 2005). The aim is to 
obviate the need for invasive procedures in areas that are planned to receive a high RTx dose 
and may be at risk of ORN if traumatised in the future (Andrews and Griffiths, 2001b).  
Access to dental care is also important during HNC treatment, when acute side-effects first 
manifest, although in practice, these issues are usually dealt with by medical staff at RTx or 
CTx review appointments (for example, palliation of mucositis) (Epstein et al., 2018).  
Access to post-treatment dental care is also essential in order to prevent and manage the late 
toxicity of HNC treatment such as radiation caries, trismus and dry mouth (Andrews and 
Griffiths, 2001a; b).  
 
 
2.10.2. Access to dental care  
 
Access to specialist dental management for these patients is scarce; approximately 85% of 
registered dentists in Australia in 2013 (Chrisopoulos et al., 2016) and 88% in New Zealand 
in 2015 were registered general practitioners. In addition, the availability of special 
needs/hospital dental specialists has not kept pace with the increasing number of HNC 
survivors within the population; Dental Council of New Zealand (DCNZ) workforce statistics 
record a total of 9 special needs dental specialists in New Zealand in 2012 and 8 in 2015 
(Dental Council of New Zealand (DCNZ), 2017). Similarly, there were 13 special needs 
dental specialists in Australia in 2012 and this had reduced to 12 in 2016 with none in 
Western Australia, Tasmania, Northern Territory or the Australian Capital Territory 
(Australian Institute of Health and Welfare (AIHW), 2014; 2019). However, both New 
Zealand and Australia data show increased numbers of total registered dentists over time 
(Australian Institute of Health and Welfare (AIHW), 2019; Dental Council of New Zealand 
(DCNZ), 2017).  
 
Furthermore, the majority of dentists in Australia work primarily in the private sector (50.8 
general dentists per 100,000 population in Australian private practice, compared with only 
7.6 dentists per 100,000 in the public sector) (Chrisopoulos et al., 2016; Dental Council of 
New Zealand (DCNZ), 2017). Likewise, the minority of New Zealand dentists worked as a 
general dentist in the public sector in 2013, with only 4% listing a District Health Board or 
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the Ministry of Health as their primary employer (Dental Council of New Zealand (DCNZ), 
2017). Consequently, it follows that the majority of HNC patients will be managed by a 
general dentist (albeit an upskilled general dentist, when accessing care in the public sector). 
This is an important point of note as these public sector dentists are a key point of contact for 
HNC patients and, even though some patients may elect to return to their usual private sector 
dentist for ongoing maintenance, these practitioners will need be in constant liaison with their 
hospital-based colleagues in order to appropriately manage these patients into the future.  
 
Although HNC MDTs that include dentists are recommended in the evidence-base, few cancer 
centres engage either experienced dentists or have integrated dental treatment facilities on site 
(Barker et al., 2005; Epstein et al., 2014; Huber and Terezhalmy, 2003; Ray-Chaudhuri et al., 
2013; Specht, 2002; Sroussi et al., 2017). For example, a UK national survey investigating the 
availability of general dental services to HNC patients being treated in MDT clinics showed 
that 34% did not have access to restorative dentistry and 41% did not have access to preventive 
dental care (Lawrence et al., 2013). An earlier survey of 20 provincial Canadian cancer care 
centres in 1999 reported that only 4.7 full-time-equivalent dentists were employed among them 
(Epstein et al., 2004). 
  
In NSW (Australia), only residents who hold means-tested concession or pension cards are 
eligible to receive free general dental care from dentists in the public sector (NSW Centre for 
Oral Health Strategy (COHS), 2017). This is also the case in other Australian States and 
Territories, although the length of waiting lists to access care vary widely. Likewise, only 
medically compromised or Community Services Card (low income concession card) holders 
are able to access dental care in the New Zealand public sector (New Zealand Ministry of 
Health, 2019a). It therefore follows that most HNC survivors will look to general dentists in 
private practice for their treatment needs. It is reported that most long-term dental care of HNC 
patients in North America is provided in the private sector (Murdoch-Kinch and 
Zwetchkenbaum, 2011), and there is nothing in the literature to suggest that this would be 
different in Australia or New Zealand. Indeed, Barker et al (Barker et al., 2005) has reported 
that only about one quarter of 212 HNC centres in North America, Europe, South America, 
Australia, and China in 2002 had integrated dental and medical services, and that most patients 
accessed their dental care in the community. Epstein et al (Epstein et al., 2018) has also reported 




After more than a decade practising as a Sydney West Cancer Network (SWCN) Head and 
Neck Service dentist, I have gained the impression that general dentists are typically 
uncomfortable treating patients with a history of HNC. Reasons anecdotally cited include 
medicolegal risk mitigation, complexity of care, volume of dental disease and knowledge gaps. 
As a result, many HNC patients report that they find it difficult to access dental care, and they 
tend to delay presentation until their dental disease is advanced (Bertl et al., 2016).  
There is evidence in the literature to support this impression, albeit none from Australasia. A 
retrospective survey of 444 UK HNC patients treated in the period January 1998 to December 
2009 found that only 69% had attended a dentist regularly post-RTx (Pace-Balzan et al., 2014). 
A German study compared dental attendance among 37 patients irradiated for HNC in 1993 
and 36 patients irradiated in 2005 and has reported that, while 94% of patients were regular 
dental attenders prior to RTx, only 53% self-reported maintaining this habit after RTx 
(Sennhenn-Kirchner et al., 2009). Similarly, Lawrence et al (Lawrence et al., 2013) reviewed 
the UK national oncology register and observed that 69% of HNC patients were self-reported 
regular dental attenders prior to RTx, but 52% reported not having been to a dentist in over 12 
months following completion of RTx. In Austria, Bertl et al (Bertl et al., 2016) noted that, six 
months after HNC treatment, only one-third of patients had visited a dentist for a check-up, 
and one third had not presented for over 12 months.  
In 2010, a random sample of 198 general dentists in the North-West of the UK was surveyed 
to assess barriers to HNC patients accessing dental treatment (Husein et al., 2011). It found 
that 53% of participants were ‘not at all’ or ‘a little’ happy to treat HNC patients, and that 64% 
of these clinicians attributed this to the treatment required being too complex. Dentist 
willingness to provide treatment differed by procedure, with 90%, 85% and 58% happy to 
perform routine restorations, periodontal work and root canal work, respectively. In contrast, 
only 28% of dentists reported that they were willing to undertake a dental extraction for a HNC 
patient (Husein et al., 2011).  
In summary, from the work that has been done internationally in this area, it would seem that 
there is generally insufficient access for HNC patients to obtain dental care. Dental services 
operating in conjunction with medical teams are rare, the willingness and ability of general 
dentists to provide care is variable and, perhaps as a result, the dental attendance of HNC 




2.10.3. Characteristics of dentists treating Head and Neck Cancer patients 
 
The literature supports the critical role that the general dentist plays in managing HNC patients 
(Burke et al., 2012; Hoffman et al., 2016; Huber and Terezhalmy, 2003; Noone and Barclay, 
2017). It specifies that appropriate general dentists should be experienced and knowledgeable 
about HNC at least, due to the complexity of the disease (Beech et al., 2014; Epstein et al., 
2014; Hancock et al., 2003; Murdoch-Kinch and Zwetchkenbaum, 2011). The British 
Association of Head and Neck Oncologists (BAHNO) has recommended that all cancer 
patients should be assessed by a ‘suitably qualified dental practitioner’ before and after 
treatment (British Association of Head and Neck Oncologists (BAHNO), 2009). The 
International Society of Oncology (ISOO) (Multinational Association of Supportive Care in 
Cancer and International Society of Oral Oncology (MASCC/ISOO), no date of publication 
specified) is even more prescriptive in stating that dentists treating HNC patients must have 
“an accurate knowledge of the burden of illness, effective prevention, and treatment of oral 
complications” (Multinational Association of Supportive Care in Cancer and International 
Society of Oral Oncology (MASCC/ISOO), no date of publication specified). Similarly, 
Epstein et al (Epstein et al., 2014) specified that such a dentist should contribute to the 
evidence-base, have lecturing experience, and have attended continuing professional 
development activities with regard to HNC. Epstein et al (Epstein et al., 2014) also commented 
that practitioners may be identified at the cancer centre, local dental hospital or within the 
community. 
 
2.10.4. Barriers to dentists providing care to Head and Neck Cancer patients 
 
Investigation of the knowledge, attitude and practise of general dentists in this area has been 
limited (Guneri et al., 2008). Indeed, my literature search identified one study investigating the 
knowledge and behaviour of general dentists in Australia, and that was about perinatal oral 
health (George et al., 2017). Almost all knowledge, attitude and behaviour surveys in the 
international dental literature have focused on aspects of HNC diagnosis rather than 
management of the dental sequelae associated with HNC treatment (Borhan-Mojabi et al., 
2012; Hertrampf et al., 2011; Horowitz et al., 2000; Rocha-Buelvas et al., 2012; Vijay Kumar 
and Suresan, 2012).  
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Moreover, most of this evidence is derived from surveying final year dental students who are 
not sufficiently clinically experienced to meet the requirements of a general dentist treating 
HNC patients as recommended in the literature, not having had the opportunity for their 
knowledge and practice to be shaped by practical experience. Students have presumably been 
used due to ease of sampling and as a means of maximising participation rates, although this 
limits the generalisability of the findings to all general dentists, and would be heavily 
influenced by the content of various dental schools teaching curricula. 
For example, in 2008, a Turkish study by Guneri et al (Guneri et al., 2008) sought to determine 
the level of knowledge of the orodental complications of HNC treatment and their 
prevention/management in a non-random sample of 380 dental students and dental specialists 
from Ege University in Izmir (Turkey), along with local dentists. The study used a standardised 
questionnaire obtained from the Turkish National Institute of Dental and Craniofacial 
Research. Guneri et al (Guneri et al., 2008) reported ‘good’ levels of basic knowledge about 
HNC therapy in the sample surveyed (although correct replies to questions ranged from 14.7% 
to 99.5%), however over half of all participants failed to correctly identify dental interventions 
that should be performed for HNC patients. This failure to turn basic knowledge into clinical 
practise is of concern in this age of evidence-based medicine; however, perhaps this is the result 
of wide variation in oral care protocols for HNC patients, even among subject matter experts, 
or a reflection of the limited clinical experience of the dental student participants. 
The quality of the few studies that my literature search identified as pertaining to dentist 
management of HNC patients is poor and the results disheartening. In a cross-sectional survey 
of general dentists and general medical practitioners in Qazvin, Iran in 2007, general dentists 
could only correctly answer between 38% and 68% of the 16 knowledge questions asked 
(Borhan-Mojabi et al., 2012). Similarly, a 2014 study of all dentists and dental specialists 
operating in the South Khorasan Province of Iran reported that the general dentists could 
answer between 51% and 83% of the 11 knowledge questions that they were asked correctly 
(Akbari et al., 2015). 
The literature is also unclear regarding whether clinical knowledge regarding management of 
HNC patients is associated with dentist demographics such as age, years in practice and gender. 
The Turkish research by Guneri et al which has been previously cited, concluded that clinician 
gender, age and type of practice are not associated with the level of HNC knowledge that a 
clinician possesses (Guneri et al., 2008). This conclusion is in contrast to other studies in the 
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literature (Akbari et al., 2015; Borhan-Mojabi et al., 2012; Clovis et al., 2002). Clovis et al 
(Clovis et al., 2002) reported a negative association between knowledge and years of practice 
among a random sample of dentists in British Columbia and Nova Scotia. Likewise, a 2007 
Iranian study by Borhan-Mojabi et al (Borhan-Mojabi et al., 2012) found that dentists with 
between 1 and 4 years of clinical experience were able to provide the correct answer between 
64% and 95% of the time for each knowledge question asked, but their colleagues with twenty 
or more years of experience only answered correctly between 49% and 71% of the time. Akbari 
et al (Akbari et al., 2015) demonstrated this same association, with ‘new graduates’ (those with 
5 or less years or less of clinical experience) answering knowledge questions correctly 55% of 
the time compared with 51% accuracy among those who had practiced for 15 years or more. 
This would make sense despite the quality weaknesses of these studies because the knowledge 
acquired during basic vocational training would likely attenuate over time, especially if not 
used on a regular basis. 
Several studies report that dentists generally feel that their undergraduate learning with regard 
to HNC was insufficient for them to provide care for HNC patients (Clovis et al., 2002; Guneri 
et al., 2008; Patel et al., 2012).  Burzynski et al (Burzynski et al., 2002) conducted a 22-question 
survey of graduating dental students at US dental schools across 3 states and has reported a 
widespread perceived lack of knowledge and skill with regard to HNC amongst those 
participants that self-selected for inclusion. The study reported that between 26% and 69% of 
respondents had never read a biopsy report and between 32% and 81% were not confident in 
their ability to interpret one (Burzynski et al., 2002). In five of the seven schools surveyed, the 
perceived lack of education regarding orofacial side-effects of cancer treatment was greater 
than 24% (Burzynski et al., 2002). Such findings may be rationalised to some degree by 
considering the demands placed on the undergraduate dental curriculum, paired with the lack 
of access that most dental schools have to this type of medically compromised patient.  
The literature offers few other suggestions regarding barriers to dentists treating HNC patients 
in practice. Kischner and Elzay (Kischner and Elzay, 1984) write that 51.2% of general dentists 
in their study reported anxiety at the thought of seeing HNC patients and 5.3% preferred not to 
treat these patients . Phenomenographic (experiential qualitative research) work out of Sweden 
has expanded on this, describing how general dentists understand and experience their role in 
treating HNC patients, including how some dentists find this to be an overwhelming emotional 
situation and feel that they have not been trained to cope adequately (Roing et al., 2006). 
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Basic dental education aside, the majority of dentists report that they have also not 
undertaken continuing professional development in this area (although most would be 
interested in undertaking HNC modules or postgraduate study) (Clovis et al., 2002). Indeed, a 
survey of 93 Southern Columbian dentists undertaken in 2009 reports a statistically 
significant correlation between dentist self-reported belief that they are adequately trained to 
undertake an oral cancer examination and having attended a formal course within the last 12 
months (Rocha-Buelvas et al., 2012). 
Other barriers reported by dentists, albeit to oral cancer screening, were a perception of 
insufficient time in the clinical appointment and lack of financial incentive (Allen and Farah, 
2015).  
In summary, there is little in the evidence base to describe the knowledge, attitude and 
behaviour of general dentists treating HNC patients, and no evidence from Australasia. From 
the poor quality studies that exist, we can conclude that the knowledge of most general dentists 
does not measure up to the standard recommended by expert authors and peak cancer care 
organisations. The willingness of general dentists to treat HNC patients for certain procedures, 
and the conversion of willingness into provision of treatment in practice is also sub-optimal, 
and may be influenced by emotional anxiety and perceived lack of knowledge as barriers to 
providing care.  
 
 
2.11. Summary  
 
The incidence and survivability of HNC is increasing worldwide and in both NSW 
(Australia) and New Zealand. At the same time, the dental profile of Australasians has 
changed; edentulism is at an all-time low and Antipodeans are retaining more of their teeth 
for longer.   
 
In addition, IMRT RTx has emerged as the standard of care in HNC and, coupled with a lack 
of evidence to support prophylactic dental extraction of teeth in the high dose field prior to 
treatment, this has meant that a more conservative treatment paradigm is being used by 




The literature is clear that HNC patients are at a higher-than-average risk of dental disease 
due to long-term side-effects associated with cancer treatment. Concurrent with the 
epidemiological trends referred to above, dentists are facing a situation when there is a rising 
number of dentate HNC survivors in the population, each bearing significant dental burden as 
a direct result of their cancer treatment.  
 
Problematically, few cancer centres operate with a dentist on their MDT and most NSW 
(Australia) and New Zealand residents are not eligible for free or subsidised dental treatment 
in the public sector. The evidence-base is supportive of general dentists treating HNC 
patients, however it suggests that they may have insufficient knowledge to do this in practice. 
There is also evidence that dentists are less-willing to treat HNC patients and perform some 
simple dental procedures for them relative to other patients, perhaps due to perceived lack of 
knowledge and the emotional toll that may be exacted. Indeed, this impression is reinforced 
by my own clinical practice, with HNC patients frequently reporting that their family dentist 
will no longer treat them and recommend that they return to a hospital dental clinic for all 
their future dental requirements.  
 
There is a paucity of information in the evidence-base to validate this impression.  No 
Australasian studies have been undertaken to examine the knowledge, attitudes and practise 
of general dentists treating HNC patients. This is the motivation for this study which seeks to 
describe access to general dental care and report on the clinical competence of general 
dentists with regard to treating HNC patients. 
 
It is hoped that by identifying gaps in the practise of general dentists treating HNC patients, 
recommendations can be made to address the barriers faced by HNC patients needing to 









Chapter Three will outline the methodological design used in this study. This will be discussed 
in terms of literature review, study design, inclusion/exclusion criteria, the sampling frame, 
sample size, sampling strategy, ethical considerations, study instruments and data analysis. 
 
 
3.2. Literature Review 
 
3.2.1. Search strategy 
 
Medline (1946-present) was searched using the subject headings (MeSH terms) “Mouth 
Neoplasms” OR “Oropharyngeal Neoplasms” AND “Health Knowledge, Attitudes, Practise” 
OR “clinical competence” OR “Attitude of Health Personnel” OR “Practice Patterns, Dentists” 
AND “Dentist” OR “General Practice, Dental”. This search returned 84 results. The same 
search was undertaken in Embase (1947-present) using Emtree subject headings, and this 
returned 12 results. 
 
Studies were also located using an identical systematic keyword search strategy in Medline, 
Embase, Web of Science (1946-present) and the Cochrane Library (2005-present) electronic 
databases. These keywords were: “mouth cancer*” OR “oral cancer*” OR “mouth neoplas*” 
OR “oral neoplas*” OR “ oropharyng* neoplas*” OR “oropharyng* cancer*” AND 
“knowledge attitude* behaviour*” OR knowledge attitude*  practice*” OR “health knowledge 
attitude* behaviour*” OR “health knowledge attitude* practice*” OR “clinical competence” 
AND “dentist” OR “general dentist” OR “general dental practitioner” OR “dental 
practitioner*” OR “dental clinician*”. This search yielded 36 results. 
 
A separate search using the same keyword strategy provided above was also undertaken in 
Web of Science (WoS) (1946-present) and this returned 52 results. Search strategies are 
provided in Appendix 1.  
 
Duplicate citations were removed manually. Relevant studies were identified by reading the 
title or the title and abstract of the papers identified in the above searches. In addition, the 
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bibliographies of key texts and papers that were highly relevant to the subject field were hand-
searched for relevant secondary references. 
 
Staff librarians from University of Otago and Western Sydney Local Health District (WSLHD) 
supervised the creation of the search strategy. They also undertook independent searches of the 
topic to ensure the comprehensiveness of the strategy, and additional relevant articles were 
identified for use.  
 
3.2.2. Inclusion/Exclusion criteria 
 
The search was restricted to English language publications. Unpublished studies were not 
included in the search strategy. Experiential and opinion pieces were also included (type IV 
evidence) because of their relevance to the topic.  
 
 
3.3. Survey design  
 
A cross-sectional descriptive epidemiological survey of general dentists registered in New 
Zealand was undertaken. Qualitative interview of key informants (general dentists identified 
as having substantial experience providing dental treatment for HNC patients) was used to 
enable further understanding of the data. 
 
 
3.4. Inclusion/exclusion criteria 
 
Dental students, Dental Specialists, Oral Health Therapists, Hygienists, Dental Therapists and 
Dental Prosthetists were excluded from participation in the survey because the study was 
specifically evaluating general dentists. In addition, these people would have had more or less 
professional training and exposure to treating HNC patients than the average general dentist in 
practice. Exclusion was built into the study design; first, the 2018 Dental Council of New 
Zealand (DCNZ) register1 which was used as the sampling frame had been filtered to include 
only dentist registrants who held registration in the general dentistry scope of practice. Second, 
                                                                
1  Obtained by the Sir John Walsh Research Institute (SJWRI) from the Dental Council of New Zealand (DCNZ) 
in March 2018. 
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the first survey question was “are you registered as a general dental practitioner?”, and this was 
intended to exclude any practitioners in the frame who may have been erroneously missed by 
the filter. A negative response automatically prompted the survey to default to the final screen 
of the survey advising the participant that there were no more questions and thanking them for 
their time.  
 
 
3.5. Sampling frame 
 
 
The sampling frame was all general dentists registered to practise in New Zealand in 2018, and 
so the 2018 DCNZ Register was used.  
 
In New Zealand, all practising dentists must be registered with the DCNZ and hold an Annual 
Practicing Certificate (APC) as per the Health Practitioners Competence Assurance Act 2003 
(New Zealand Parlimentary Councel Office, 18 Sept 2003) and Health Practitioners 
Competence Assurance Amendment Act 2019 (New Zealand Parlimentary Councel Office, 11 
April 2019). The DCNZ is a professional regulatory body that is charged with ensuring that 
dental practitioners in New Zealand meet and maintain standards as a means of protecting the 
health and safety of the public. The DCNZ maintains a public register containing details of all 
registered practitioners, who consent to having these details made publicly available at the time 
of their annual registration. 
 
 
3.6. Sampling strategy 
 
 
Eight hundred general dentists that were registered in the general dentistry scope of practice 
with the DCNZ in 2018 were randomly selected to be invited into the study using the random 
selection procedure in SPSS. 
   
I anticipated a participation rate of 50% (or less) from the evidence-base: Cook et al (Cook et 
al., 2009) undertook a systematic review of 350 postal surveys sent to healthcare professionals 
in 2009 and reported a 57.5% (95% CI 55.2-59.8%) response rate; and, in 1995, Chapman 
(Chapman, 1995) surveyed 350 Australian dentists using a postal survey and obtained a 45% 
response rate. Similarly, a postal survey about demographics, practice arrangements and 
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standards which was distributed to a random sample of 351 New Zealand general dentists in 
2016 achieved a 53.5% response rate (Lee et al., 2018). Web-based surveys had previously 
been found to have similar return rates to postal surveys in a study of private sector dental fees 
carried out by the Australian Dental Association (ADA) in 2016 (Australian Dental Association 
(ADA), 2017).  
 
 
3.7. Sample size  
 
 
The study aimed to investigate the knowledge, attitude and practising behaviours of general 
dentists in treating patients with a history of HNC.   
 
Because this study was the first of its kind in Australasia, the required sample size had to be 
calculated based on data from a related study in Iran which had reported knowledge levels 
among dentists in 2014 (Akbari et al., 2015). In that study, 50.7% of participants were male 
(Akbari et al., 2015). The mean knowledge score for all dentists in this study was 72%, when 
knowledge score was converted from mean score to percentage of all questions answered 
correctly (Akbari et al., 2015). The calculation was made using G*Power software to provide 
80% power at an alpha of 0.05 (95% confidence interval). A total sample size of 788 dentists 
was required. This was rounded up to 800 for the purposes of the study. The calculation is 
provided in Appendix 2. 
 
 
3.8. Ethical considerations 
 
Ethical approval was sought and obtained from Western Sydney Local Health District Human 
Research Ethics Committee (WSLHD-HREC) (Appendix 3) and the University of Otago 
Human Ethics Committee (Appendix 4). Approval was also sought from Te Rūnanga o Ngāi 
Tahu, as the principal Māori iwi (tribe) of the southern region of New Zealand, extending from 
Blenheim, Mount Mahanga and Kahurangi Point to Stewart Island in the South Island of New 
Zealand (Appendix 5). 
 
Informed consent was not collected from survey participants because it was implied by 
participants taking the online survey. For the second phase of the study, written informed 
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consent was collected from key informant participants prior to the author undertaking face-to-
face interviews with these people (Appendix 6).  
 
All study materials were stored electronically on the investigator’s New South Wales (NSW) 
Health computer which is only accessible using the investigator’s username and password.  
Similarly, data collected using Qualtrics software (the digital survey platform used; see section 
3.9.1) was secured by a username and password known only to the investigator. 
 
 




A 15 item self-administered web-based survey was developed by several general dentists that 
were identified by the investigator as having significant experience in providing dental care to 
HNC patients, using Qualtrics software.  Data were collected in the 4 domains of demographic 
characteristics (8 questions), knowledge (2 questions), attitude (1 question) and practise (4 
questions). This survey is reproduced in Appendix 7. The time to complete the survey was not 
restricted. 
 
Most questions were multiple choice (some permitting multiple answers and some permitting 
free text). One of the two knowledge questions consisted of 5 sub-questions and the attitude 
question had 9 sub-questions, both of which were answerable on a Likert scale. 
 
The draft survey was pre-tested on a group of 10 general dentists to evaluate it in terms of 
structure, content, language and acceptability; that is, to establish content validity. These 
participants were convenience sampled from a pool of 130 dentists employed at Westmead 
Hospital, Western Sydney Local Health District (WSLHD) in Sydney, Australia. The survey 
was modified according to feedback. 
 
Eight hundred randomly sampled general dental registrants from the DCNZ Register were 
invited into the survey on 27th September 2018, via email. This invitation was sent to the email 
account address provided to DCNZ on annual registration, and was distributed via Qualtrics 
software. The email contained summarised information on the purpose of the study and the 
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importance (and the likely burden) of participation. It contained a hyperlink to the study and a 
URL that could be copied and pasted to a browser, as a fail-safe should the link not work. An 
email reminder was distributed to all invitees who had failed to participate after one week, and 
again after two weeks, in order to bolster participation. 
 
Participation in this study was voluntary and a completed survey implied informed consent. 
 
All responses were anonymous (the investigator was blinded to the participant identities). 
 
 
3.9.2. Key informant interviews 
 
The results of the survey were discussed with key informants to identify where and to what 
extent they aligned with, or differed from, expectations based on their clinical experience (data 
triangulation).  
 
These four key informants were identified, purposively sampled by the investigator based on 
geographical availability and invited into the study based on their extensive experience 
providing dental treatment for patients with HNC. These key informants were all Sydney 
(Australia) based (and were therefore not part of the study frame). These individuals had a 
cumulative total of 115 years of clinical experience as registered general dentists, with the least 
experienced informant having 14 years of experience and the most experienced informant 
having 51 years of experience. All four informants had a work history across both public and 
private sectors. One had clinical experience with HNC patients in both New Zealand and 
Australia. All four informants had worked at multiple different sites/LHDs within the NSW 
public health system. Three of the four were Sydney University graduates and one was a New 
Zealand dental graduate. One of the informants currently worked for two Sydney HNC MDTs 
concurrently (SWCN and St George Hospital, Sydney). Collectively, these people constitute 
the total dental support provided to SWCN HNC MDT which currently receives over 500 new 
patient referrals per annum. Together, these key informants have 83 years of cumulative 
experience working for SWCN HNC MDT. 
 
Informed consent was collected from each key informant prior to interview. The Participant 




The investigator conducted one-on-one, face-to-face semi-structured interviews of 30 minutes 
to 1 hour duration each with four key informants. The interview structure is presented in 
Appendix 8, and Appendix 9 is the template that was used by the interviewer to record data 
during the interviews. 
 
 
3.10. Data analysis 
 
Data were exported from Qualtrics to SPSS Version 25 (as a .sav file). The investigator cleaned 
the dataset manually by deleting the data associated with a research supervisor and the 
University of Otago Human Ethics Committee representative (neither of whom fit the inclusion 
criteria for participation) trialling the survey online. 
 
All data manipulation and analysis was performed by the investigator within SPSS Version 25 
using written syntax code (Appendix 10). Following the computation of summary statistics, 
differences in proportions were elucidated using cross-tabulations and chi-square statistics 
(with P<0.05). Differences in means used analysis of variance. 
 









Email invitations to participate were sent to 800 dentists registered in the general dentistry 
scope of practice, who had been randomly sampled from the 2018 DCNZ register. 
  
The initial invitation yielded a 7.3% response rate after one week. A further invitation was 
emailed to non-responders and, two weeks after the initial invitation, participation had 
increased to 19.4%. A third invitation was emailed one week later to those who had failed to 
respond to the previous two invitations, and this further bolstered the participation rate to 
20.4%.   
 
 
4.2. Sample Characteristics 
 
Table 3 summarises the characteristics of the responding sample.
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Table 3. Age group and practicing characteristics by sex (brackets contain column 
percentages unless otherwise indicated). 
 Sex 
 Malea Femalea Total 
Mean age (SD)   52.0 (13.7)  41.5 (11.6)b    46.8 (13.7)  
Age group (years)    
<35  12 (32.4)  25 (67.6)b   37 (24.0)  
35-49  17 (35.4)  31 (64.6)   48 (31.2)  
50-59  24 (61.5)  15 (38.5)   39 (25.3)  
60+  25 (83.3)    5 (16.7)   30 (19.5)  
NZ-trained    
No  24 (47.1)  27 (52.9)   51 (33.1) 
Yes  54 (52.4)  49 (47.6) 103 (66.9) 
Any public practice experiencec    
No  70 (54.3)  59 (45.7)d 129 (86.0) 
Yes    6 (28.6)  15 (71.4)   21 (14.0)  
Practice location    
Urban  67 (51.1)  64 (48.9) 131 (85.1) 
Rural  11 (47.8)  12 (52.2)   23 (14.9) 
Years in practice    
<10  11 (29.7)  26 (70.3)b   37 (24.0) 
10-19  15 (51.7)  14 (48.3)   29 (18.8)  
20-29    9 (29.0)  22 (71.0)   31 (20.1)  
30-39  24 (68.6)  11 (31.4)   35 (22.7)  
40-49  16 (84.2)    3 (15.8)   19 (12.3)  
50+    3 (100.0)    0 (0.0)     3 (1.9)  
Practice sector    
Private  70 (54.3)  59 (45.7) 129 (83.8) 
Public    0 (0.0)    7 (100.0)     7 (4.5) 
   Both private and  
     public 
   6 (42.9)    8 (57.1)   14 (9.1) 
Not practising    2 (50.0)    2 (50.0)     4 (2.6) 
    
Total  78 (50.6)  76 (49.4) 154 (100.0) 
a Row percentages 
b P<0.001 




Roughly equal numbers of male and female dentists participated in this study. The age 
distributions of males and females differed. Female participants were, on average, over a 
decade younger than male participants, with less variability in their age distribution.  
 
About one quarter of all participants were aged 35 years or younger and about another quarter 
were in their fifties. One fifth of all participants were aged 60 years or more. Overall, most 
participants were aged 35 to 49 years, indicating around 15 years of clinical experience. 
One in seven of all survey participants reported that they had experience working in the 
public dental sector. Female dentists were more likely to have worked in the public system 
than their male colleagues. Indeed, no male participant reported that he currently worked in 
the public sector alone; however, almost one in ten female respondents did. 
 
Sex was associated with years in clinical practice. Male respondents were most likely to have 
been in the dental industry for longer. Fewer than 20% of female respondents had practised 
for thirty years or more in the sample, while over half of all males had (including three 











4.3. Knowledge of HNC and treatment side-effects 
 
Participants were presented with a series of 11 signs and symptoms and asked to indicate which 
were common side-effects of HNC radiotherapy (RTx). Table 4 presents data on the 
participant’s knowledge of common RTx side-effects, with data presented as a percentage of 
all questions which were answered correctly. 
 
 
Table 4. Respondent knowledge of common radiotherapy (RTx) side-effects (brackets 
contain row percentages unless otherwise indicated). 
 Response 
 Correct Incorrect 
Gastritis 137 (89.0) 17 (11.0) 
Higher caries incidencea 144 (93.5) 10 (6.5) 
Higher osteoradionecrosis 
riska 
139 (90.3) 15 (9.7) 
Problems wearing denturesa 133 (86.4) 21 (13.6) 
Restricted mouth openinga   99 (64.3) 55 (35.7) 
Permanent loss of taste   64 (41.6) 90 (58.4) 
Mucositisa 128 (83.1) 26 (16.9) 
Colitis 140 (90.9) 14 (9.1) 
Dry moutha 148 (96.1)   6 (3.9) 
Nephrosis 146 (94.8)   8 (5.2) 
Problems swallowinga 126 (81.8) 28 (18.2) 
acommon side-effects of HNC RTx acknowledged in the evidence base. 
 
 
Overall, respondents had good levels of knowledge of most common HNC RTx side-effects 
(more than 80% of respondents selected the correct response for most signs/symptoms).  
Respondents scored poorly, however, with regard to knowledge of restricted mouth opening 
and loss of taste; more than half of all respondents erroneously believed that HNC RTx was 











Table 5. Correct responses to knowledge questions by participant characteristics. 
 Number of correct responses out of 11 total 
 Mean Standard deviation (SD) 
Sex   
   Male   6.7    2.1 
   Female   6.8    2.1 
Age group   
  <35   6.6    2.4 
  35-49   6.5    2.1 
  50-59   7.6    1.6 
  60+   6.5    2.0 
NZ trained   
  No   6.6    2.2 
  Yes   6.9    2.0 
Public sector experience   
  No   6.8    2.1 
  Yes   6.9    2.0 
Practice location   
  Urban    6.8    2.1 
  Rural   6.8    2.2 
Years in practice   
  <10   6.7    2.5 
  10-19   6.6    2.2 
  20-29   6.7    1.9 
  30-39   7.4    1.4 
  40-49   6.7    1.7 
  50+   4.0    3.6 
Practice sector   
  Private   6.8    2.1 
  Public   7.9    1.1 
  Both public and private   6.4    2.2 
  Not working   7.3    2.1 
Number of HNC patients seen in practice in previous 12 months   
  None   6.4    1.9a 
  1-5   7.2    1.5 
  6-19   7.3    0.9 
  20+   8.5    1.4 
   




Dentists who had recently seen higher numbers of HNC patients had a higher mean 














Participants were asked to respond to four knowledge statements on a Likert scale of strongly 
agree, agree, neither agree nor disagree, disagree or strongly disagree. Table 6 summarises 
responses to each of those HNC patient knowledge statements. 
 
 
Table 6. Participant responses to common knowledge statements (brackets indicate row 
percentages unless otherwise indicated). 








“Dry mouth after radiotherapy is 
temporary.  Saliva goes back to 
normal with time as saliva glands 
heal”a 
 
 3 (2.0) 30 (20.3) 25 (16.9) 67 (45.3) 23 (15.5) 
“More than half of all people treated 
for HNC will survive for 5 years or 
longer”a   
 
 9 (5.8) 56 (37.8) 51 (34.5) 28 (18.9)   4 (2.7) 
“Radiotherapy directly damages the 
teeth”b.  
 
 2 (1.4)   6 (4.1) 11 (7.5) 88 (59.9) 40 (27.2) 
“Non-smokers and non-drinkers 
don’t get HNC”a 
 
 1 (0.7)   0 (0.0)   5 (3.4) 50 (33.8) 92 (62.2) 
a missing data for 6 respondents 





Most respondents chose to agree/strongly agree or disagree/strongly disagree with the five 
knowledge statements posed; that is, the minority ‘sat on the fence’ choosing to neither agree 
nor disagree with the knowledge statement. Over one-third of all respondents chose this 
option for the question on five-year survival however. 
 
Fewer respondents felt ‘strongly’ one way or the other compared with simply agreeing or 
disagreeing with the knowledge statements posed; that is, fewer respondents were resolute 







Tables 7 to 11 summarise participant responses to each of the four individual knowledge 




Table 7. Knowledge of statement 1 by sample characteristics (brackets contain row 
percentages unless otherwise indicated). 
 “Dry mouth after radiotherapy is temporary.  Saliva 
goes back to normal with time as saliva glands 
heal”. 
 Incorrect response Correct responsea 
Sex   
   Male   31 (41.3)   44 (58.7) 
   Female   27 (37.0)   46 (63.0) 
Age group   
  <35   15 (42.9)   20 (57.1) 
  35-49   17 (37.0)   29 (63.0) 
  50-59   13 (33.3)   26 (66.6) 
  60+   13 (46.4)   15 (53.6) 
NZ trained    
  No   25 (52.1)   23 (47.9)c 
  Yes   33 (33.0)   67 (67.0) 
Public Sector experience   
  No   51 (41.1)   73 (58.9) 
 Yes      5 (25.0)   15 (75.0) 
Practice location   
  Urban   49 (38.9)   77 (61.1) 
  Rural     9 (40.9)   13 (59.1) 
Years in practice   
  <10   13 (38.2)   21 (61.8) 
  10-19   11 (39.3)   17 (60.7) 
  20-29   13 (41.9)   18 (58.1) 
  30-39   12 (34. 3)   23 (65.7) 
  40-49     8 (44.4)   10 (55.6) 
  50+     1 (50.0)     1 (50.0) 
Practice sector   
  Private   51 (41.1)   73 (58.9) 
  Public     3 (42.9)     4 (57.1) 
  Both private and public     2 (15.4)   11 (84.6) 
  Not working     2 (50.0)     2 (50.0) 
Number of HNC patients seen in practice in 
previous 12 months 
  
  None   23 (62.2)   14 (37.8)d 
  1-5   31 (33.0)   63 (67.0) 
  6-19     2 (22.2)     7 (77.8) 
  20+     0 (0.0)     6 (100.0) 
   
Totalb   58 (37.6)   90 (58.4) 
a salivary quantity and quality is permanently reduced by HNC RTx. Correct response is the 
number of those participants who disagreed/strongly disagreed with this knowledge 
statement.  Incorrect response is the number of those participants that agree/strongly 
agreed/neither agreed nor disagreed with this knowledge statement. 







More than half of the New Zealand graduates (but only one-third of the remainder) provided 
a correct response. 
 
There was a clear gradient between provision of a correct response to knowledge statement 1 
and HNC patient flow in the previous year in practice; dentists who reported that they had 
seen more HNC patients over the last year were most likely to respond correctly, and dentists 







Table 8. Knowledge of statement 2 by sample characteristics (brackets contain row 
percentages unless otherwise indicated). 
 
 “More than half of all people treated for HNC will 
survive for 5 years or longer”. 
 Incorrect response Correct responsea 
Sex   
   Male   37 (49.3)   38 (50.7) 
   Female   46 (63.0)   27 (37.0) 
Age group   
  <35   25 (71.4)   10 (28.6) 
  35-49   26 (56.5)   20 (43.5) 
  50-59   17 (43.6)   22 (56.4) 
  60+   15 (53.6)   13 (46.4) 
NZ trained    
  No   25 (52.1)   23 (47.9) 
  Yes   58 (58.0)   42 (42.0) 
Public Sector experience   
  No   70 (56.5)   54 (43.5) 
 Yes      9 (45.0)   11 (55.0) 
Practice location   
  Urban   70 (55.6)   56 (44.4) 
  Rural   13 (59.1)     9 (40.9) 
Years in practice   
  <10   22 (64.7)   12 (35.3) 
  10-19   19 (67.9)     9 (32.1) 
  20-29   15 (48.4)   16 (51.6) 
  30-39   16 (45.7)   19 (54.3) 
  40-49   11 (61.1)     7 (38.9) 
  50+     0 (0.0)     2 (100.0) 
Practice sector   
  Private   70 (56.5)   54 (43.5) 
  Public     4 (57.1)     3 (42.9) 
  Both private and public     5 (38.5)     8 (61.5) 
  Not working     4 (100.0)     0 (0.0) 
Number of HNC patients seen in practice in 
previous 12 months 
  
  None   18 (48.6)   19 (51.4) 
  1-5   55 (58.5)   39 (41.5) 
  6-19     6 (66.7)     3 (33.3) 
  20+     3 (50.0)     3 (50.0) 
   
Totalb   83 (53.9)   65 (42.2) 
a Australian Institute of Health and Welfare (AIHW) data 2010-2014 report 70% 5-year relative 
survival.  No comparative data was able to be sourced for New Zealand. Correct response is 
the number of those participants who agreed/strongly agreed with this knowledge statement; 
Incorrect response is the number of those participants that disagreed/strongly disagreed/neither 
agreed nor disagreed with this knowledge statement. 






There were no apparent differences by respondent characteristics. Half of all male 
participants, but only one-third of females provided a correct response to knowledge 
statement 2.   
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Table 9. Knowledge of statement 3 by sample characteristics (brackets contain row 
percentages unless otherwise indicated). 
 “Radiotherapy directly damages the teeth”. 
 Incorrect response Correct responsea 
Sex   
   Male   10 (13.5)   64 (86.5) 
   Female     9 (12.3)   64 (87.7) 
Age group   
  <35     2 (5.9)   32 (94.1) 
  35-49     6 (13.0)   40 (87.0) 
  50-59     7 (17.9)   32 (82.1) 
  60+     4 (14.3)   24 (85.7) 
NZ trained    
  No   10 (20.8)   38 (79.2)c 
  Yes     9 (9.1)   90 (90.9) 
Public Sector experience   
  No   18 (14.6) 105 (85.4) 
 Yes      1 (5.0)   19 (95.0) 
Practice location   
  Urban   16 (12.8) 109 (87.2) 
  Rural     3 (13.6)   19 (86.4) 
Years in practice   
  <10     1 (2.9)   33 (97.1) 
  10-19     4 (14.8)   23 (85.2) 
  20-29     6 (19.4)   25 (80.6) 
  30-39     6 (17.1)   29 (82.9) 
  40-49     1 (5.6)   17 (94.4) 
  50+     1 (50.0)     1 (50.0) 
Practice sector   
  Private   18 (14.6) 105 (85.4) 
  Public     0 (0.0)     7 (100.0) 
  Both private and public     1 (7.7)   12 (92.3) 
  Not working     0 (0.0)     4 (100.0) 
Number of HNC patients seen in practice 
in previous 12 months 
  
  None     4 (10.8)   33 (89.2) 
  1-5   14 (14.9)   80 (85.1) 
  6-19     1 (12.5)     7 (87.5) 
  20+     0 (0.0)     6 (100.0) 
   
  Totalb   19 (12.9) 128 (87.1) 
a  RTx has not been shown to directly damage teeth. Correct response is the number of those 
participants who disagreed/strongly disagreed with this knowledge statement. Incorrect 
response is the number of those participants that agreed/strongly agreed/neither agreed nor 
disagreed with this knowledge statement. 





Graduates with a New Zealand qualification were significantly more likely to provide a 
correct response to this knowledge statement.  
 





Table 10. Knowledge of statement 4 by sample characteristics (brackets contain row 
percentages unless otherwise indicated). 
 “Non-smokers and non-drinkers don’t get 
HNC”. 
 Incorrect response Correct responsea 
Sex   
   Male     3 (4.0)   72 (96.0) 
   Female     3 (4.1)   70 (95.9) 
Age group   
  <35     0 (0.0)   35 (100.0) 
  35-49     2 (4.3)   44 (95.7) 
  50-59     2 (5.1)   37 (94.9) 
  60+     2 (7.1)   26 (92.9) 
NZ trained    
  No     4 (8.3)   44 (91.7) 
  Yes     2 (2.0)   98 (98.0) 
Public Sector experience   
  No     6 (4.8) 118 (95.2) 
 Yes      0 (0.0)   20 (100.0) 
Practice location   
  Urban     5 (4.0) 121 (96.0) 
  Rural     1 (4.5)   21 (95.5) 
Years in practice   
  <10     0 (0.0)   34 (100.0) 
  10-19     1 (3.6)   27 (96.4) 
  20-29     2 (6.5)   29 (93.5) 
  30-39     1 (2.9)   34 (97.1) 
  40-49     1 (5.6)   17 (94.4) 
  50+     1 (50.0)     1 (50.0) 
Practice sector   
  Private     6 (4.8) 118 (95.2) 
  Public     0 (0.0)     7 (100.0) 
  Both private and public     0 (0.0)   13 (100.0) 
  Not working     0 (0.0)     4 (100.0) 
Number of HNC patients seen in practice 
in previous 12 months 
  
  None     3 (8.1)   34 (91.9) 
  1-5     2 (2.1)   92 (97.9) 
  6-19     1 (11.1)     8 (88.9) 
  20+     0 (0.0)     6 (100.0) 
   
  Totalb     6 (3.8) 142 (92.2) 
a Oropharyngeal cancer is strongly associated with HPV status, independent of alcohol and 
tobacco consumption patterns. Correct response is the number of those participants who 
disagreed/strongly disagreed with this knowledge statement.  Incorrect response is the 
number of those participants that agreed/strongly agreed/neither agreed nor disagreed with 
this knowledge statement. 




There were no apparent differences by respondent characteristics. The overwhelming 































Table 11 presents the mean number (and standard deviation) of correct responses to all 15 
knowledge challenges (11 RTx side-effects knowledge questions and 4 knowledge statements 




Table 11.  Mean HNC knowledge, by sample characteristics.  
 Correct responses out of 15 questions totala 
 Mean  SD 
Sex   
   Male     9.5      2.6 
   Female     9.6      2.7 
Age group   
  <35     9.2      3.1d 
  35-49     9.3      2.6 
  50-59   10.6      2.0 
  60+     9.1      2.6 
NZ trained    
  No     9.2      2.7 
  Yes     9.8      2.6 
Public Sector experience   
  No     9.5      2.7 
 Yes    10.0      2.7 
Practice location   
  Urban     9.6      2.6  
  Rural     9.5      3.0 
Years in practice    
  <10     9.4      3.4b 
  10-19     9.2      2.6 
  20-29     9.6      2.3 
  30-39   10.4      1.7 
  40-49     9.4      2.2 
  50+     5.7      5.5 
Practice sector   
  Private     9.5      2.7 
  Public   10.9      1.6 
  Both private and public     9.6      3.1 
  Not working     9.8      2.6 
Number of HNC patients seen in practice 
in previous 12 months 
  
  None     9.1      2.0c 
  1-5   10.1      1.9 
  6-19   10.1      1.3 
  20+   12.0      1.5 









The mean knowledge score was strongly associated with the volume of HNC patients that 
respondents reported seeing in practice over the previous year. There was a consistent 
gradient, whereby those who had seen more patients had higher knowledge scores. 
 
Overall knowledge score was associated with age group, however a one-way ANOVA test 
demonstrated that the difference was between the 50-59 year age bracket and the other age 
groups rather than a clear gradient of greater knowledge with advancing age. That is, 
participants aged 50-59 years demonstrated statistically better knowledge than those in older 
and younger age brackets. 
 
There was an association detected between years in practice and overall knowledge, however 
knowledge scores in the <10, 10-19, 20-29 and 40-49 years in practice groups were much the 
same. Instead, the difference detected was with the 30-39 years in practice group 
demonstrating higher than average knowledge scores and the most experienced clinicians 
























Table 12 presents data on respondents’ HNC-related continuing professional development 
(CPD) in the last 5 years (that is, dentists who report having upskilled their knowledge in this 
area of practice).  
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Table 12. Recent HNC CPD by sample characteristics (brackets contain row 
percentages unless otherwise indicated). 
 Undertaken HNC-related CPD in last 5 years 
 No Yes 
Sex   
   Male   41 (54.7)   34 (45.3) 
   Female   36 (49.3)   37 (50.7) 
Age group   
  <35   19 (54.3)    16 (45.7) 
  35-49   29 (63.0)     17 (37.0 )   
  50-59   13 (33.3)     26 (66.7)   
  60+   16 (57.1)     12 (42.9)   
NZ trained   
  No   20 (41.7)     28 (58.3) 
  Yes   57 (57.0)     43 (43.0)   
Public Sector experience   
  No   69 (55.6)     55 (44.4)b   
  Yes      6 (30.0)     14 (70.0)   
Practice location   
  Urban   64 (50.8)     62 (49.2)   
  Rural   13 (59.1)      9 (40.9)   
Years in practice   
  <10   18 (52.9)   16 (47.1) 
  10-19   16 (57.1)   12 (42.9) 
  20-29   16 (51.6)   15 (48.4) 
  30-39   14 (40.0)   21 (60.0) 
  40-49   11 (61.1)     7 (38.9) 
  50+     2 (100.0)     0 (0.0) 
Practice sector   
  Private   69 (55.6)     55 (44.4)   
  Public     2 (28.6)       5 (71.4)   
  Both private and public     4 (30.8)       9 (69.2)   
  Not working     2 (50.0)       2 (50.0)   
Number of HNC patients seen in practice 
in previous 12 months 
  
  None   24 (64.9)     13 (35.1)c   
  1-5   47 (50.0)     47 (50.0)   
  6-19     1 (44.4)     5 (55.6)   
  20+     1 (16.7)      4 (83.3)   
   
  Totala   76 (52.1)   70 (48.0) 









HNC patient flow was positively associated with having undertaken recent HNC continuing 
professional development (CPD); respondents who reported having seen higher numbers of 
HNC patients in their practice over the last year were most likely to have done some HNC-
related CPD in the last 5 years. There was a strong gradient observed between CPD and the 
volume of HNC patients seen in practice for both those respondents who reported having 
undertaken CPD in this area (positive gradient) and those who had not (negative gradient). 
 
Public sector dental experience was associated with having undertaken CPD on HNC in the 
last five years.  
 
Although no association could be demonstrated, New Zealand graduates were less likely to 














Tables 13 to 21 summarise participant responses to each of 9 attitude statements posed, by 




Table 13. Attitude to statement 1, by sample characteristics (brackets contain row 
percentages unless otherwise indicated). 
 “I have been adequately trained to manage the 
dental needs of HNC patients”. 
 Agree Neither agree 
nor disagree 
Disagree 
Sexa    
   Male   17 (23.0)   23 (31.1)   34 (45.9) 
   Female   19 (27.1)   20 (28.6)   31 (44.3) 
Age groupa    
  <35     7 (21.9)   13 (40.6)   12 (37.5) 
  35-49   11 (24.4)   14 (31.1)   20 (44.4) 
  50-59   11 (28.2)   10 (25.6)   18 (46.2) 
  60+     7 (25.0)     6 (21.4)   15 (53.6) 
NZ traineda    
  No   12 (25.0)   14 (29.2)   22 (45.8) 
  Yes   24 (25.0)   29 (30.2)   43 (44.8) 
Public Sector experienceb    
  No   28 (23.3)   35 (29.2)   57 (47.5) 
 Yes      6 (30.0)     6 (30.0)     8 (40.0) 
Practice locationa    
  Urban   31 (25.0)   38 (30.6)   55 (44.4) 
  Rural     5 (25.0)     5 (25.0)   10 (50.0) 
Years in practicea    
  <10     7 (21.9)   13 (40.6)   12 (37.5)d 
  10-19     5 (18.5)     9 (33.3)   13 (48.1) 
  20-29     9 (30.0)   11 (36.7)   10 (33.3) 
  30-39     9 (25.7)     8 (22.9)   18 (51.4) 
  40-49     5 (27.8)     2 (11.1)   11 (61.1) 
  50+     1 (50.0)     0   (0.0)     1 (50.0) 
Practice sectora    
  Private   28 (23.3)   35 (29.2)   57 (47.5) 
  Public     2 (28.6)     3 (42.9)     2 (28.6) 
  Both private and public     4 (30.8)     3 (23.1)     6 (46.2) 
  Not working     2 (50.0)     2 (50.0)     0   (0.0) 
Number of HNC patients 
seen in practice in previous 
12 monthsc 
   
  None     7 (20.0)   12 (34.3)   16 (45.7) 
  1-5   24 (26.1)   24 (26.1)   44 (47.5) 
  6-19     1 (11.1)     5 (55.6)     3 (33.3) 
  20+     4 (66.7)     1 (16.7)     1 (16.7) 
    
Total   36 (23.4)   43 (27.9)   65 (42.2) 
a missing data for 9 respondents 
b missing data for 12 respondents   





There was a distinct gradient in responses whereby those with more clinical experience were 
more likely to have an opinion one way or the other. Clinical experience was associated with 
disagreement with this attitude statement; those dentists with the most years of experience 
least felt that their dental school training had prepared them to see HNC patients in practice. 
 
About one quarter of participants felt that dental school had adequately prepared them to treat 
HNC patients and another quarter were unsure. Just under half of all dentists disagreed that 
this was the case. Two-thirds of dentists who saw large numbers of HNC patients in their 
practices over the previous twelve months felt that they had been adequately trained to see 







Table 14. Attitude statement 2, by sample characteristics (brackets contain row 
percentages unless otherwise indicated). 
 “General dentists should be able to provide dental 
treatment for HNC patients”. 
 Agree Neither agree 
nor disagree 
Disagree 
Sex a    
   Male   59 (80.8)     8 (11.0)     6 (8.2) 
   Female   54 (75.0)   13 (18.1)     5 (6.9) 
Age group a    
  <35   29 (82.9)     4 (11.4)     2 (5.7) 
  35-49   37 (80.4)     7 (15.2)     2 (4.3) 
  50-59   31 (83.8)     3 (8.1)     3 (8.1) 
  60+   16 (59.3)     7 (25.9)     4 (14.8) 
NZ trained a    
  No   41 (85.4)     3 (6.3)     4 (8.3) 
  Yes   72 (74.2)   18 (18.6)     7 (7.2) 
Public Sector experience b    
  No   94 (77.0)   18 (14.8)   10 (8.2) 
 Yes    17 (85.0)     3 (15.0)     0 (0.0) 
Practice location a    
  Urban   95 (76.0)   20 (16.0)   10 (8.0) 
  Rural   18 (90.0)     1 (5.0)     1 (5.0) 
Years in practice a    
  <10   28 (82.4)     4 (11.8)     2 (5.9) 
  10-19   25 (89.3)     2 (7.1)     1 (3.6) 
  20-29   23 (74.2)     7 (22.6)     1 (3.2) 
  30-39   25 (75.8)     4 (12.1)     4 (12.1) 
  40-49   10 (58.8)     4 (23.5)     3 (17.6) 
  50+     2 (100.0)     0 (0.0)     0 (0.0) 
Practice sector a    
  Private   94 (77.0)   18 (14.8)   10 (8.2) 
  Public     7 (100.0)     0 (0.0)     0 (0.0) 
  Both private and public   10 (76.9)     3 (23.1)     0 (0.0) 
  Not working     2 (66.7)     0 (0.0)     1 (33.3) 
Number of HNC patients 
seen in practice in previous 
12 months c 
   
  None   31 (83.8)     4 (10.8)     2 (5.4) 
  1-5   68 (73.9)   16 (17.4)     8 (8.7) 
  6-19     9 (100.0)     0 (0.0)     0 (0.0) 
  20+     4 (66.7)     1 (16.7)     1 (16.7) 
    
Total 113 (73.4)   21 (13.6)   11 (7.1) 
a missing data for 9 respondents  
b missing data for 12 respondents 






There were no apparent differences by respondent characteristics. 
 
Three quarters of dentists felt that dental treatment for HNC patients fell within the scope of 




Table 15. Attitude statement 3, by sample characteristics (brackets contain row 
percentages unless otherwise indicated). 
 “I am confident in giving advice to HNC patients about their 
mouth and teeth”. 
 Agree Neither agree nor disagree Disagree 
Sexa    
   Male   49 (65.3)   22 (29.3)     4 (5.3)d 
   Female   37 (51.4)   20 (27.8)   15 (20.8) 
Age groupa    
  <35   17 (50.0)   10 (29.4)     7 (20.6) 
  35-49   27 (58.7)   13 (28.3)     6 (13.0) 
  50-59   25 (64.1)   11 (28.2)     3 (7.7) 
  60+   17 (60.7)     8 (28.6)     3 (10.7) 
NZ traineda    
  No   28 (58.3)   13 (27.1)     7 (14.6) 
  Yes   58 (58.6)   29 (29.3)   12 (12.1) 
Public Sector experiencec    
  No   70 (56.9)   35 (28.5)   18 (14.6) 
 Yes    13 (65.0)     6 (30.0)     1 (5.0) 
Practice locationa   75 (59.5)   36 (28.6)   15 (11.9) 
  Urban   11 (52.4)     6 (28.6)     4 (19.0) 
  Rural   11 (52.4)     6 (28.6)     4 (19.0) 
Years in practicea    
  <10   17 (51.5)   11 (33.3)     5 (15.2) 
  10-19   15 (53.6)     6 (21.4)     7 (25.0) 
  20-29   19 (61.3)   11 (35.5)     1 (3.2) 
  30-39   23 (65.7)     7 (20.0)     5 (14.3) 
  40-49   11 (61.1)     6 (33.3)     1 (5.6) 
  50+     1 (50.0)     1 (50.0)     0 (0.0) 
Practice sectora    
  Private   70 (56.9)   35 (28.5)   18 (14.6) 
  Public     4 (57.1)     3 (42.9)     0 (0.0) 
  Both private and public     9 (69.2)     3 (23.1)     1 (7.7) 
  Not working   86 (58.5)   42 (28.6)   19 (12.9) 
Number of HNC patients 
seen in practice in previous 
12 monthsb 
   
  None   17 (47.2)   10 (27.8)     9 (25.0)e 
  1-5   55 (58.5)   29 (30.9)   10 (10.6) 
  6-19     8 (88.9)     1 (11.1)     0 (0.0) 
  20+     5 (83.3)     1 (16.7)     0 (0.0) 
    
Total   86 (55.8)   42 (27.3)   19 (12.3) 
a missing data for 7 respondents  
b missing data for 9 respondents 
c missing data for 11 respondents 





There was an association between sex and self-perceived confidence; females were less 
confident in their ability to provide advice to HNC patients about their mouth and teeth. 
 
Confidence in providing orofacial advice to HNC patients was also associated with the 
number of HNC patients that a respondent reported seeing in practice over the previous year, 
with more confidence reported by dentists that had seen greater numbers of HNC patients. 
 
There were no other apparent differences by respondent characteristics.  
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Table 16. Attitude statement 4, by sample characteristics (brackets contain row 
percentages unless otherwise indicated). 
 “Treating HNC patients is a risk to my professional 
registration”. 
 Agree Neither agree nor 
disagree 
Disagree 
Sexa    
   Male      1 (1.8)     0 (0.0)   56 (98.2)b 
   Female      4 (7.5)     6 (11.3)   43 (81.1) 
Age groupa    
  <35     1 (3.7)     3 (11.1)   23 (85.2) 
  35-49     1 (2.6)     1 (2.6)   36 (94.7) 
  50-59     2 (8.7)     2 (8.7)   19 (82.6) 
  60+     1 (4.5)     0 (0.0)   21 (95.5) 
NZ traineda    
  No      3 (7.7)     0 (0.0)   36 (92.3) 
  Yes      2 (2.8)     6 (8.5)   63 (88.7) 
Public Sector experiencec    
  No     5 (5.2)     3 (3.1)   89 (91.8) 
 Yes      0 (0.0)     2 (18.2)     9 (81.8) 
Practice locationa    
  Urban     3 (3.2)     3 (3.2)   89 (93.7)d 
  Rural     2 (13.3)     3 (20.0)   10 (66.7) 
Years in practicea    
  <10     1 (3.8)     3 (11.5)   22 (84.6) 
  10-19     1 (4.3)     1 (4.3)   21 (91.3) 
  20-29     1 (4.2)     0 (0.0)   23 (95.8) 
  30-39     2 (8.7)     2 (8.7)   19 (82.6) 
  40-49     0 (0.0)     0 (0.0)   13 (100.0) 
  50+     0 (0.0)     0 (0.0)     1 (100.0) 
Practice sectora    
  Private     5 (5.2)     3 (3.1)   89 (91.8)e 
  Public     0 (0.0)     2 (66.7)     1 (33.3) 
  Both private and public     0 (0.0)     0 (0.0)     8 (100.0) 
  Not working     0 (0.0)     1 (50.0)     1 (50.0) 
Number of HNC patients 
seen in practice in previous 
12 monthsc 
   
  None     2 (6.3)     2 (6.3)   28 (87.5) 
  1-5     2 (2.9)     4 (5.9)   62 (91.2) 
  6-19     1 (14.3)     0 (0.0)     6 (85.7) 
  20+     0 (0.0)     0 (0.0)     1 (100.0) 
    
Total     5 (3.2)     6 (3.9)   99 (64.3) 
a missing data for 44 respondents  
b P=0.009 
c missing data for 46 respondents 





There was a sex difference in the attitude that HNC patients posed a threat to professional 
registration. While most males and females disagreed with this attitude statement and were 
comfortable that HNC patients posed no additional threat to their registration, more females 
than males were unsure of how they felt.   
 
Rural-based dentists were more likely to agree with this attitude statement than urban-based 
practitioners. 
 
Public and private dentists felt differently about this knowledge statement. More than two-
thirds of public dentists were unsure how they felt and, although most private practitioners 
disagreed with this statement, it was an issue for a small proportion of this group. 
 




Table 17. Attitude statement 5, by sample characteristics (brackets contain row 
percentages unless otherwise indicated). 
 “I am not confident in providing dental care for 
HNC patients”. 
 Agree Neither agree 
nor disagree 
Disagree 
Sexa    
   Male     8 (12.5)   13 (20.3)   43 (67.2) 
   Female   12 (19.4)   13 (21.0)   37 (59.7) 
Age groupa    
  <35     4 (12.1)     8 (24.2)   21 (63.6) 
  35-49     7 (18.4)     8 (21.1)   23 (60.5) 
  50-59     4 (12.5)     7 (21.9)   21 (65.6) 
  60+     5 (21.7)     3 (13.0)   15 (65.2) 
NZ traineda    
  No   10 (24.4)     4 (9.8)   27 (65.9)c 
  Yes   10 (11.8)   22 (25.9)   53 (62.4) 
Public Sector experienceb    
  No   18 (16.5)   21 (19.3)   70 (64.2) 
 Yes      2 (13.3)     4 (26.7)     9 (60.0) 
Practice locationa    
  Urban   15 (14.2)   20 (18.9)   71 (67.0) 
  Rural     5 (25.0)     6 (30.0)     9 (45.0) 
Years in practicea    
  <10     3 (9.4)     9 (28.1)   20 (62.5) 
  10-19     6 (23.1)     4 (15.4)   16 (61.5) 
  20-29     3 (12.0)     4 (16.0)   18 (72.0) 
  30-39     5 (17.9)     6 (21.4)   17 (60.7) 
  40-49     2 (15.4)     3 (23.1)     8 (61.5) 
  50+     1 (50.0)     0 (0.0)     1 (50.0) 
Practice sectora    
  Private   18 (16.5)   21 (19.3)   70 (64.2) 
  Public     0 (0.0)     1 (20.0)     4 (80.0) 
  Both private and public     2 (20.0)     3 (30.0)     5 (50.0) 
  Not working     0 (0.0)     1 (50.0)     1 (50.0) 
Number of HNC patients 
seen in practice in previous 
12 monthsa 
   
  None      8 (23.5)     8 (23.5)   18 (52.9) 
  1-5   11 (13.8)   15 (18.8)   54 (67.5) 
  6-19     1 (11.1)     2 (22.2)     6 (66.7) 
  20+     0 (0.0)     1 (50.0)     1 (50.0) 
    
Total   20 (13.0)   26 (16.9)   80 (51.9) 
a missing data for 28 respondents 
b missing data for 30 respondents 




One quarter of New Zealand graduates were unsure about their clinical confidence in treating 
HNC patients compared with one in ten overseas trained dentists.  Conversely one quarter of 
overseas trained graduates indicated that they were not confident in treating HNC patients, 
whereas only one in ten New Zealand graduates felt this way. Roughly equal proportions of 
both New Zealand and overseas trained graduates disagreed with attitude statement 5. 
 
Half of all dentists disagreed in total with attitude statement 5; only one in ten felt identified 





























Table 18. Attitude statement 6, by sample characteristics. 
 “Treating HNC patients is too hard relative to the 
financial reward that I get from it”. 
 Agree Neither agree 
nor disagree 
Disagree 
Sexb    
   Male     6   (9.1)   12 (18.2)   48 (72.7) 
   Female     6 (10.0)     9 (15.0)   45 (75.0) 
Age groupb    
  <35     2   (6.3)     4 (12.5)   26 (81.3) 
  35-49     2   (5.3)     7 (18.4)   29 (76.3) 
  50-59     5 (15.2)     6 (18.2)   22 (66.7) 
  60+     3 (13.0)     4 (17.4)   16 (69.6) 
NZ trainedb    
  No     4   (9.8)     8 (19.5)   29 (70.7) 
  Yes     8   (9.4)   13 (15.3)   64 (75.3) 
Public Sector experiencea    
  No   11 (10.1)   21 (19.3)   77 (70.6) 
 Yes      1 (7.1)     0 (0.0)   13 (92.9) 
Practice locationb    
  Urban     9 (8.5)   18 (17.0)   79 (74.5) 
  Rural     3 (15.0)     3 (15.0)   14 (70.0) 
Years in practiceb    
  <10     2 (6.5)     3 (9.7)   26 (83.9) 
  10-19     1 (4.0)     5 (20.0)   19 (76.0) 
  20-29     1 (4.2)     4 (16.7)   19 (79.2) 
  30-39     6 (20.0)     8 (26.7)   16 (53.3) 
  40-49     2 (14.3)     1 (7.1)   11 (78.6) 
  50+     0 (0.0)     0 (0.0)     2 (100.0) 
Practice sectorb    
  Private   11 (10.1)   21 (19.3)   77 (70.6) 
  Public     1 (20.0)     0 (0.0)     4 (80.0) 
  Both private and public     0 (0.0)     0 (0.0)     9 (100.0) 
  Not working     0 (0.0)     0 (0.0)     3 (100.0) 
Number of HNC patients 
seen in practice in previous 
12 monthsc 
   
  None     3 (9.4)     4 (12.5)   25 (78.1) 
  1-5     8 (9.9)   15 (18.5)   58 (71.6) 
  6-19     1 (14.3)     1 (14.3)     5 (71.4) 
  20+     0 (0.0)     1 (25.0)     3 (75.0) 
    
Total    12 (7.8)    21 (13.6)    93 (60.4) 
a missing data for 31 respondents 
b missing data for 28 respondents  









































Table 19. Attitude statement 7, by sample characteristics (brackets contain row 
percentages unless otherwise indicated). 
 “I would like to attend CPD courses about 
managing the dental needs of HNC patients”. 
 Agree Neither agree 
nor disagree 
Disagree 
Sexb    
   Male   45 (60.0)   16 (21.3)   14 (18.7) 
   Female   56 (77.8)   10 (13.9)     6 (8.3) 
Age groupb    
  <35   21 (61.8)    8 (23.5)     5 (14.7) 
  35-49   37 (80.4)    5 (10.9)     4 (8.7) 
  50-59   29 (74.4)    6 (15.4)     4 (10.3) 
  60+   14 (50.0)    7 (25.0)     7 (25.0) 
NZ trainedb    
  No   38 (79.2)     5 (10.4)     5 (10.4) 
  Yes   63 (63.6)   21 (21.2)   15 (15.2) 
Public Sector experiencea    
  No   84 (67.7)   22 (17.7)   18 (14.5) 
 Yes    14 (73.7)     4 (21.1)     1 (5.3) 
Practice locationb    
  Urban   85 (67.5)   23 (18.3)   18 (14.3) 
  Rural   16 (76.2)     3 (14.3)     2 (9.5) 
Years in practiceb    
  <10   23 (69.7)     6 (18.2)     4 (12.1) 
  10-19   20 (71.4)     6 (21.4)     2 (7.1) 
  20-29   24 (77.4)     4 (12.9)     3 (9.7) 
  30-39   26 (74.3)     4 (11.4)     5 (14.3) 
  40-49     6 (33.3)     6 (33.3)     6 (33.3) 
  50+     2 (100.0)     0 (0.0)     0 (0.0) 
Practice sectorb    
  Private   84 (67.7)   22 (17.7)   18 (14.5) 
  Public     4 (66.7)     2 (33.3)     0 (0.0) 
  Both private and public   10 (76.9)     2 (15.4)     1 (7.7) 
  Not working     3 (75.0)     0 (0.0)     1 (25.0) 
Number of HNC patients 
seen in practice in previous 
12 monthsc 
   
  None   28 (75.7)     6 (16.2)     3 (8.1) 
  1-5   64 (68.1)   15 (16.0)   15 (16.0) 
  6-19     4 (50.0)     3 (37.5)     1 (12.5) 
  20+     4 (66.7)     1 (16.7)     1 (16.7) 
    
Total 101 (65.6)   26 (16.9)   20 (13.0) 
a missing data from 11 respondents 
b missing data from 7 respondents 





There were no apparent differences by respondent characteristics. 
 







Table 20.  Attitude statement 8, by sample characteristics (brackets contain row 
percentages unless otherwise indicated). 
 “Dental disease is inevitable in patients that have 
had HNC RTx”. 
 Agree Neither agree 
nor disagree 
Disagree 
Sexb    
   Male   16 (22.5)   23 (32.4)   32 (45.1) 
   Female   15 (21.4)   19 (27.1)   36 (51.4) 
Age groupb    
  <35     8 (23.5)   13 (38.2)   13 (38.2) 
  35-49     8 (18.6)   11 (25.6)   24 (55.8) 
  50-59     9 (24.3)     9 (24.3)   19 (51.4) 
  60+     6 (22.2)     9 (33.3)   12 (44.4) 
NZ trainedb    
  No   12 (26.1)   13 (28.3)   21 (45.7) 
  Yes   19 (20.0)   29 (30.5)   47 (49.5) 
Public Sector experiencea    
  No   28 (23.5)   35 (29.4)   56 (47.1) 
 Yes      3 (16.7)     7 (38.9)     8 (44.4) 
Practice locationb    
  Urban   27 (22.5)   34 (28.3)   59 (49.2) 
  Rural     4 (19.0)     8 (38.1)     9 (42.9) 
Years in practiceb    
  <10     8 (24.2)   12 (36.4)   13 (39.4) 
  10-19     5 (18.5)     8 (29.6)   14 (51.9) 
  20-29     4 (13.8)     7 (24.1)   18 (62.1) 
  30-39   10 (30.3)     9 (27.3)   14 (42.4) 
  40-49     4 (23.5)     5 (29.4)     8 (47.1) 
  50+     0 (0.0)     1 (50.0)     1 (50.0) 
Practice sectorb    
  Private   28 (23.5)   35 (29.4)   56 (47.1) 
  Public     2 (28.6)     2 (28.6)     3 (42.9) 
  Both private and public     1 (9.1)     5 (45.5)     5 (45.5) 
  Not working     0 (0.0)     0 (0.0)     4 (100.0) 
Number of HNC patients 
seen in practice in previous 
12 monthsc 
   
  None     8 (22.2)   11 (30.6)   17 (47.2) 
  1-5   21 (23.6)   25 (28.1)   43 (48.3) 
  6-19     0 (0.0)     4 (44.4)     5 (55.6) 
  20+     1 (20.0)     2 (40.0)     2 (40.0) 
    
Total   31 (20.1)   42 (27.3)   68 (44.2) 
a missing data from  17 respondents 
b missing data from 13 respondents 





There were no apparent differences by respondent characteristics. 
 
Just under one quarter of all participants agreed with this attitude statement.  Just over one 






























Table 21. Attitude statement 9, by sample characteristics (brackets contain row 
percentages unless otherwise indicated). 
 “I would prefer to refer patients with a history of 
HNC to a specialist for management”. 
 Agree Neither agree 
nor disagree 
Disagree 
Sexb    
   Male   16 (22.9)   19 (27.1)   35 (50.0) 
   Female   20 (29.9)   20 (29.9)   27 (40.3) 
Age groupb    
  <35   14 (41.2)     8 (23.5)   12 (35.3) 
  35-49     8 (19.0)     9 (21.4)   25 (59.5) 
  50-59     9 (26.5)   11 (32.4)   14 (41.2) 
  60+     5 (18.5)   11 (40.7)   11 (40.7) 
NZ trainedb    
  No   19 (41.3)   14 (30.4)   13 (28.3)d 
  Yes   17 (18.7)   25 (27.5)   49 (53.8) 
Public Sector experiencea    
  No   29 (24.6)   36 (30.5)   53 (44.9) 
 Yes      7 (43.8)     2 (12.5)     7 (43.8) 
Practice locationb    
  Urban   32 (27.8)   30 (26.1)   53 (46.1) 
  Rural     4 (18.2)     9 (40.9)     9 (40.9) 
Years in practiceb    
  <10   13 (39.4)     9 (27.3)   11 (33.3) 
  10-19     6 (22.2)     5 (18.5)   16 (59.3) 
  20-29     5 (19.2)     6 (23.1)   15 (57.1) 
  30-39   10 (31.3)   13 (40.6)     9 (28.1) 
  40-49     2 (11.8)     4 (23.5)   11 (64.7) 
  50+     0 (0.0)     2 (100.0)     0 (0.0) 
Practice sectorb    
  Private   29 (24.6)   36 (30.5)   53 (44.9) 
  Public     3 (50.0)     0 (0.0)     3 (50.0) 
  Both private and public     4 (40.0)     2 (20.0)     4 (40.0) 
  Not working     0 (0.0)     1 (33.3)     2 (66.7) 
Number of HNC patients 
seen in practice in previous 
12 monthsc 
   
  None   15 (40.5)   10 (27.0)   12 (32.4) 
  1-5   17 (19.8)   27 (31.4)   42 (48.8) 
  6-19     2 (22.2)     1 (11.1)     6 (66.7) 
  20+     2 (66.7)     1 (33.3)     0 (0.0) 
    
Total   36 (23.4)   39 (25.3)   62 (40.3) 
a missing data from 20 respondents 
b missing data from 17 respondents 





Overseas acquired dental training was associated with the preference to refer HNC patients to 
specialists for dental treatment. More New Zealand trained dentists felt that HNC patients could 





























Table 22 presents summary data for respondent attitude by sample characteristics across all 9 
attitude statements. Note that the polarity of questions 4-6 and 8-9 and their respective 




Table 22.  Mean attitude, by sample characteristics. 
 Strongly agree/agree responses out of 9 
statements totala 
 Mean  SD 
Sex     
   Male     4.7      1.7 
   Female     4.6      1.6 
Age groupa   
  <35     4.6      1.9 
  35-49     4.8      1.6 
  50-59     4.8      1.4 
  60+     4.1      1.7 
NZ trained    
  No     4.9      1.8 
  Yes     4.5      1.5 
Public Sector experienceb   
  No     4.6      1.7 
 Yes      4.6      1.5 
Practice location    
  Urban     4.7      1.6 
  Rural     4.2      2.0 
Years in practice    
  <10     4.6      2.0 
  10-19     4.9      1.7 
  20-29     5.1      1.1 
  30-39     4.5      1.3 
  40-49     3.9      1.6 
  50+     3.7      3.2 
Practice sector     
  Private     4.6      1.7 
  Public     4.6      1.3 
  Both private and public     4.6      1.6 
  Not working     4.8      2.1 
Number of HNC patients seen in practice 
in previous 12 monthsc 
  
  None     5.0      1.5 
  1-5     4.7      1.3 
  6-19     5.1      1.6 
  20+     4.3      1.2 
a missing data for 1 respondent 
b missing data for 4 respondents 











The data for agreed responses to the nine attitude statements posed were normally distributed.  
 
There were no apparent differences by respondent characteristics overall, although it is noted 
that the responses from older dentists and dentists with more years in practice show a subtle 












































Table 23 presents data on the number of HNC patients that respondents reported having seen 





Table 23.  Number of HNC patients that dentist has seen in practice over the previous 
12 months by dentist characteristics (brackets contain row percentages unless otherwise 
indicated). 
 Number of HNC patients seen in practice over the 
previous 12 months 
    None   1-5    6-19    20+ 
Sexa     
   Male   15 (20.5)   52 (71.2)    4 (5.5)    2 (2.7) 
   Female   22 (30.1)   42 (57.5)    5 (6.8)    4 (5.5) 
   Total     37 (25.3)     94 (64.4)    9 (6.2)    6 (4.1) 
Age groupa     
  <35   12 (35.3)   17 (50.0)    4 (11.8)    1 (2.9) 
  35-49   13 (28.9)   28 (62.2)    3 (6.7)    1 (2.2) 
  50-59     4 (10.8)   31 (83.8)    1 (2.7)    1 (2.7) 
  60+     7 (26.9)   16 (61.5)    1 (3.8)    2 (7.7) 
  Total   36 (25.4)   92 (64.8)    9 (6.3)    5 (3.5) 
Years in practice     
   <10   13 (38.2)   16 (47.1)    3 (8.8)    2 (5.9) 
   10-19   10 (35.7)   15 (53.6)    3 (10.7)    0 (0.0) 
   20-29     5 (16.7)   22 (73.3)    2 (6.7)    1 (3.3) 
   30-39     4 (11.4)   29 (82.9)    1 (2.9)    1 (2.9) 
   40-49     4 (23.5)   11 (64.7)    0 (0.0)    2 (11.8) 
   50+     1 (50.0)     1 (50.0)    0 (0.0)    0 (0.0) 
   Total   37 (25.3)   94 (64.4)    9 (6.2)    6 (4.1) 
Sector of practicea     
   Private   31 (25.4)  85 (69.7)    4 (3.3)    1 (1.6)c 
   Public    2 (28.6)    2 (28.6)    2 (28.6)    1 (14.3) 
   Both    3 (23.1)    5 (38.5)    3 (23.1)    2 (15.4) 
   Not practising    1 (25.0)    2 (50.0)    0 (0.0)    1 (25.0) 
   Total  37 (25.3)  94 (64.4)    9 (6.2)    6 (4.1) 
Location of practicea     
  Urban   31 (25.6)   79 (65.3)    6 (5.0)    5 (4.1) 
  Rural     5 (23.8)   13 (61.9)    3 (14.3)    0 (0.0) 
  Total   36 (25.4)   92 (64.8)    9 (6.3)    5 (3.5) 
Public sector experienceb      
   No  31 (25.4)  85 (69.7)    4 (3.3)    2 (1.6)c 
   Yes    5 (25.0)    7 (35.0)    5 (25.0)    3 (15.0) 
   Total  36 (25.4)  92 (64.8)    9 (6.3)    5 (3.5) 
NZ trained a       
   No   19 (40.4)   26 (55.3)    1 (2.1)      1 (2.1)d 
   Yes   17 (17.9)   66 (69.5)    8 (8.4)    54 (4.2) 
   Total    36 (25.4)   92 (64.8)    9 (6.3)      5 (3.5) 
a  missing data for 8 respondents 







One quarter of dentists reported not having seen any HNC patients over the previous 12 
months, and about two-thirds of dentists had had minimal contact with HNC patients during 
this same period, seeing only between 1 and 5 patients. Few dentists overall reported having 
seen between 5 and 19 HNC patients in the previous 12 months, and fewer than one in twenty 
reported having seen 20 or more HNC patients in their practice over the previous year.   
 
Both current public sector employment and experience working in the public sector (working 
for the District Health Boards in the local hospitals) were associated with having seen a 
greater number of HNC patients in the previous year of practice.  
 
New Zealand trained respondents reported seeing higher numbers of HNC patients in the 












Table 24 presents data on respondent clinical practice for HNC patients in the previous year 
and theoretical willingness to provide various dental procedures for HNC patients. 
 
Table 24. Dentist experience providing and willingness to provide various dental 
treatments (brackets contain percentage of all participants, unless otherwise indicated). 
. 
 Number of dentists who have 
provided this service for a 
HNC patient in last year of 
practicea 
Number of dentists who would 
be willing to provide this 
service for a HNC patienta 
Filling 100 (64.9) 146 (94.8) 
Simple extraction   30 (19.5)   84 (54.5) 
Surgical extraction   10 (6.5)   28 (18.2) 
Endodontic service   17 (11.0) 115 (74.7) 
Fixed prosthodontics   10 (6.5)   94 (61.0) 
Oral hygiene instruction   99 (64.3) 147 (95.5) 
Diet instruction   76 (49.4) 137 (89.0) 
Fluoride treatment   73 (47.4) 140 (90.9) 
Referral   25 (16.2) 110 (71.4) 
Scale   84 (54.5) 140 (90.9) 
Nothing   20 (13.0) N/A 
a data missing for 8 participants. 
 
For every common dental service/procedure listed, the proportion of participants that had 
actually delivered this service in practice for a HNC patient was less than theoretical 
willingness, which was to be expected as not all HNC patient would require every procedure 
listed. 
 
Almost all participants indicated that they would be theoretically happy to provide fillings for 
HNC patients. Two thirds of these dentists actually had provided this service for at least one 
HNC patient in the past year in practice.  
 
In contrast, less than one in 5 dentists declared that they would undertake a surgical 
extraction for a HNC patient and about one in fifteen practitioners had actually delivered this 
service for a HNC patient in the previous year.  
 
One in ten dentists that had seen a HNC patient in their practice in the previous year had 






Table 25 contains data on advice that respondents would provide to HNC patients in practice. 
 
Table 25. Advice respondents would provide to HNC patients in practice (brackets 
contain percentage of all participants). 
Advice  Number of respondents  
No advice     3 (1.9) 
Diet advicea 115 (74.7) 
Obtain regular dental check-upsa 141 (91.6) 
OHIa 140 (90.9) 
Use a high conc fluoride toothpastea 125 (81.2) 
Use dry mouth productsa 132 (85.7) 
Increase water consumptiona 119 (77.3) 
Use CPP-ACPa 103 (66.9) 
Eat frequently to stimulate saliva   23 (14.9) 
Chew sugar-free guma 119 (77.3) 
Avoid alcohol and coffeea   57 (37.0) 
Avoid sugar in tea and coffeea   87 (56.5) 
Advice on ORN riska 112 (72.7) 
Pain control advicea   53 (34.4) 
Smoking cessation advicea   89 (57.8) 
Mouth opening exercisesa   45 (29.2) 
Suck lemons     3 (1.9) 
Use mouthwasha   74 (48.1) 
a evidence-based clinical advice (good advice).   
 
Respondents who indicated that they would give bad advice to HNC patients were in the 
minority. Three-quarters of all respondents identified that diet advice was important for HNC 
patients, and nine out of 10 would advise regular dental checks and provide oral hygiene 
instruction for these patients.  
 
Fewer respondents indicated that they would ‘drill down’ into diet instruction with HNC 
patients; just over one third would recommend avoiding common diuretic beverages such as 
alcohol and coffee, and just over half would recommend avoiding sugar in tea and coffee.  
 







Table 26 presents the average number of items of good advice (out of 15) that respondents 
selected, by sample characteristics. 
 
 
Table 26.  Mean correct advice (out of 15 total items of good advice listed), by sample 
characteristics. 
 Number of good advice statements selected 
out of 15 
 Mean  SD 
Sexa   
   Male     4.7      1.7 
   Female     4.6      1.6 
Age groupa   
  <35     4.6      1.9 
  35-49     4.8      1.6 
  50-59     4.8      1.4   
  60+     4.1      1.7   
NZ traineda   
  No     4.9      1.8   
  Yes     4.5      1.5 
Public Sector experienceb    
  No     4.6      1.7 
 Yes      4.6      1.5 
Practice locationa   
  Urban     4.7      1.6 
  Rural     4.2      2.0 
Years in practicea   
  <10     4.6      2.0 
  10-19     4.9      1.7 
  20-29     5.1      1.1  
  30-39     4.5      1.3    
  40-49     3.9      1.6   
  50+     3.7      3.2    
Practice sectora   
  Private     4.6      1.7 
  Public     4.6      1.3 
  Both private and public     4.6      1.6 
  Not working     4.8      2.1 
Number of HNC patients seen in practice 
in previous 12 monthsc 
  
  None     5.0      1.5 
  1-5     4.7      1.3 
  6-19     5.1      1.6 
  20+     4.3      1.2 
a missing data for 5 respondents 
b missing data for 9 respondents 




There were no apparent differences by respondent characteristics. 
 
Respondents selected, on average, no more than one third of all items of good advice (out of 















Table 27 presents data on the average number of items of poor clinical advice that 
respondents would give to HNC patients (out of 3 total) 
 
Table 27.  Mean incorrect advice (out of 3 total items of bad advice listed), by sample 
characteristics. 
 Number of bad advice statements selected out 
of 3 
 Mean  SD 
Sexa    
   Male     0.2      0.4 
   Female     0.2      0.4 
Age groupa    
  <35     0.2      0.4 
  35-49     0.1      0.4 
  50-59     0.2      0.4 
  60+     0.2      0.4 
NZ traineda    
  No     0.3      0.5 
  Yes     0.2      0.4 
Public Sector experienceb    
  No     0.2      0.4 
 Yes      0.1      0.4 
Practice locationa   
  Urban     0.2      0.4 
  Rural     0.1      0.3 
Years in practicea   
  <10     0.2      0.4 
  10-19     0.1      0.4 
  20-29     0.1      0.3 
  30-39     0.3      0.4 
  40-49     0.2      0.4 
  50+     0.0      0.0 
Practice sectora     
  Private     0.2      0.4d 
  Public     0.1      0.4 
  Both private and public     0.1      0.4 
  Not working     0.8      0.5 
Number of HNC patients seen in practice 
in previous 12 monthsc  
  
  None     0.2      0.5 
  1-5     0.2      0.4 
  6-19     0.2      0.4 
  20+     0.5      0.5 
a missing data for 5 respondents 
b missing data for 9 respondents 




On average, respondents selected less than one item of incorrect advice (out of 3 total). Those 
dentists that were currently not working in practice were the most likely to select an item of 
bad advice. Dentists working solely in private practice were more likely to provide bad 






4.6. Qualitative Results 
 
Key informants undertook a semi-structured interview with the investigator. Their comments 
were grouped and analysed according to the themes of knowledge, attitude and practise 





Table 28. Thematic analysis of qualitative data. 
Theme 1: Knowledge 
• (‘sufficient knowledge’ is): “answering most questions right”; “practising in a risk 
adverse manner”; “not necessarily the same thing as sufficient knowledge to pass 
dental school”; “the most important thing is to be a sound general dentist with great 
communication skills”. 
• “There must be a real difference in the undergraduate curriculum in NZ with regard to 
HNC dentistry.  University of Sydney students get one lecture and attend one cancer 
clinic.  Somehow NZ graduates are more knowledgeable, so maybe they have a better 
curriculum”. 
• (64% knowledge challenges answered correctly overall) “That is pleasantly surprising 
as I thought most dentists wouldn’t be up to date with HPV”. 
• “The split on 5 year survival was 50/50, so I think most people just guessed” 
• “It makes sense that those dentists that see the most patients are most knowledgeable 
because this is an area where you can’t learn from a textbook- you have to put in the 
hours on the clinical floor”. 
• “Only those dentists working in this space would really know about taste dysfunction 
because you get that knowledge from talking to the patients themselves”. 
 
 
Theme 2: Attitude 
• “Dentists are usually ok to do stuff like fillings”.  “It’s in their scope”. 
• “most dentists will drop their forceps as soon as you tell them you have had radiation and 
refer you on to someone they don’t like very much because they don’t want to be the one 
that causes the ORN and gets deregistered” 
• Impossible to comment whether dentists are doing CPD and then going onto see more 
patients or if they are doing CPD in response to demand from patients (chicken or egg 
reasoning). 
• House Surgeon in NZ- in-services, Grand Rounds, lectures as part of job. 
•  “With HPV as the new thing in cancer, some dentists don’t feel comfortable discussing 
sexual practices with the patient and would prefer to avoid the patient all together”. 
• “Dentists are capable of seeing HNC patients- it is just basic dentistry shaped by a unique 
set of patient factors- same as with any other medically compromised patient”. 
• Dentists get jaded over time, they learn from situations that have burnt them in the past, 
so maybe this is why the more experienced ones have a bad attitude- they have 
experienced the same situation before and that experience has taught them to avoid it in 
the future”. “Dentists get jaded in all areas of dentistry”. 
• “The dentists that see the most patients score better in confidence but I couldn’t tell you if 
confidence lends itself to seeing patients or it is the other way around”. 
• “I wouldn’t think that managing these people was taught (at Dental School) much in the 
past as these people didn’t present to practice- they were too sick and debilitated”. 
• “Otago seems to better prepare graduates for HNC practice so they don’t consume as 
much HNC CPD or maybe it is just that HNC CPD is not available”. 
• “Dentistry is a business. Dentists are going to do the CPD that sets them up best to make 






Theme 3: Practise 
• “In my experience dentists don’t want to treat HNC patients- working up their 
treatment takes too long compared with the fee charged for relatively basic dentistry”. 
• “They refer patients into the public sector stating that they can best be managed 
there”; “in general, if they don’t know how to manage the patient they do nothing or 
else refer them to someone else”. 
• “I am always hearing from patients that their dentist told them to go back to the 
hospital for treatment”. 
• “Dentists are worried that their treatment will fail and they will get complaints about 
this to the Board”.   
• “Most HNC patients can’t have stuff like bridges and implants done so private 
dentists are not too interested in treating them”. 
• “I’m worried that if I give diet advice it will directly negate the advice given to them 
by the dietician”. 
• “No idea (why dentists aged 60+ year would see larger numbers of HNC patients), 
probably because so few dentists were actually identified as seeing big numbers of 
patients”. 
• “(At Westmead Hospital) we commonly get patients from private dentists- sometimes 
because of the volume of work required, sometimes because of the relative risk 
associated with certain procedures, sometimes it seems like it just an easy-out for the 
dentist”. 
• “Dentists are worried they are going to get sued when the patient gets 
osteoradionecrosis”. 
• “Dentists don’t feel like they were taught enough at dental school to manage these 
patients”. 
• “I am really surprised that registration and remuneration were not shown to be reasons 
that dentists don’t like to treat”; “that is contrary to my experience”. 
• “HNC patients get sent to my practice through word of mouth because a lot of them 
know one another and my colleagues know I work for the cancer centre”. 
• (50% frequency of smoking cessation advice) “Maybe because we are seeing more 
and more HPV-positive cancers now which tend to crop up in a younger, healthier 
subset of the population”; “not all our patients live at the Woolpack Hotel anymore”. 
• “In our clinic (Crown Princess Mary Cancer Centre, Westmead) there are more male 
dentists than female dentists but empathy plays a big role”. 
• “Females are probably more sympathetic than male dentists- I remember seeing this 
in my readings- that’s probably why they see more HNC patients”. 
•  “It’s frustrating, getting these referrals from dentists in private to do fillings for HNC 
survivors with the excuse that the patient is best managed in a hospital environment”. 
• “I don’t know a lot of dentists that see HNC patients in their private practice”. 
• “Rural sector dentists may see more HNC patients because they have less options 






Chapter Five: Discussion 
 
After providing an overview of the findings, this chapter will discuss the strengths and 
weaknesses of the study. It will then consider the findings with regard to what the study adds 
to the body of knowledge in this area.   
 
5.1  Overview  
 
The epidemiology of HNC has changed over the last decade, and survivability has improved. 
At the same time, more Australasians are remaining dentate as they age. As such, more HNC 
survivors are presenting to general dental practice for treatment than ever before; however, 
little is known about the capacity of general dentists to treat this complex group of patients. 
 
While there have been some studies undertaken to assess the competence of general dentists 
in screening and diagnosing HNC, it is believed that this study is the first to evaluate the 
knowledge, attitude and practise of general dentists providing dental treatment to HNC 
patients. It therefore addresses a knowledge gap in the evidence-base. 
 
The aims of this study are: 
1. To summarise what is currently known in the literature with regard to general dentists 
treating patients with a history of HNC treatment; 
2. To describe who, where and how general dental practitioners are treating HNC 
patients currently; and 
3. To identify gaps in practice or barriers to providing dental care and make 
recommendations. 
 
5.2  Weaknesses of the study 
 
There were weaknesses in this study that should not be overlooked when assessing findings 






5.2.1 Response rate 
 
The response rate for this survey was just 20.4% overall (after three waves of invitation 
emails had been sent). Surveys of health professionals typically have lower response rates 
than that of the general population (Asch et al., 1997; Cummings et al., 2001), but this 
response rate was less than that achieved by previous work, which according to a meta-
analysis of 48 surveys conducted by Cho et al in 2013, averaged out at 53% overall (Cho et 
al., 2013).  
 
The response rates achieved by previous surveys of dental professionals alone varies widely; 
Tan and Burke (Tan and Burke, 1997) reviewed 77 papers published between 1989 and 1992 
and reported response rates between 17% and 100%. A recent electronic survey of all 7 
State/Territory branches of the Australian Dental Association (ADA) and associated dental 
specialist associations has reported a 7.6% (n=801) response from general dentists with 
regard to dental implants (Guo, 2015). Similarly, Marino et al (Marino et al., 2017) reported a 
9.4% response rate (n=380) from 3343 oral health professionals invited to participate in a 36-
item survey conducted in Victoria (Australia) between September 2014 and March 2015. A 
2016 postal survey of 351 New Zealand general dentists regarding demographics, practise 
arrangements and standards achieved a response rate of 53.5% (Lee et al., 2018). 
 
It should be noted that the survey response rates of healthcare workers have fallen over time 
(Cho et al., 2013; Cook et al., 2009; Funkhouser et al., 2017). A systematic review of all such 
surveys conducted between 2000 and 2010 which used a 60% response rate as benchmark, 
found that only 36% of surveys met or exceeded this response rate to survey invitation 
between 2005 and 2008, while it was 61% among those conducted between 1998 and 2000 
(McLeod et al., 2013). 
 
Several explanations have been proposed for low response rates (or high non-response rates) 
from the health sector. Horner et al (Horner et al., 1993) discussed the concept of 
‘questionnaire fatigue’, where invitees decline to participate because they are saturated with 
requests. McLeod et al (McLeod et al., 2013) proposed that increased clinical and 
administrative workloads are factors contributing to low response rates, although the latter 
has not been explicitly demonstrated. Klabunde et al (Klabunde et al., 2012) suggested that 
office staff may screen postal and electronic mail and therefore act as ‘gatekeepers’, 
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preventing surveys reaching the clinicians themselves. In Sudman’s seminal 1985 paper on 
this topic (Sudman, 1985), lack of time, perceived lack of importance, concerns about privacy 
and bias, and survey structure that does not allow for a full range of responses, are offered as 
reasons for poor response rates among healthcare workers. Several authors have suggested 
that the survey topic may be a factor, with topics of interest to particular groups achieving 
almost double the response rate of those that were less relevant (Martin, 1994; Tan and 
Burke, 1997). It has also been reported that, the longer the questionnaire (in other words, the 
greater the respondent burden), the lower the response rate (Bogen, 1996). Difficulty 
contacting members of a sample to participate may also be a factor, as was found in the initial 
pilot of this survey in NSW Australia (which is described in section 3.9.1), where access to 
the contact details of potential participants was heavily restricted by organisational privacy 
policy. 
 
Various methods of bolstering survey response rates have been described. Monetary 
incentives have been found to increase them (Asch et al., 1998; Brueton et al., 2014; Cho et 
al., 2013), with larger incentives being associated with higher response rates (Halpern et al., 
2002). Non-monetary incentives appear to be ineffective (Brueton et al., 2014; Cho et al., 
2013; Halpern et al., 2002). Unfortunately, incentivisation in any form was not permitted in 
this study due to local ethics committee restrictions and the lack of budget to finance 
incentives. 
 
Survey reminders are also associated with higher response rates. Cook et al (Cook et al., 
2009) reported an adjusted odds ratio (OR) of 1.3 (95% CI 1.1-1.6) for surveys that followed 
up non-respondents over those that did not; that is, surveys that followed up non-respondents 
achieved, on average, 30% more responses than those that did not. This study design used 
two reminders for non-participants as a response-enhancement strategy. The initial wave of 
invitations yielded only 7.3% participation, with a second follow-up invitation sent after one 
week boosting this to 19.4%.  A further reminder one week later resulted in 20.4% total 
participation. This is still not very high, although it is better than response rates from some of 
the Australian dental surveys carried out relatively recently and described previously (Guo, 
2015; Marino et al., 2017). 
 
The response rate could have been bolstered by using a whole-population (census) approach 
to sampling (that is, distributing the survey invitation to everyone on the 2018 DCNZ 
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Register of General Dental Practitioners); however, there was little to be gained by such an 
approach because, as discussed later in this chapter, the study sample was representative of 
the population of general dentists in New Zealand. In addition, such an approach may well be 
seen as a waste of scarce resources (lower cost-effectiveness), trading a small sampling error 
for a large non-response error (Dillman et al., 2009) and unnecessarily jeopardising future co-
operation from the dental community through contributing to ‘questionnaire fatigue’ and also 
to ‘respondent fatigue’, when participants grow bored mid-survey and the quality of their 
responses deteriorates as a result (Egleston et al., 2011). 
   
Ho et al (Ho et al., 2007) stated that low response rates are the main threat to survey validity. 
Locker (Locker, 2000) wrote that response rate is usually viewed as an indicator of data 
quality. However, a poor response rate is only a source of error if non-responders and 
responders are inherently different (Locker, 2000; Tan and Burke, 1997); that was not the 
case in this survey, where the responders were demographically representative of the general 
dental practitioner population in New Zealand, even though four out of every five dentists 
who were invited to participate chose not to do so. 
 
However, it should be noted that it was not practically possible to obtain data on the non-
respondents at an individual level, so it is possible that those who elected not to participate 
were actually the richest source of meaningful data. Methods of assessing this which have 
been used previously by investigators include conducting a follow-up survey of non-
responders (Locker et al., 1990; Slade et al., 1995) or running dual survey strategies (Locker, 
1993), however these were not practically possible. Derivation of non-respondent 
information from the sampling frame (Slade et al., 1995) and comparison of respondent 
characteristics according to the difficulty in obtaining a response (Locker and Grushka, 1988) 
were possible to some extent, however were not undertaken due to time restrictions.  
 
Although this study’s response rate of 20.4% was greater than that of some of the previous 
surveys of dental professionals reported in the evidence-base, the low response rate was, 
nonetheless, a threat to the internal validity of the study since it provided low numbers for the 








The author has worked for Sydney West Cancer Network (SWCN) for over 15 years as a 
Head and Neck Oncology Dentist. As such, it would have been ideal to carry out this study in 
NSW (Australia). Unfortunately, despite receiving ethics approval for this (Appendix 3) and 
the survey being piloted here, this was not logistically possible. Access to the desired 
sampling frame was obstructed. Neither the Australian Healthcare Practitioner Agency 
(AHPRA) nor the NSW Branch of the Australian Dental Council (ADC) would permit access 
to member registers or distribute participation invitations to registrants on behalf of 
researchers. The Australian Dental Association (ADA) also would not permit access to their 
register for research purposes due to privacy and confidentiality business rules. That body 
did, however, consent to including a link to the study in their e-newsletter which was 
distributed to all members in July 2018. This method of invitation proved to be ineffective, 
with only a 1.2% participation rate achieved after one month, during which time the study 
was also advertised on the NSW ADA Facebook page. As such, further ethics approval was 
obtained (Appendix 4) and the survey was subsequently re-distributed in New Zealand, 
where the restrictions pertaining to accessing dentists’ details for the purposes of research 
were more reasonable and supportive of research. 
 
Accordingly, the findings of this study have questionable generalisability to the NSW 
(Australia) setting. Some features of the New Zealand dental industry are replicated in the 
Australian context, such as restricted access to public dental services, a public/private service 
mix and a predominantly user-pays system. Care paradigms for HNC are similar in both 
countries. Longitudinal dental workforce data from both Australia and New Zealand 
demonstrate the same patterns of increasing feminisation and multiculturalism over the last 
three decades. However, some aspects of the industry differ between the two countries: 
Australia reported that about 15% of dentists were employed in public practice in 2013 
(Australian Institute of Health and Welfare (AIHW), 2016)  whereas, in New Zealand, only 
5% of dentists worked in the public sector at roughly the same time (Dental Council of New 
Zealand (DCNZ), 2017). This indicates an important difference in the workforce sector 
employment pattern between the two countries. For this reason, the study findings may have 
limited value for a researcher working with HNC patients in Australia. Thus, the aim of 
conducting a similar study in Australia remains a valid one. 
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The survey design called for participants to self-report aspects of their clinical practice 
pertaining to HNC patients over the previous 1 to 5 years. As such, the data validity may 
have been subject to bias on the part of the respondent, both in terms of accuracy of memory 
(recall bias) and honesty of report (performance/reporting bias). In addition, the participants’ 
responses may have been subject to some degree of respondent fatigue, as previously 
discussed, as the survey was quite lengthy. Determining the extent of this was not possible 
within the time available or the design of the current study. 
 
The design of several of the survey questions themselves was also problematic. A single tick 
box whereby respondents could indicate whether they agreed (by checking the box provided) 
or not (by not checking the box provided) with the oral care advice or knowledge statement 
posed was provided. This meant that missing data were indistinguishable from negative 
response data. This inadvertent design flaw constituted a missed opportunity for data 
collection; it could have been mitigated by the survey providing both ‘yes’ and ‘no’ tick 
boxes, or restricting the participant from moving onto the next question until the current 
question had been completed. 
 
Similarly, answers for several survey questions (Q10, Q11) were captured using a Likert 
scale which provided the participant with the options of selecting ‘strongly agree’, ‘agree’, 
‘neither agree nor disagree’, ‘disagree’ or ‘strongly disagree’, as answers. These options are 
inherently and subjectively biased; one person’s ‘strongly agree’ may be another’s ‘agree’.  
 
Moreover, the survey was designed to filter out ineligible individuals (non-dentists and dental 
specialists) with the first survey question: “are you registered as a general dental 
practitioner?”  A negative response to this question would circumvent the survey and take the 
participant directly to the final “thank you for participating” screen. Specialists were also 
excluded from the sampling frame. Nonetheless, some survey respondents may have held 
dual registration in both general and specialist scopes of practice and therefore may have 
participated as general dentists but used specialist-level knowledge to answer the survey 
questions. Because the investigator was blinded as to identifying individual participants, this 
information could not be retrieved from the sampling frame retrospectively, and it was 
therefore impossible to estimate the degree of error that this may have introduced. On 
reflection, it would have been ideal to ask a follow-up question to filter out dual registrants, 




Comparison of data to the population as a whole was also problematic; the representativeness 
of the study sample was judged relative to older population statistics. That is, the sampling 
frame used was the 2018 DCNZ dental register; however, age and sex data for this dataset 
had yet to be analysed and published due to recency of collection. Instead data from the next-
most-current DCNZ workforce analysis (2015) was used as a means of judging the 
representativeness of the study sample (Dental Council of New Zealand (DCNZ), 2017). 
While it would have been ideal to compare 2018 population demographic data against that 
collected for the sample derived from the 2018 DCNZ sampling frame, it is unlikely that the 
2018 dataset demographics would have differed significantly from those collected in 2015. 
No major changes to the New Zealand socio-political climate that may have impacted on the 
composition of the dental workforce occurred between 2015 and 2018, such as relaxing of 
skilled immigration, recognition of equivalency for a broader range of overseas dental 
qualifications or changing the New Zealand undergraduate program to a postgraduate one (as 
has been done in several Australian universities). As such, using 3-year-old population 
demographic data to judge the representativeness of the sample was unlikely to be an 
important source of error. 
 
Another source of an undetermined degree of error may have been respondents 
misunderstanding of what constitutes HNC. No definition of HNC was provided in the 
survey, so it is possible that respondents answered the questions based on their experiences 
treating patients with non-HNC diseases that manifest clinically in the head and neck, such as 
Hodgkin’s Lymphoma (which is classified as a haematological cancer).  
 
Furthermore, quantitative data were interpreted by key informants (general dentists with 
considerable experience in managing HNC patients) from Sydney, Australia in order to 
provide context to the results. NSW dentists were also used to pilot the survey. This was a 
flaw in the study design and it would have been preferable for pilot participants and key 
informants to be from the sample frame. It is possible that this may have limited the 
interpretation and therefore the utility of the qualitative data obtained from the key 






5.3  Strengths of the study 
 
This study also had strengths that should be noted; these are discussed in the following 
section. 
 
5.3.1 Generalisability of findings  
 
As previously discussed, summary demographic data from the study sample were compared 
against published population statistics derived from analysis of the 2015 DCNZ Register of 
General Dental Practitioners (Dental Council of New Zealand (DCNZ), 2017).   
 
Population statistics for sex in 2015 were 38.1% female and 61.9% male (Dental Council of 
New Zealand (DCNZ), 2017) which is consistent with that of study participants which were 
41.5% female and 52.0% male. The mean age of all dentists in 2015 was 37.8 years (Dental 
Council of New Zealand (DCNZ), 2017), while it was 46.8 (+/-13.7) years in the study 
sample. New Zealand graduates accounted for 68.7% of all dentists in 2015 (Dental Council 
of New Zealand (DCNZ), 2017) and 66.9% of study participants. Dentist age was also 
comparable between the two sets of data (study sample percentage in brackets following 
2015 population percentage for the age ranges <35, 35-49, 50-60 and 60+ years): 26.0 (24.0), 
34.0 (31.2); 24.0 (25.3), 16.0 (19.5) (Dental Council of New Zealand (DCNZ), 2017) . 
 
This suggests that, at least where sex, mean age, country of graduation and age group are 
concerned, there were no systematic differences between the source population and the study 
sample (although standard deviations were broad due to the small size of the sample). That is, 
the sample used was broadly representative of general dentists in New Zealand, and the 
relatively low response rate to invitation into the study did not introduce marked bias. 
  
It is noted, however, that only 2.6% of study respondents reported that they were not 
currently practising, which is significantly lower than the 19% represented in the 2015 DCNZ 
workforce analysis (Dental Council of New Zealand (DCNZ), 2017). This observation may 
indicate that some degree of intrinsic sample error is present, but not necessarily, because 
although the study excluded non-practising dentists (those without an Annual Practising 
Certificate; APC) from the sampling frame before drawing the sample, some non-practising 
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dentists still elect to renew their APC as a contingency or through habit, so the rate was 
expected to be lower than the national average, but not nil. 
 
 
5.3.2  Novelty 
 
While some effort to quantify the barriers, from a clinician’s perspective, to accessing 
radiation oncology services has recently been undertaken (Sundaresan et al., 2015), the 
investigator believes that this study represents the first attempt at quantifying the anecdotal 
difficulties that HNC patients report in accessing general dental practice. Hence the study 
findings are noteworthy in their ability to help address a knowledge gap in the evidence-base 
pertaining to general dental practice and HNC patients.  
 
 
5.3.3 Design issues 
 
The sampling frame used (2018 DCNZ Register of General Dental Practitioners) was a valid 
one for all dentists in New Zealand. Because all practising dentists are required to be on this 
register by law, it provides a complete list of all working dentists in the country at a given 
point in time. In addition, the sampling frame was collated in the same year that the study 
was run, which would have reduced the risk of non-response due to dentists having moved 
practices or changed their email address over time. In fact, the non-contact rate (percent of all 
surveys sent that were undeliverable by the server) of the survey was just 4% (35 out of 800 
invitations emailed). It should be noted, however, that there is no evidence that those who 
were successfully contacted differed from those who were unable to be contacted, so the 
overall effect of this is unknown.  
 
The inclusion and exclusion criteria used in this study were appropriate, and therefore a 
strength. The majority of HNC patient’s access dental care via general practice, and general 
dentists were the focus of this study, so it is logical that non-dentists and dental specialists be 
excluded from participating in the study.  
 
A strategic choice was made to run the survey from the proprietary Qualtrics survey platform, 
a robust design choice. Raw data could simply be exported to SPSS software for analysis, 
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which eliminated the opportunity for transfer of information errors that would have been 
inherent with manual data entry or transcription required with a mail or phone survey. The 
digital survey platform also had other advantages, such as providing real-time mobile access 
for participants, which would have improved response rates: participants could complete the 
survey while going about their daily lives rather than having to allocate time to complete it.  
It is worth noting that, while such a platform eliminated the need for a trained interviewer and 
therefore controlled costs and eliminated the possibility of data entry or transcription error, 
this would have been at the expense of sacrificing the advantages associated with using a 
skilled facilitator, such as greater understanding of how and why participants responded as 
they did and information derived from participant interaction. 
 
The investigator was blinded to the identity of the participants (although the participants were 
aware of the identities of the researchers), which also contributed to design strength. A 
random sample was generated from the 2018 DCNZ Register of General Dental Practitioners 
by an independent party using SPSS, and no identifying data were made available to the 
investigator. Instead, respondents were assigned sequential ‘participant numbers’ based on 
the order in which they submitted their completed survey. This would have contributed to 
robust internal validity through limiting detection bias; however, the trade-off was that it 
limited options for dealing with missing data because the sampling frame could not be mined 
for information retrospectively. 
 
The overall study used mixed methodology, and this also contributed to a sound design. Key 
informants, who were dentists with extensive experience in treating HNC patients, were 
interviewed and the qualitative data derived from these sessions were thematically analysed 
to augment, explain and provide depth of understanding to the quantitative data gathered 




5.3 Study Findings 
 
A number of research questions pertaining to the knowledge, attitude and practise of general 
dentists treating HNC patients were posed at the outset of this study.  This section will 





5.4.1 Knowledge Domain 
 
 
i. Do general dentists have sufficient knowledge to treat HNC patients? 
The literature review conducted for this study suggests that most general dentists providing 
dental treatment for HNC patients fail to meet the knowledge standard recommended by key 
authors and expert organisations operating in this space, including having an accurate 
knowledge of HNC and the prevention and treatment of associated dental complications 
(Epstein et al., 2014; Multinational Association of Supportive Care in Cancer and 
International Society of Oral Oncology (MASCC/ISOO), no date of publication specified). 
This study found that dentists actually have a practically good level of knowledge overall 
(overall mean knowledge score of 9.6 questions answered correctly out of 15 questions total, 
or 64% of knowledge questions answered correctly overall). They have better knowledge of 
the more common orodental side-effects associated with HNC RTx, however poorer 
awareness of the ‘fine detail’ of these effects (such as the permanence of taste dysfunction) 
and of less common side-effects.  
Key informants were pleasantly surprised at the level of overall knowledge particularly that 
over 90% of respondents knew that patients without the traditionally associated risk factors of 
cigarette and alcohol consumption could get HNC; this is a relatively new concept associated 
with the emergence of HPV as a causative agent. 
Key respondents commented that roughly half of all respondents thought that HNC had less 
than 50% 5-year survivability and the other half thought that the prognosis was better than 
that, which might suggest that most participants took an educated guess on this question, 
albeit one informed by their clinical experience. 
There was a clear positive gradient between the number of HNC patients seen in practice 
over the previous year and the ability of the dentist to identify the knowledge statement “dry 
mouth after radiotherapy is temporary, saliva goes back to normal with time as saliva glands 
heal” as false. Dentists who reported little or no professional contact with HNC patients were 
most likely to answer incorrectly; those with a moderate flow of HNC patients through their 
practice answered accurately more frequently; and the 6 respondents who saw the greatest 
number of HNC patients (20 or more per annum) all answered correctly. Key respondents 
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were not surprised by this pattern since such knowledge is typically a function of clinical 
experience in a particular area.  
There was a significant difference detected between the ability of New Zealand dental 
graduates and overseas graduates to answer this question correctly; New Zealand graduates 
performed significantly better. While this was not the case for all 15 knowledge statements 
combined, New Zealand graduates were also able to identify that RTx does not directly 
damage the teeth more reliably than international graduates. Key informants summarised that 
New Zealand graduates seemed to have better knowledge of some aspects of RTx side-effects 
and postulated that this may be a direct reflection of the superior dental curriculum at Otago 
University. 
Akbari et al (Akbari et al., 2015) has observed a significant difference between the 
knowledge of dentists with between 1 and 4 years of clinical experience and those with over 
20 years of clinical experience; the most inexperienced clinicians scored best and their most 
seasoned colleagues scored worst. However, a different pattern was found in the current 
study, with dentists aged 50-59 years and those with 30-39 years’ experience (probably the 
same individuals) having statistically higher mean knowledge scores (number of questions 
answered correctly out of 15 questions total) than all other age and clinical experience 
groups. This may be due to the smaller size of the Akbari et al sample compared with this 
study; only 80 dentists were invited into the former study, and 800 were invited into the 
current one (although both studies were ‘top heavy’ in terms of most participants falling into 
the least clinically experienced strata). 
Interestingly, when provided with a Likert scale (‘strongly agree’, ‘agree’, ‘neither agree nor 
disagree’, ‘disagree’, ‘strongly disagree’), the minority of participants elected to ‘sit on the 
fence’ in answering most of the 4 knowledge statements.  This may be an indication that they 
felt confident in their answers to the knowledge questions and goes against the central 
tendency effect where participants tend to rate in the middle of a scale. 
It is debatable whether the ability of New Zealand general dentists to answer just over 60% of 
knowledge questions correctly constitutes them having ‘accurate’ knowledge of HNC dental 
oncology as specified by the Multinational Association of Supportive Care in Cancer and 
International Society of Oral Oncology (MASCC/ISOO) (Multinational Association of 
Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO), no 
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date of publication specified). Taken literally, the dictionary (Collins English Dictionary 
2012 electronic version, 2012) defines ‘accurate’ to be “without error”, which suggests that 
anything less than all respondents answering all questions correctly constitutes insufficient 
knowledge to treat HNC patients in practice, which is what the literature review suggested. 
However, expecting this level of knowledge is unrealistic, and key informants commented 
that it is good enough to have a qualified dentist who is able to answer the majority of the 
knowledge questions posed in the survey correctly, and who practises in a risk-adverse 
manner similar to that employed when treating other medically complex dental patients.  
 
5.4.2 Attitude Domain 
 
 
i. Are general dentists in New Zealand sufficiently confident in their ability to treat 
HNC patients?  
 
Three of the nine attitude statements posed directly assessed clinician confidence in 
managing HNC patients: “I have been adequately trained to manage the dental needs of HNC 
patients”; “I am confident in giving advice to HNC patients about their mouth and teeth”; and 
“I am not confident in providing dental care for HNC patients”.   
Dentists who felt that their training was adequate to prepare them for treating HNC patients 
in practice were in the minority. In fact, only one in four dentists overall felt that dental 
school had prepared them sufficiently to treat HNC patients, which reflects a considerable 
lack of clinical confidence among general dental practitioners in New Zealand. This finding 
is consistent with previous work involving dentists in Turkey, Iran, US, Nova Scotia and 
British Columbia (Burzynski et al., 2002; Clovis et al., 2002; Guneri et al., 2008; Patel et al., 
2012). 
The practitioners who felt that their training had suitably prepared them to treat HNC patients 
were those who also reported having seen the most HNC patients in practice over the 
previous year. The direction of that particular association was unable to be determined; that 
is, it was not possible to determine if clinical experience bred confidence or whether robust 
dental school training led to these practitioners accepting more HNC patients for treatment in 
practice. Follow-up qualitative research with respondents may have provided clarity here, but 
this was not possible due to time pressures and blinded design.  
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Confidence in giving oral care advice was positively associated with HNC patient flow over 
the previous year; the practitioners with the most confidence in this area were those who had 
seen the most HNC patients in the past year (or conversely, those who had seen the most 
HNC patients were the most confident). Again, the direction of the cause-effect relationship 
(or indeed causation, rather than just correlation) is unable to be determined without further 
investigation that was not permitted by the design of this study. 
Conversely, practitioners with the most years’ experience working in practice were most 
likely to feel that their dental school training had not provided them with sufficient 
preparation to treat HNC patients in the real world. Key respondents commented that 
management of HNC patients was historically probably not taught well in dental school as 
HNC patients did not present to general practice in decades past; they were either already 
edentulous, were rendered edentulous through aggressive pre-RTx dental assessment 
paradigms, or they were too disabled to seek care as a result of the severity of traditional RTx 
orofacial side-effects. 
New Zealand trained graduates fared well; 25% of overseas trained graduates reported not 
feeling confident in treating HNC patients, but only 10% of New Zealand graduates felt this 
way, which could be a reflection of the quality of the domestic dental curriculum.  
There was no apparent differences noted in the overall attitude of dentists to treating HNC 
patients (that is, the mean number of ‘agree’/’strongly agree’ responses out of 9 attitude 
statements posed). However, the data did show as subtle gradient reflecting poorer attitudes 
with advancing age and greater clinical experience. Key informants commented that this 
same pattern would likely be seen other areas of general dentistry as well, where practitioners 
become ‘jaded’ with time as a result of years of experience. 
 
ii. Are general dentists willing to see HNC patients in their practices?  
 
Two of the five attitude statements posed reflected willingness to treat HNC patients in 
practice; “general dentists should be able to provide dental treatment for HNC patients” and 
“I would prefer to refer patients with a history of HNC to a specialist for management”.  
 
The study findings show that over three quarters of dentists believe that dental treatment for 
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HNC patients falls within the scope of practice for a generalist, although a higher proportion 
of overseas-trained dentists indicated that they would prefer to refer HNC patients to a 
specialist for management (than their New Zealand trained counterparts).  Key informants 
commented that this was further praise for the University of Otago course. 
 
 
iii. What treatments are dentists happy to deliver for HNC patients? 
 
More dentists reported that they would be willing to perform basic dental treatments than 
those who reported actually having performed these treatments in the previous year for one or 
more HNC patients in practice. This is not surprising; the theory-practice dichotomy, where 
there is a disconnect between academic knowledge and clinical practice is prevalent 
throughout healthcare. It represents the gap between ideal and real-world practice, or between 
the theory underpinning practice and the implicit conscious and subconscious experiential 
influences that shape clinical decision-making. For example, a dentist may be technically 
capable and know that the evidence-base supports general dentists carrying out routine dental 
work for HNC survivors, however a bad past experience where there was a poor clinical 
outcome (such as delayed healing or a restoration failure) may mean that the dentist avoids 
performing certain procedures for HNC patients in the future. This may be the reason why 
one in ten dentists who saw a HNC patient in the previous 12 months reported that they 
provided no treatment or advice; it is illogical to believe that these patients presented without 
treatment need because they are at high risk of severe and rapid-onset dental disease.  
 
Only half of all dentists reported that they would provide smoking cessation intervention 
(SCI) for patients with HNC that smoked. At face value, this would seem to be an 
unreasonably low rate. Up until about fifteen years ago, HNC was seen almost exclusively in 
heavy smokers, and the link between carcinogenesis and smoking is firmly established in the 
evidence-base. In addition, targeting risk factors that are shared by different chronic illnesses 
is an established public health approach to disease prevention that is taught in every dental 
school curriculum in Australia and New Zealand. Both the Australian Dental Association 
(ADA) and New Zealand Dental Association (NZDA), as the peak associations for dental 





And yet, the low rate in this study is consistent with rates reported in the evidence-base. In a 
survey undertaken in Victoria (Australia) in 1993, 55% of dentists reported that they 
encouraged patients who smoked to quit. Eleven years later, in 2004, Brady et al (Brady et 
al., 2004) surveyed 204 New Zealand dentists and reported a similar rate. 
 
So, dentists are aware of the causal association between HNC and smoking, but around half 
of them are not giving SCI. One of the explanations for this provided in the evidence-base is 
a knowledge-practice disconnect; dentists feel that they are not trained sufficiently to deliver 
SCI. Other reasons include risk of patient alienation (Mullins, 1994) and concerns about 
remuneration and effectiveness (Skegg 1995).  
 
The survey found that dentists were more willing to perform non-invasive treatments, such as 
fillings, and less willing to provide invasive procedures, such as extraction of teeth. In fact, 
there was a clear gradient between increasing procedural invasiveness and reduced 
willingness to perform a procedure on the part of the dentist. As such, fewer dentists 
indicated that they would perform a surgical extraction (gum surgery, removal of bone with 
or without tooth sectioning) compared with those who would undertake a simple extraction 
(elevation and forceps alone). Similarly, more dentists indicated that they would perform a 
filling than would scale and root plane (debridement of the tooth root where it anchors into 
the jawbone) for a HNC patient. This finding is consistent with work by Husein et al (Husein 
et al., 2011)  from 2010 in the UK. 
 
This makes sense considering that osteoradionecrosis (ORN) is arguably the most morbid of 
all side-effects associated with HNC treatment, and that trauma to irradiated bone is 
associated with ORN. Anecdotally, it is the most ‘feared’ consequence of providing dental 
treatment for a HNC patient, and it is likely that dentists have greater awareness of ORN than 
other health professionals, as it is heavily emphasised in most dentistry curricula. This, 
coupled with the increasingly litigious climate in dentistry today (and the corresponding 











The study findings show a strong positive gradient between HNC continuing professional 
development (CPD) and the number of HNC patients that a dentist saw in practice over the 
previous 12 months. Key informants were unable to comment whether attending CPD 
precipitated HNC patient flow, or whether an increase in HNC patients presenting in practice 
was an impetus for the dentist to seek out CPD in this area. Qualitative research, such as 
focus groups or one-on-one interview of respondents may have clarified this point, however 
blinding, study timeframe and consent issues made this impossible. 
Public sector work experience was also associated with having completed HNC CPD. This is 
likely explained by dental graduates having more exposure to HNC patients in public sector 
jobs, and these positions having a significant component of on-the-job CPD associated with 
them. For example, one key informant reported that, as a new graduate dentist employed as a 
House Surgeon with Capital and Coast District Health Board (New Zealand) in the early 
2000s, she received regular HNC CPD, including mandatory attendance at the annual New 
Zealand Hospital and Community Dentistry Conference, weekly ‘grand rounds’ meetings and 
regular didactic CPD sessions, all of which were structured into the position description for 
her role. 
Although no association was demonstrated, New Zealand graduates were less likely to have 
undertaken HNC CPD in the previous 5 years than their overseas-graduated colleagues. Key 
informants felt that this may be because the New Zealand dental school curricula better 
prepared graduates for working with HNC patients in practice or, alternatively, was a 
reflection of the scarcity of HNC CPD programs available to general dentists in New 
Zealand. 
No association was detected between self-reported interest in future HNC related CPD and 
any of the sample characteristics. The survey found that 60% of all dentists were interested in 
undertaking HNC CPD, however only 48% had done so in the last 5 years. This finding is 
consistent with work undertaken by Clovis et al (Clovis et al., 2002) who reported that most 
dentists were interested in completing HNC CPD, however the majority had not undertaken 
any recently. Key informants felt that most dentists would be interested in this topic because 
116 
 
the demand for dental care among HNC patients has increased in practice, however, because 
HNC patients tended to cluster with experienced practitioners, perhaps only these dentists 
would seek out HNC CPD. Key informants also commented that dentistry is a business and, 
as such, only a defined amount of clinical time can be sacrificed for professional 
development, so dentists may elect to undertake CPD that is related to more substantial 
and/or financially lucrative parts of their practice, such as implants or orthodontics.  
 
 
5.4.3 Behaviour Domain 
 
 
i. Are general dentists in New Zealand seeing HNC patients in their practices? 
 
 
This study has found that most HNC patients are seen by a small minority of general dental 
practitioners. In fact, one in four dentists reported that they had not seen a single HNC patient 
in the 12 months prior in this study. Two in three dentists had seen only small numbers in the 
same period. 
  
This is consistent with the pattern of patient flow reported by key informants in this space; 
patients self-select to particular dental practices, largely based on word of mouth 
recommendation from other cancer care patients that they encounter while accessing medical 
services. In some cases patients may be referred to a particular dentist by another cancer care 
healthcare provider who may have successfully worked with this dentist in the past. 
 
 
ii. What are the characteristics of general dentists who treat HNC patients? 
 
 
This study found that those dentists who treat large numbers of HNC patients (20 or more per 
annum) are most likely to be female, 60 years of age or more, New Zealand graduates and have 
public sector work experience. These practitioners are most likely to work between both private 
and public sectors, and practise in urban areas.  
Key informants agreed that female dentists may indeed see more HNC patients than their 
male colleagues. They noted that entry-level dental officer positions in the major teaching 
hospitals in Sydney and other public sector clinics are primarily filled by female graduates, 
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and that these dentists would get significant exposure to treating HNC patients. One key 
informant made reference to literature suggesting that female doctors were more empathetic 
than their male counterparts (Berg et al., 2011), and commented that empathy is critical when 
working with HNC patients. 
 
The study found that dentists aged 60 years or older were most likely to see larger numbers of 
HNC patients. Although key informants were unable to explain this finding, it likely resulted 
from the small number of dentists in this group (only 5 dentists who reported seeing 20 or 
more HNC patients in the last year answered this question) or because younger associates 
tend to refer complicated patients to older and more experienced dentists within their 
practices.  
 
Key informants also commented that dentists with public sector work experience would be 
more comfortable seeing HNC patients for routine dental care as they would have the most 
formative experience with medically compromised patients.  
 
 
iii. What treatment have general dentists performed for HNC patients? 
 
The current study has found that more dentists are theoretically willing to provide dental 
treatment for HNC patients than the number who report actually having provided that 
treatment in the previous year. This pattern holds for all basic dental treatments, irrespective 
of their degree of invasiveness. This disparity represents the gap between ideal and real-
world practice, and the difficulty that clinicians have in putting theoretical knowledge into 
clinical action, all across healthcare. 
 
As discussed previously, the study has found that dentists were less willing to consider 
performing invasive dental treatment than non-invasive treatment. The current study has 
found that this same gradient exists in practice; dentists were most likely to report having 
performed non-invasive procedures for HNC patients in the previous year, and least likely to 
have performed invasive treatment. For example, about 65% of participants reported that they 
had done a filling for a HNC patient during this timeframe, however only 6.5% had 




Few dentists indicated that they would deliver items of poor advice (that is, advice that was 
detrimental or not recommended in the evidence-base), such as eating frequently to stimulate 
saliva. This indicates a reasonably good level of knowledge regarding oral care practices in 
this area. 
 
The study also found that dentists were more likely to provide oral hygiene instruction than 
diet instruction for HNC patients. Fewer still reported that they would drill down into the 
specifics of diet strategy, such as reducing sugar in tea and coffee and increasing daily water 
consumption. Key respondents felt that this may be because dental practitioners felt that they 
were not sufficiently knowledgeable with regards to diet advice. One key informant 
commented that he was wary of giving dietary advice, as it was often contradicted by the 
cancer clinic dieticians who encouraged patients to snack regularly on carbohydrate-rich 




iv. What are the barriers to general dentists treating HNC patients? 
 
 
The study found that most dentists did not feel that treating HNC patients put their 
professional registration at risk. Nor did the majority consider lack of financial remuneration 
to be a barrier to them providing treatment. This was in contrast to both the anecdotal 
evidence that informed this study, and the expectations of all of the key informants who 
participated in interpreting the data; this feedback was that most dentists did not want to treat 
HNC patients because they had a higher-than-average risk of treatment failure, and that may 
lead to complaints being made against the dentist to DCNZ (as the regulatory body for the 
dental profession in New Zealand). Key informants reported that other reasons that have been 
given by dentists who elect not to treat HNC patients include not wanting to cause 
osteoradionecrosis, and because HNC patients were generally unsuitable for the kind of fixed 
prosthetic work that bears the largest profit margin in dentistry. 
Perhaps this dichotomy can be explained by another study finding; few dentists had actually 
seen one or more HNC patient in the previous 12 months. That is, most dentists reported that 
their feelings aligned with the ideal ethical and moral response to this question: that they 
would treat HNC patients like any other patient, however the majority of clinicians had not 
had these ideals challenged and shaped by real-world exposure to HNC patients, which 
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would limit the validity of their responses beyond the theoretical. Indeed, only one in ten 
dentists who had seen a HNC patient in the previous year reported having actually performed 
a dental treatment, which suggests a degree of avoidance, especially given that HNC patients 
carry a greater burden of dental disease than the average patient. Such behaviour is in 
alignment with psychological theory suggesting that individuals will always act to maximise 
their own best interests (psychological egoism) (Wikipedia, 2019). 
The number of respondents who answered these questions was quite small, with the majority 
of participants indicating that they were unsure how they felt about the registration statement 
in particular, which may also indicate professional discomfort in admitting to selecting 
patients based on remuneration potential and lack of professional risk. 
The study found that rural-based dentists were more likely to feel that HNC patients were a 
risk to their registration than urban-based dentists. This may be because most dentists work in 
metropolitan areas and therefore professional advice and support is more readily available to 
these urban clinicians. Furthermore, because of the scarcity of rural practitioners, dentists 
working in these areas are often forced to be ‘a jack of all trades’ out of necessity, and this 
may result in them working at the limits of their scope of practice. Most rural dentists 
indicated they were ‘unsure’ about how they felt with regard to this statement, so this finding 






Chapter Six: Recommendations 
 
This chapter will identify and discuss the actions that I, as the investigator, feel should arise 
from this research. 
  
 
6.1 Improve access to professional populations for Australian researchers. 
 
This study was initially planned and piloted in NSW (Australia). Unfortunately though, 
AHPRA, the ADA nor the ADC would permit access to their member lists for research.  
These organisations referenced privacy and confidentiality protocols as the reason for this. A 
compromised method of survey distribution was negotiated by the investigator with the 
ADA, and an advertisement was placed in the July 2018 e-newsletter sent to members asking 
them to navigate to the ADA website, log into the members-only portal, access the survey 
link and undertake the questionnaire. This method of recruitment was not satisfactory; it 
introduced unacceptable bias (as respondents self-selected to participate), and only resulted in 
a 1.2% response rate, which was grossly insufficient for statistical analysis. The survey was 
eventually re-planned and undertaken in New Zealand because there was an established and 
reasonable process in place there for investigators to access lists of potential survey 
participants for research purposes. 
 
Both the ADA and ADC publish key governance documents that are the blueprint for how 
dental care is to be provided in Australia. Healthy Mouths Healthy Lives (Council of 
Australian Governments (COAG) Health Council, 2015) is the current Australian National 
Oral Health Plan authored by The Council of Australian Governments (COAG) as the peak 
intergovernmental agency in Australia. Similarly, the ADA publishes The Australian Dental 
Health Plan (Australian Dental Association (ADA), 2016). Both of these documents heavily 
emphasise prioritisation of dental treatment for patients at high risk of dental disease as a 
result of a special need (such as secondary to cancer treatment). The former document targets 
research and development as a foundation area for action. It would therefore seem that the 
absence of a pathway which affords researchers access to dentists, for the purposes of 
describing access to dental care for priority populations in Australia, is at odds with the 




Creation of such a pathway must include a careful risk-benefit analysis which weighs privacy 
and confidentiality rights against ethical obligation to participate in research (which could be 
seen as a public good). Concerns about worsening the problem of questionnaire fatigue 
would need to be balanced against the risks associated with not having a clear, evidence-
based picture of population oral health, such as poorly directed efforts, wasted resources and 
creation of unsustainable change. 
 
Another issue to debate is who should sponsor this revolution. Groups have more power than 
individuals in the political space; perhaps an organisation such as the National Research 
Council or Australian Research Centre for Population Oral Health (ARCPOH) would be an 
appropriate advocate. 
 
Clearly, this is not a simple process or decision. Australia can be encouraged by the fact that 
parallel organisations in New Zealand have successfully implemented protocols that support 
both research and national oral health goals, without unduly compromising practitioner 
rights. This study utilised such a pathway through the DCNZ. A similar system may be 
replicated or modified to suit the Australian context.  
 
 
6.2 Complete the picture: further research in this space. 
 
As described previously, the findings of this study may not translate to the Australian context 
because the composition and distribution of the Australian dental workforce differs somewhat 
from that of New Zealand. Consequently, in order to get a clear picture of how HNC patients 
are accessing dental care in Australia, this research would need to be undertaken in Australia. 
The obvious problem has been discussed above- getting access to a representative sampling 
frame. 
 
Another way to further research in this space may be to look at access to dental care from the 
HNC patient perspective. Affordability of services, availability of dental services and 
information about services are some aspects of access to care that have not been examined by 





6.3 Build clinician knowledge and confidence. 
 
This study has reported that New Zealand graduates scored better than their overseas trained 
counterparts in terms of knowledge, attitude and practise in providing dental treatment for 
HNC patients. It would be worth doing some comparative work to assess where the 
differences and similarities exist between various undergraduate dental programs, at least in 
Australia and New Zealand. This work could be used to amend dental curricula to maximise 
graduate outcomes such as awareness, practical application and clinical confidence in this 
space. For example, HPV vaccination programs in New Zealand and Australia (Cancer 
Council Australia, 2019; New Zealand Ministry of Health, 2019b) are now available to a 
broader age range of both sexes, and although most dentists in this study were aware of the 
causal association between HPV and HNC, this is not common knowledge in the wider 
community where discussion around HPV vaccination has almost solely been in relation to 
prevention of cervical cancer. Indeed, dentists have not been trained to assess HPV risk as 
part of taking a routine medical history, provide sexual hygiene advice to their younger 
patients or advocate for HPV vaccination as a preventative dental public health strategy, all 
of which they now need to be doing in practice. 
 
It is also important to build new-graduate learning pathways that consolidate and enhance 
graduate competencies in treating these complex patients. Undergraduate dental curricular 
demands and the limited access that most dental schools have to HNC patients explains why 
it is so hard for students to gain sufficient knowledge and experience treating HNC patients. 
Medical students undertake a compulsory prevocational ‘Trainee Intern’ year of closely 
supervised clinical practice in a public health facility before they are able to graduate as 
registered practitioners (Medical Board of Australia, 2019; Medical Council of New Zealand, 
2019). This year is valuable in that it allows the clinician an opportunity to put theoretical 
knowledge into practice, reinforces learning, builds self-reliance and allows the clinician to 
get experience treating complex patients that they may not otherwise encounter in practice. 
This is not the case in dentistry; public sector employment is optional and most graduates 
proceed directly into private practice as autonomous practitioners with little or no direct 
oversight. Perhaps a compulsory year of full-time supervised public practice prior to 
graduation should be considered as a means of augmenting the dental curricula in both 
Australia and New Zealand dental schools. Other ideas include creation of ‘residency 
programs’ and ‘short-course qualifications’ such as a Diploma in Hospital Dentistry which 
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could be run out of the major dental hospitals. Dentistry and Medicine have become 
divergent professions over time and in the last few years we have begun to talk about 
bridging the gap and integrating the two roles in the pursuit of holistic health and wellbeing; 
that is, ‘putting the mouth back into health’ (Hayashi and Wilson, 10 Jan 2017; University of 
Sydney, 2019). Perhaps one way of pursuing this is to borrow from our medical colleagues in 
terms of how they train and season their new graduates.   
 
Experienced dentists should also have opportunities to access updates in evidence-based 
practice and knowledge in the form of available CPD opportunities. These ‘one-day courses’, 
‘lectures’ or ‘workshops’ could be facilitated by the universities, various professional 
associations (such as the ADA or NZDA), and the public hospitals themselves. 
 
 
6.4 Build supportive frameworks/models of care into the healthcare system. 
 
As discussed in the literature review, MDTs with dental input are the current gold-standard 
for the delivery of patient-centric cancer care for the HNC patient. One can look at these 
integrated services as being medically necessary; if HNC patients do not receive timely and 
appropriate care, they have an increased risk of dental morbidity during and after cancer 
treatment which will impact upon their ability to complete cancer treatment and their quality 
of life. 
 
Nonetheless, few MDTs worldwide include a dentist or dental team (Barker et al., 2005; 
Epstein et al., 2004; Epstein et al., 2014; Huber and Terezhalmy, 2003; Lawrence et al., 
2013; Ray-Chaudhuri et al., 2013; Specht, 2002; Sroussi et al., 2017); expertise is scarce 
among dentists, and public funding for such positions is lacking. In NSW (Australia), public 
sector dental services are block-funded based on activity targets being met, with no weighting 
to account for patient complexity and no additional funding to provide support to medical 
services (New South Wales Government, 2019). As such, it is counterintuitive from a 
business perspective for hospital dentists to be rostered to work in low output, high acuity, 
high complexity clinical scenarios such as HNC MDTs. 
 
In the US, major HNC centres such as Memorial Sloan Kettering (New York) and MD 
Anderson (Arizona, Florida, New Jersey, Texas) deliver dental care for HNC patients through 
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integrated onsite dental clinics. These centres are privately funded by the consumer. In 
contrast, Australian and New Zealand governments provide generous social welfare safety 
nets, and view healthcare as an essential public good. As such, urgent medically-essential 
treatment is publically funded. Consequently, there is considerably less demand for the user-
pays model of cancer care in Australasia (although it does exist in this space- for example, 
Chris O’Brien Lifehouse in Sydney). Nonetheless, there are some aspects of the US-style of 
service delivery that may translate to the Australasian context, such as establishment of 
funded hospital appointments for dentists to work within cancer teams. 
 
Similarly, there is no universally accepted model of care for dental treatment of the HNC 
patient.  Instead, dental intervention is determined at the individual clinician level (Barker et 
al., 2005). There is much work to be done in this space with the aim of compiling evidence-
based guidelines to shape services and guide appropriate dental treatment decisions for HNC 
patients. 
 
It is also time that public funding of dental services is reviewed. As previously mentioned, 
funding of public dental services, at least in NSW (Australia), is currently contingent upon 
hospitals meeting productivity targets (New South Wales Government, 2019). Such systems 
do not account for the increasing acuity and complexity of the patients who currently present 
for treatment in today’s aging society, where patients take longer than ever to treatment plan 
and treat safely. As such, the current method of funding is rapidly becoming unsustainable 
and irrelevant. In fact, discussion around how to broadly reform funding is already underway 
in Australia with release of the 2018 Australian Productivity Commission report (Australian 
Government Productivity Commission, 2018) which advocates for a more consumer-directed 
approach to healthcare funding which maximises both clinical and patient outcomes, through 
a focus on targeted preventative care. Although initial drafts of this report have been 
somewhat unfavourably received by the dental profession (Australian Dental Association 
(ADA), 14 July 2017), it represents acknowledgment that public dental service funding is in 
need of broad reform, and that upstream preventive care is more efficacious than palliative 
tertiary intervention. 
 
Enhanced support through greater transparency of existing healthcare pathways is another 
piece of work that can be undertaken. Local content experts in this space are primarily 
located in the public sector, at the major dental teaching hospitals. However, as an area of 
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practice, HNC dentistry is not a specialty of its own, and straddles the disciplines of Special 
Needs Dentistry, Oral Medicine, General Practice Dentistry, Prosthodontics and Oral 
Surgery. As such, it is often difficult for external clinicians to identify who they should 
contact for advice in managing the dental needs of HNC patients. This issue could be 
addressed relatively easily by teaching hospitals providing adequate and current content on 
their websites.  
 
Similarly, external dentists are also unclear on how to access oral health pathways should 
they need to refer HNC patients. Some work is currently being done in this space; 
HealthPathways is an initiative that provides online manuals for the assessment, management 
and referral of over 550 health conditions (Western Sydney HealthPathways, 2019). It is 
currently in place in New Zealand and the UK, and is in the process of being rolled out in 







Chapter Seven: Conclusion  
 
This study has found that, although most dentists feel that dentistry for the HNC patient falls 
within the scope of the general dentist, very few actually see any HNC patients in practice. 
Indeed, most HNC patients tend to self-select practitioners that routinely treat large numbers 
of HNC patients and ‘cluster’ at these practices. These dentists are typically female, 
metropolitan-based, have had public sector work experience and currently work across both 
public and private sectors. 
 
In general, the knowledge of New Zealand general dentists does not measure up to that which 
is prescribed by expert authors and key cancer organisations in the evidence-base. Those 
dentists that see the most HNC patients meet this standard, but overall levels of knowledge 
are only fair. Nonetheless, key informants in this area are satisfied that, in the real world, the 
knowledge level demonstrated by general practitioners is sufficient.  
 
This study found that New Zealand graduates rated favourably in terms of knowledge, 
attitude and behaviour, when compared with their overseas-trained colleagues. The study also 
found that there was a moderate appetite for CPD in this area of practice. 
 
What is concerning, is the lack of confidence in their ability to treat HNC patients that was 
reported by respondents in this study. Most dentists felt that dental school had not sufficiently 
prepared them to see HNC patients in the real world. Although most dentists reported that 
they would be willing to perform basic dental treatment for a patient with a history of HNC, 
the conversion rate into practice was much lower. As a rule of thumb, the more invasive the 
procedure, the less dentists were willing to perform it, or had performed it, for a HNC patient 
in the previous year in practice. This study could not adequately identify the barriers 
preventing HNC patient’s receiving dental care however; the reasons put forward by key 
informants were at odds with quantitative data. 
 
Alarmingly, both the findings of this study and the literature review demonstrate, at least in 
the opinion of this researcher, unacceptable rates of smoking cessation advice being given to 
HNC patients. This is in spite of the reasonable level of knowledge demonstrated by 




Although the results of this study are generalisable to New Zealand dentists as a population, 
and may indeed be able to be replicated and repeated, it is unlikely that they would apply to 
the Australian context. Indeed, unless restrictions that currently prevent researchers accessing 
dentists in Australia are reviewed and relaxed somewhat, it is unlikely that we will be able to 
obtain a clear idea of how HNC patients access dental care in Australia. If nothing else, this 
research has had value in identifying that current privacy and confidentiality restrictions 
invoked by Australian dental organisations are a genuine risk to future research. 
 
If this study were to be repeated in the future, I would advocate for alteration of the design to 
allow for retrospective examination of the sampling frame, to allow for mining of missing 
data, and so focus groups of participants could be run to provide more qualitative data around 
some of the findings. For example, to establish if dentists sought HNC CPD because HNC 
patients were accessing their practices, or if dentists were simply more confident in accepting 
HNC patients in their practices after attending CPD sessions. This would come at the expense 
of introducing some bias however, as the investigator would no longer be blinded to the 
identity of the participants, but this could be avoided through obtaining funding with which to 
employ a trained facilitator who is not privy to the survey results. Ideally, it would also have 
been ideal to have more key informants to collect data from, however, as this study has 
demonstrated, experienced dentists in this space are few and far between. These people 
would be best sourced from the New Zealand context in terms being able to address New 
Zealand derived data. 
 
Finally, modern healthcare is designed around patient-centred care, and patient-reported 
outcomes are key performance indicators.  As such, studies of HNC patients themselves 
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Appendix 1: Literature search strategies 
 











c. Embase via OvidSP (1947-Aug 2018), Medline via OvidSP (1946-Aug 2018), Cochrane Database of Systematic Reviews (2005-
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t tests - Means: Difference between two independent means (two groups) 
Analysis:      A priori: Compute required sample size  
Input:            Tail(s)                                             =   Two 
                      Effect size d                                    =   0.2 
                      α err prob                                       =   0.05 
                      Power (1-β err prob)                      =   0.8 
                      Allocation ratio N2/N1                   =   1 
Output:         Noncentrality parameter δ             =   2.8071338 
                      Critical t                                          =   1.9629867 
                      Df                                                    =   786 
                      Sample size group 1                      =   394 
                      Sample size group 2                      =   394 
                      Total sample size                           =   788 
                      Actual power                                  =   0.8005931 
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Appendix 9: Key informant interview data collection template 
 
Semi-structured interview- raw data collection template:  
 
a. Knowledge Domain 
 
i. Do general dentists in New Zealand have sufficient knowledge to treat HNC patients? 
What do you think we may find? 
 
 
Brief explanation of how this item 
was evaluated by the survey. 
Knowledge questions: Q9 (common side-effects of RTx- 11 items); Q10 (4 knowledge statements); Q10 “I have 





Literature review suggests knowledge insufficient, survey finds 64% of all questions/statements answered 
correctly. 
Participants identified common side-effects correctly more frequently than rarer ones. 
Positive association between number of patients seen in the last 12 months and knowledge. Stat sig better mean 
knowledge score for 50-59YO and 30-39 years’ experience groups cf other groups. 
How do these findings align with 
your expectations?  
 
How/why do you think we may have 
got this result? 
 




b. Attitude Domain 
 
i. Are general dentists in New Zealand sufficiently confident in their ability to treat HNC patients? 
What do you think we may find?  
Brief explanation of how this item 
was evaluated by the survey. 
Q11 “I am confident in giving advice to HNC patients about their mouth and teeth”; “I am not confident in 
providing treatment for HNC patients”; “I have been adequately trained to manage the dental needs of HNC 
patients”. 
Findings. No sig diff however subtle gradient of poorer attitude with greater experience. 
How do these findings align with 
your expectations?  
 
How/why do you think we may have 
got this result? 
 
What do you think this means?  
 
ii.  Are general dentists in New Zealand willing to see HNC patients in their practices?  
What do you think we may find?  
Brief explanation of how this item 
was evaluated by the survey. 





¾ agree that HNC dentistry is in general practice scope. 
More overseas graduates compared with NZ graduates would refer rather than treat.  
NZ grads saw more HNC patients. 
Public experience and some degree of current public sector dental employment association with increased HNC 
patient flow. 
How do these findings align with 
your expectations?  
 
How/why do you think we may have 
got this result? 
 




iii. What treatments would general dentists be happy to deliver for HNC patients? 
What do you think we may find?  
Brief explanation of how this item 
was evaluated by the survey. 
Q14 
Findings. Non-invasive>invasive 
How do these findings align with 
your expectations?  
 
How/why do you think we may have 
got this result? 
 
What do you think this means?  
 
 
iv.  Are general dentists interested in continuing professional development on this topic? 
What do you think we may find?  
Brief explanation of how this item 
was evaluated by the survey. 
Q10 “I have done some CPD on HNC in the last five years”; Q11 “I would like to attend CPD on managing the 




Positive gradient between number of patients seen and likelihood of having done CPD. 
Public sector work experience association with having done CPD. 
60% interested in future CPD. 
How do these findings align with 
your expectations?  
 
How/why do you think we may have 
got this result? 
 




c. Practice (Behaviour) Domain 
 
i. Are general dentists in New Zealand seeing HNC in their practices?  
 
What do you think we may find?  
Brief explanation of how this item 
was evaluated by the survey. 
Q12 “how many HNC patients have you seen in your practice over the last 12 months?” 
Findings. Minority of dentists see the bulk of the patients. 
How do these findings align with 
your expectations?  
 
How/why do you think we may have 
got this result? 
 
What do you think this means? For discussion: how do patients find these dentists in your experience? 
 
 
ii. What are the characteristics of general dentists that treat HNC patients? 
What do you think we may find?  
Brief explanation of how this item 
was evaluated by the survey. 
Q2-8. 
Findings. HNC patient flow associated with female gender, 60+ YO age bracket, public sector work experience, NZ degree, 
current public employment. 
How do these findings align with 
your expectations?  
 
How/why do you think we may have 
got this result? 
 






iii. What treatments have general dentists performed for HNC patients?  
What do you think we may find?  
Brief explanation of how this item 
was evaluated by the survey. 
Q13 “what did you do?” (for the HNC patients you have treated). 





More dentists report willingness to provide treatments compared with actually having performed the treatment 
in practice. 
50% provide smoking cessation. 
1 in 10 that have treated a HNC patient provided no treatment. 
More dentists provided non-invasive care cf invasive treatment. 
How do these findings align with 
your expectations?  
 
How/why do you think we may have 
got this result? 
 
What do you think this means?  
 
iv. Where are HNC patients accessing care?  
What do you think we may find?  
Brief explanation of how this item 
was evaluated by the survey. 
Q12 “how many HNC patients have you seen in your practice over the last 12 months?” crosstabs Q2-8. 
Findings. Minority of dentists see majority of patients. 
How do these findings align with 
your expectations?  
 
How/why do you think we may have 
got this result? 
 




v. What are the barriers to general dentists treating HNC patients?  
What do you think we may find?  
Brief explanation of how this item 
was evaluated by the survey. 
Q11 “treating HNC is too hard compared to the financial reward I get from it”; “I have been adequately trained to 




Financial reward and prof registration not associated. 
 
Only ¼ felt dent school was adequate- the exception was dentists seeing a lot of HNC patients felt they had been 
well trained.  
How do these findings align with 
your expectations?  
 
How/why do you think we may have 
got this result? 
 





Appendix 10: SPSS Syntax code 
 
* Encoding: UTF-8. 
means age by sex/stats anova. 
 
means agegroup by sex/stats anova. 
 
recode age (lowest thru 34=1) (35 thru 49=2) (50 thru 59=3) (60 thru highest=4) into agegroup. 
exe. 
freq agegroup. 
crosstabs agegroup by sex/stats=chisq/cells count row. 
means agegroup by sex/stats anova. 
 
recode degree (2=1) (else=0) into bdsotago. 
value labels bdsotago 0 'No' 1'Yes". 
exe. 
freq bdsotago. 
crosstabs bdsotago by sex/stats=chisq/cells count row. 




recode pubpriv (2 thru 3=1) (1=0) into publicany. 









crosstabs publicany by sex/stats=chisq/cells count row. 




crosstabs location by sex/stats=chisq/cells count row. 
means location by sex/stats anova. 
 
recode yrsprac (lowest thru 9=1) (10 thru 19=2) (20 thru 29=3) (30 thru 39=4) (40 thru 49=5) (50 thru highest=6) into yrspracgp. 




crosstabs yrspracgp by sex/stats=chisq/cells count row. 
means yrspracgp by sex/stats anova. 
 
crosstabs pubpriv by sex/stats=chisq/cells count row. 
means pubpriv by sex/stats anova. 
 
recode HNCptspa (0=1) (1 thru 5=2) (6 thru 19=3)(20 thru highest=4) into HNCptsgp. 








crosstabs HNCptsgp by sex/stats=chisq/cells count row. 
means HNCptsgp by sex/stats anova. 
filter off. 
crosstabs sex by HNCptsgp/stats=chisq/cells count row. 
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crosstabs agegroup by HNCptsgp/stats=chisq/cells count row. 
means agegroup by HNCptsgp/stats anova. 
filter off. 
crosstabs agegroup by HNCptsgp/stats=chisq/cells count row. 










crosstabs publicany by HNCptsgp/stats=chisq/cells count row. 
means publicany by HNCptsgp/stats anova. 
filter off. 
crosstabs publicany by HNCptsgp/stats=chisq/cells count row. 








crosstabs bdsotago by HNCptsgp/stats=chisq/cells count row. 
means bdsotago by HNCptsgp/stats anova. 
filter off. 
crosstabs bdsotago by HNCptsgp/stats=chisq/cells count row. 










crosstabs location by HNCptsgp/stats=chisq/cells count row. 
means location by HNCptsgp/stats anova. 
filter off. 
crosstabs location by HNCptsgp/stats=chisq/cells count row. 








crosstabs pubpriv by HNCptsgp/stats=chisq/cells count row. 
means pubpriv by HNCptsgp/stats anova. 
filter off. 
crosstabs pubpriv by HNCptsgp/stats=chisq/cells count row. 
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crosstabs yrspracgp by HNCptsgp/stats=chisq/cells count row. 
means yrspracgp by HNCptsgp/stats anova. 
filter off. 
crosstabs yrspracgp by HNCptsgp/stats=chisq/cells count row. 
















recode Q9_1 (1=1) (missing=2) into Q9_1Gastritis. 





recode Q9_2 (1=1) (missing=2) into Q9_2Caries. 





recode Q9_3 (1=1) (missing=2) into Q9_3ORN. 







recode Q9_4 (1=1) (missing=2) into Q9_4pros. 





recode Q9_5 (1=1) (missing=2) into Q9_5trismus. 





recode Q9_6 (1=1) (missing=2) into Q9_6permtaste. 







recode Q9_7 (1=1) (missing=2) into Q9_7muc. 





recode Q9_8 (1=1) (missing=2) into Q9_8Colitis. 





recode Q9_9 (1=1) (missing=2) into Q9_9Xero. 







recode Q9_10 (1=1) (missing=2) into Q9_10Nephrosis. 





recode Q9_11 (1=1) (missing=2) into Q9_11Swallow. 





freq q9_1gastritis q9_2caries q9_3orn q9_4pros q9_5trismus q9_6permtaste q9_7muc q9_8colitis q9_9xero q9_10nephrosis q9_11swallow  . 
count ncorrect = q9_1gastritis q9_2caries q9_3orn q9_4pros q9_5trismus q9_6permtaste q9_7muc q9_8colitis q9_9xero q9_10nephrosis 
q9_11swallow (1) . 
var labels ncorrect 'Number of correct responses on side-effects' . 
exe . 
freq ncorrect/stats mean stddev med/hist .  





freq Q10_1 Q10_2 Q10_3 Q10_4 Q10_5. 
exe. 
 
recode Q10_1 (1 thru 2=1) (3=2) (4 thru 5=3) into Q10_1gp. 





recode Q10_2 (1 thru 2=1) (3=2) (4 thru 5=3) into Q10_2gp. 





recode Q10_3 (1 thru 2=1) (3=2) (4 thru 5=3) into Q10_3gp. 







recode Q10_4 (1 thru 2=1) (3=2) (4 thru 5=3) into Q10_4gp. 





recode Q10_5 (1 thru 2=1) (3=2) (4 thru 5=3) into Q10_5gp. 





recode Q10_5gp (1 thru 2=1) (3 thru 5=0) into Q10_5gpsimple. 








crosstabs sex by Q10_5gpsimple/stats=chisq/cells count row. 
means sex by Q10_5gpsimple/stats anova. 
 
crosstabs agegroup by Q10_5gpsimple/stats=chisq/cells count row. 
means agegroup by Q10_5gpsimple/stats anova. 
 
crosstabs bdsotago by Q10_5gpsimple/stats=chisq/cells count row. 
means bdsotago by Q10_5gpsimple/stats anova. 
 
crosstabs publicany by Q10_5gpsimple/stats=chisq/cells count row. 
means publicany by Q10_4simple/stats anova. 
 
crosstabs location by Q10_5gpsimple/stats=chisq/cells count row. 
means location by Q10_5gpsimple/stats anova. 
 
crosstabs yrspracgp by Q10_5gpsimple/stats=chisq/cells count row. 
means yrspracgp by Q10_5gpsimple/stats anova. 
 
crosstabs pubpriv by Q10_5gpsimple/stats=chisq/cells count row. 




crosstabs HNCptsgp by Q10_5gpsimple/stats=chisq/cells count row. 
means HNCptsgp by Q10_5gpsimple/stats anova. 
 
recode Q10_1 (1 thru 3=0) (4 thru 5=1) into Q10_1simple. 





crosstabs sex by Q10_1simple/stats=chisq/cells count row. 
means sex by Q10_1simple/stats anova. 
 
crosstabs agegroup by Q10_1simple/stats=chisq/cells count row. 
means agegroup by Q10_1simple/stats anova. 
 
crosstabs bdsotago by Q10_1simple/stats=chisq/cells count row. 





crosstabs publicany by Q10_1simple/stats=chisq/cells count row. 
means publicany by Q10_1simple/stats anova. 
 
crosstabs location by Q10_1simple/stats=chisq/cells count row. 
means location by Q10_1simple/stats anova. 
 
crosstabs yrspracgp by Q10_1simple/stats=chisq/cells count row. 
means yrspracgp by Q10_1simple/stats anova. 
 
crosstabs pubpriv by Q10_1simple/stats=chisq/cells count row. 
means pubpriv by Q10_1simple/stats anova. 
 
crosstabs HNCptsgp by Q10_1simple/stats=chisq/cells count row. 
means HNCptsgp by Q10_1simple/stats anova. 
 
recode Q10_2 (1 thru 2=1) (3 thru 5=0) into Q10_2simple. 






crosstabs sex by Q10_2simple/stats=chisq/cells count row. 
means sex by Q10_2simple/stats anova. 
 
crosstabs agegroup by Q10_2simple/stats=chisq/cells count row. 
means agegroup by Q10_2simple/stats anova. 
 
crosstabs bdsotago by Q10_2simple/stats=chisq/cells count row. 
means bdsotago by Q10_2simple/stats anova. 
 
crosstabs publicany by Q10_2simple/stats=chisq/cells count row. 
means publicany by Q10_2simple/stats anova. 
 
crosstabs location by Q10_2simple/stats=chisq/cells count row. 
means location by Q10_2simple/stats anova. 
 
crosstabs yrspracgp by Q10_2simple/stats=chisq/cells count row. 
means yrspracgp by Q10_2simple/stats anova. 
 
crosstabs pubpriv by Q10_2simple/stats=chisq/cells count row. 
means pubpriv by Q10_2simple/stats anova. 
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crosstabs HNCptsgp by Q10_2simple/stats=chisq/cells count row. 
means HNCptsgp by Q10_2simple/stats anova. 
 
recode Q10_3 (1 thru 3=0) (4 thru 5=1) into Q10_3simple. 





crosstabs sex by Q10_3simple/stats=chisq/cells count row. 
means sex by Q10_3simple/stats anova. 
 
crosstabs agegroup by Q10_3simple/stats=chisq/cells count row. 
means agegroup by Q10_3simple/stats anova. 
 
crosstabs bdsotago by Q10_3simple/stats=chisq/cells count row. 
means bdsotago by Q10_3simple/stats anova. 
 
crosstabs publicany by Q10_3simple/stats=chisq/cells count row. 




crosstabs location by Q10_3simple/stats=chisq/cells count row. 
means location by Q10_3simple/stats anova. 
 
recode Q10_4 (1 thru 3=0) (4 thru 5=1) into Q10_4simple. 





crosstabs sex by Q10_4simple/stats=chisq/cells count row. 
means sex by Q10_4simple/stats anova. 
 
crosstabs agegroup by Q10_4simple/stats=chisq/cells count row. 
means agegroup by Q10_4simple/stats anova. 
 
crosstabs bdsotago by Q10_4simple/stats=chisq/cells count row. 





crosstabs publicany by Q10_4simple/stats=chisq/cells count row. 
means publicany by Q10_4simple/stats anova. 
 
crosstabs location by Q10_4simple/stats=chisq/cells count row. 
means location by Q10_4simple/stats anova. 
 
crosstabs yrspracgp by Q10_4simple/stats=chisq/cells count row. 
means yrspracgp by Q10_4simple/stats anova. 
 
crosstabs pubpriv by Q10_4simple/stats=chisq/cells count row. 
means pubpriv by Q10_4simple/stats anova. 
 
crosstabs HNCptsgp by Q10_4simple/stats=chisq/cells count row. 
means HNCptsgp by Q10_4simple/stats anova. 
 
freq q9_1gastritis q9_2caries q9_3orn q9_4pros q9_5trismus q9_6permtaste q9_7muc q9_8colitis q9_9xero q9_10nephrosis q9_11swallow 
q10_1simple q10_2simple q10_3simple q10_4simple. 
count ncorrect = q9_1gastritis q9_2caries q9_3orn q9_4pros q9_5trismus q9_6permtaste q9_7muc q9_8colitis q9_9xero q9_10nephrosis 
q9_11swallow q10_1simple q10_2simple q10_3simple q10_4simple (1). 




freq ncorrect/stats mean stddev med/hist .  
means ncorrect by sex agegroup bdsotago publicany yrsprac pubpriv age HNCptspa HNCptsgp yrspracgp age location/stats anova. 
 
recode Q11_1 (1 thru 2=1) (3=2)  (4 thru 5=3) into Q11_1simple. 





crosstabs sex by Q11_1simple/stats=chisq/cells count row. 
means sex by Q11_1simple/stats anova. 
 
crosstabs agegroup by Q11_1simple/stats=chisq/cells count row. 
means agegroup by Q11_1simple/stats anova. 
 
crosstabs bdsotago by Q11_1simple/stats=chisq/cells count row. 
means bdsotago by Q11_1simple/stats anova. 
 
crosstabs publicany by Q11_1simple/stats=chisq/cells count row. 




crosstabs location by Q11_1simple/stats=chisq/cells count row. 
means location by Q11_1simple/stats anova. 
 
crosstabs yrspracgp by Q11_1simple/stats=chisq/cells count row. 
means yrspracgp by Q11_1simple/stats anova. 
 
crosstabs pubpriv by Q11_1simple/stats=chisq/cells count row. 
means pubpriv by Q11_1simple/stats anova. 
 
crosstabs HNCptsgp by Q11_1simple/stats=chisq/cells count row. 
means HNCptsgp by Q11_1simple/stats anova. 
 
recode Q11_2 (1 thru 2=1) (3=2)  (4 thru 5=3) into Q11_2simple. 








crosstabs sex by Q11_2simple/stats=chisq/cells count row. 
means sex by Q11_2simple/stats anova. 
crosstabs agegroup by Q11_2simple/stats=chisq/cells count row. 
means agegroup by Q11_2simple/stats anova. 
 
crosstabs bdsotago by Q11_2simple/stats=chisq/cells count row. 
means bdsotago by Q11_2simple/stats anova. 
 
crosstabs publicany by Q11_2simple/stats=chisq/cells count row. 
means publicany by Q11_2simple/stats anova. 
 
crosstabs location by Q11_2simple/stats=chisq/cells count row. 
means location by Q11_2simple/stats anova. 
 
crosstabs yrspracgp by Q11_2simple/stats=chisq/cells count row. 
means yrspracgp by Q11_2simple/stats anova. 
 
crosstabs pubpriv by Q11_2simple/stats=chisq/cells count row. 





crosstabs HNCptsgp by Q11_2simple/stats=chisq/cells count row. 
means HNCptsgp by Q11_2simple/stats anova. 
 
recode Q11_3 (1 thru 2=1) (3=2)  (4 thru 5=3) into Q11_3simple. 





crosstabs sex by Q11_3simple/stats=chisq/cells count row. 
means sex by Q11_3simple/stats anova. 
 
crosstabs agegroup by Q11_3simple/stats=chisq/cells count row. 
means agegroup by Q11_3simple/stats anova. 
 
crosstabs bdsotago by Q11_3simple/stats=chisq/cells count row. 





crosstabs publicany by Q11_3simple/stats=chisq/cells count row. 
means publicany by Q11_3simple/stats anova. 
 
crosstabs location by Q11_3simple/stats=chisq/cells count row. 
means location by Q11_3simple/stats anova. 
 
crosstabs yrspracgp by Q11_3simple/stats=chisq/cells count row. 
means yrspracgp by Q11_3simple/stats anova. 
 
crosstabs pubpriv by Q11_3simple/stats=chisq/cells count row. 
means pubpriv by Q11_3simple/stats anova. 
 
crosstabs HNCptsgp by Q11_3simple/stats=chisq/cells count row. 
means HNCptsgp by Q11_3simple/stats anova. 
 
recode Q11_4 (1 thru 2=1) (3=2)  (4 thru 5=3) into Q11_4simple. 







crosstabs sex by Q11_4simple/stats=chisq/cells count row. 
means sex by Q11_4simple/stats anova. 
 
crosstabs agegroup by Q11_4simple/stats=chisq/cells count row. 
means agegroup by Q11_4simple/stats anova. 
 
crosstabs bdsotago by Q11_4simple/stats=chisq/cells count row. 
means bdsotago by Q11_4simple/stats anova. 
 
crosstabs publicany by Q11_4simple/stats=chisq/cells count row. 
means publicany by Q11_4simple/stats anova. 
 
crosstabs location by Q11_4simple/stats=chisq/cells count row. 
means location by Q11_4simple/stats anova. 
 
crosstabs yrspracgp by Q11_4simple/stats=chisq/cells count row. 





crosstabs pubpriv by Q11_4simple/stats=chisq/cells count row. 
means pubpriv by Q11_4simple/stats anova. 
 
crosstabs HNCptsgp by Q11_4simple/stats=chisq/cells count row. 
means HNCptsgp by Q11_4simple/stats anova. 
 
recode Q11_5 (1 thru 2=1) (3=2)  (4 thru 5=3) into Q11_5simple. 





crosstabs sex by Q11_5simple/stats=chisq/cells count row. 
means sex by Q11_5simple/stats anova. 
 
crosstabs agegroup by Q11_5simple/stats=chisq/cells count row. 
means agegroup by Q11_5simple/stats anova. 
 
crosstabs bdsotago by Q11_5simple/stats=chisq/cells count row. 




rosstabs publicany by Q11_5simple/stats=chisq/cells count row. 
means publicany by Q11_5simple/stats anova. 
 
crosstabs location by Q11_5simple/stats=chisq/cells count row. 
means location by Q11_5simple/stats anova. 
 
crosstabs yrspracgp by Q11_5simple/stats=chisq/cells count row. 
means yrspracgp by Q11_5simple/stats anova. 
 
crosstabs pubpriv by Q11_5simple/stats=chisq/cells count row. 
means pubpriv by Q11_5simple/stats anova. 
 
crosstabs HNCptsgp by Q11_5simple/stats=chisq/cells count row. 
means HNCptsgp by Q11_5simple/stats anova. 
 
recode Q11_6 (1 thru 2=1) (3=2)  (4 thru 5=3) into Q11_6simple. 







crosstabs sex by Q11_6simple/stats=chisq/cells count row. 
means sex by Q11_6simple/stats anova. 
 
crosstabs agegroup by Q11_6simple/stats=chisq/cells count row. 
means agegroup by Q11_6simple/stats anova. 
 
crosstabs bdsotago by Q11_6simple/stats=chisq/cells count row. 
means bdsotago by Q11_6simple/stats anova. 
 
rosstabs publicany by Q11_6simple/stats=chisq/cells count row. 
means publicany by Q11_6simple/stats anova. 
 
crosstabs location by Q11_6simple/stats=chisq/cells count row. 
means location by Q11_6simple/stats anova. 
 
crosstabs yrspracgp by Q11_6simple/stats=chisq/cells count row. 




crosstabs pubpriv by Q11_6simple/stats=chisq/cells count row. 
means pubpriv by Q11_6simple/stats anova. 
 
crosstabs HNCptsgp by Q11_6simple/stats=chisq/cells count row. 
means HNCptsgp by Q11_6simple/stats anova. 
 
recode Q11_7 (1 thru 2=1) (3=2)  (4 thru 5=3) into Q11_7simple. 





crosstabs sex by Q11_7simple/stats=chisq/cells count row. 
means sex by Q11_7simple/stats anova. 
 
crosstabs agegroup by Q11_7simple/stats=chisq/cells count row. 
means agegroup by Q11_7simple/stats anova. 
 
crosstabs bdsotago by Q11_7simple/stats=chisq/cells count row. 





crosstabs publicany by Q11_7simple/stats=chisq/cells count row. 
means publicany by Q11_7simple/stats anova. 
 
crosstabs location by Q11_7simple/stats=chisq/cells count row. 
means location by Q11_7simple/stats anova. 
 
crosstabs yrspracgp by Q11_7simple/stats=chisq/cells count row. 
means yrspracgp by Q11_7simple/stats anova. 
 
crosstabs pubpriv by Q11_7simple/stats=chisq/cells count row. 
means pubpriv by Q11_7simple/stats anova. 
 
crosstabs HNCptsgp by Q11_7simple/stats=chisq/cells count row. 
means HNCptsgp by Q11_7simple/stats anova. 
 
recode Q11_8 (1 thru 2=1) (3=2)  (4 thru 5=3) into Q11_8simple. 






crosstabs sex by Q11_8simple/stats=chisq/cells count row. 
means sex by Q11_8simple/stats anova. 
 
crosstabs agegroup by Q11_8simple/stats=chisq/cells count row. 
means agegroup by Q11_8simple/stats anova. 
 
crosstabs bdsotago by Q11_8simple/stats=chisq/cells count row. 
means bdsotago by Q11_8simple/stats anova. 
 
crosstabs publicany by Q11_8simple/stats=chisq/cells count row. 
means publicany by Q11_8simple/stats anova. 
 
crosstabs location by Q11_8simple/stats=chisq/cells count row. 
means location by Q11_8simple/stats anova. 
 
crosstabs yrspracgp by Q11_8simple/stats=chisq/cells count row. 




crosstabs pubpriv by Q11_8simple/stats=chisq/cells count row. 
means pubpriv by Q11_8simple/stats anova. 
crosstabs HNCptsgp by Q11_8simple/stats=chisq/cells count row. 
means HNCptsgp by Q11_8simple/stats anova. 
 
recode Q11_9 (1 thru 2=1) (3=2)  (4 thru 5=3) into Q11_9simple. 





crosstabs sex by Q11_9simple/stats=chisq/cells count row. 
means sex by Q11_9simple/stats anova. 
 
crosstabs agegroup by Q11_9simple/stats=chisq/cells count row. 
means agegroup by Q11_9simple/stats anova. 
 
crosstabs bdsotago by Q11_9simple/stats=chisq/cells count row. 




crosstabs publicany by Q11_9simple/stats=chisq/cells count row. 
means publicany by Q11_9simple/stats anova. 
crosstabs location by Q11_9simple/stats=chisq/cells count row. 
means location by Q11_9simple/stats anova. 
 
crosstabs yrspracgp by Q11_9simple/stats=chisq/cells count row. 
means yrspracgp by Q11_9simple/stats anova. 
 
crosstabs pubpriv by Q11_9simple/stats=chisq/cells count row. 
means pubpriv by Q11_9simple/stats anova. 
 
crosstabs HNCptsgp by Q11_9simple/stats=chisq/cells count row. 
means HNCptsgp by Q11_9simple/stats anova. 
 
*recoding for changing polarity of question through recoding 
 






recode Q11_5 (1=3) (2=3) (3=3) (4=1) (5=1) into Q11_5revpol. 
exe. 
 
recode Q11_6 (1=3) (2=3) (3=3) (4=1) (5=1) into Q11_6revpol. 
exe.  
 
recode Q11_8 (1=3) (2=3) (3=3) (4=1) (5=1) into Q11_8revpol. 
exe. 
 
recode Q11_9 (1=3) (2=3) (3=3) (4=1) (5=1) into Q11_9revpol. 
exe. 
 
freq Q11_1simple q11_2simple Q11_3simple Q11_4revpol Q11_5revpol Q11_6revpol Q11_7simple Q11_8revpol Q11_9revpol. 
count ncorrect = Q11_1simple q11_2simple Q11_3simple  Q11_7simple (1) Q11_4revpol Q11_5revpol Q11_6revpol Q11_8revpol Q11_9simple 
(1). 
var labels ncorrect 'Number of agreed responses' . 
exe . 
freq ncorrect/stats mean stddev med/hist .  







freq Q13_1 Q13_2 Q13_3 Q13_4 Q13_5 Q13_6 Q13_7 Q13_8 Q13_9 Q13_10  Q13_11. 
exe. 
 
freq Q14_1 Q14_2 Q14_3 Q14_4 Q14_5 Q14_6 Q14_7 Q14_8 Q14_9 Q14_10. 
exe. 
 




count ncorrect = q15_2 Q15_3  Q15_4 Q11_5 Q15_6 Q15_7 Q15_8 Q15_10 Q15_11 Q15_12 Q15_13 Q15_14 Q15_15 Q15_16 Q15_18 (1). 
var labels ncorrect 'Number of agreed responses' . 
exe . 
freq ncorrect/stats mean stddev med/hist .  
means ncorrect by sex agegroup bdsotago publicany yrsprac pubpriv age HNCptspa HNCptsgp yrspracgp age location/stats anova . 
 
count ncorrect = q15_1 Q15_9  Q15_17 (1).  




freq ncorrect/stats mean stddev med/hist .  
means ncorrect by sex agegroup bdsotago publicany yrsprac pubpriv age HNCptspa HNCptsgp yrspracgp age location/stats anova . 
 
oneway ncorrect by agegroup/posthoc = lsd alpha(.05) . 
 
oneway ncorrect by yrspracgp/posthoc = lsd alpha(.05) . 
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